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1 Chapter 1: Introduction 
 
1.1 Abstract: 
 
Background: GDM is a state of glucose intolerance first diagnosed in pregnancy. It is a 
pre-diabetes state, predisposing both the mother and offspring to future risk of diabetes. 
GDM is associated with increased risk to macrosomia, adiposity, Caesarean Section 
(CS) delivery, shoulder dystocia, and neonatal hypoglycaemia. SA have a greater than 
two fold risk of both GDM and future diabetes risk compared to WC. However, despite 
having higher levels of hyperglycaemia in pregnancy, SA babies are amongst the 
smallest babies in the world.  
The mechanism behind this increased glycaemic risk in SA is complex, multifactorial 
and unclear. Disordered hypothalamic-pituitary-adrenal axis (HPA) has been linked to 
adult diabetes, obesity and metabolic syndrome in WC but has not been studied in SA. 
The current management of GDM is largely based on evidence from studies in WC and 
has been extrapolated to other ethnic groups such as SA. This includes: diagnostic 
criteria to define GDM, postnatal screening methods for postpartum glucose 
abnormalities, effect of GDM on offspring birth weight (BW) and fetal growth in GDM. 
Through this research we aim to explore the ethnic differences between SA and WC in 
the applicability of diagnostic criteria, post partum screening methods, effect of GDM 
on BW, fetal growth patterns in GDM and also examine ethnic differences in HPA 
activity as a potential mechanism underlying the increased glycaemic risk in SA in 
pregnancy. 
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Methods: 
i. Retrospective analysis of a routinely collected multicentre data (n=14477) over a 
3-year period was used to study the applicability of various GDM diagnostic 
criteria and post partum screening methods. A subgroup analysis of the above 
data set was used to compare fetal growth between SA and WC (177 WC and 
160 SA).  
ii. A retrospective analysis of a large birth weight cohort (n=53,128) from 
Leicestershire between 1994 and 2006 was used to compare the effect of 
maternal diabetes and GDM on BW in SA and WC.  
iii. To examine fetal growth in SA, a retrospective case control analysis of serial 
fetal biometry was performed between GDM and control population from India. 
(178 controls and 153 GDM) 
iv. To explore underlying HPA dysfunction as a potential mechanism for increased 
glycemia in SA and ethnic differences in HPA behaviour a prospective cohort 
study comprising of high risk pregnant SA and WC women was performed. 
Diurnal salivary and urinary cortisol excretion was studied in relation to 
glycaemia in SA and WC (n=100, 50 SA, 50WC) 
Results:  
i. The newer IADPSG detects obese women with mild fasting hyperglycaemia. 
The benefits of treatment of hyperglycemia are not well established. The 
increase in detection rates of GDM with the new NICE and IADPSG criteria 
were uniform across ethnic groups in a selectively screened population.   
25 
 
ii. Postnatal screening with oral glucose tolerance test (OGTT) is associated with 
poor uptake in all ethnic groups, which improves substantially with using 
HbA1c. SA were more likely to attend postnatal screening with HbA1c 
compared to WC. Screening for postnatal diabetes using FPG is more likely to 
miss women of non-WC ethnicity owing to the larger proportion of post-load 
glucose abnormalities. 
iii. The BW increase associated with maternal diabetes was lower in SA by 139g 
compared to WC.  
iv. Important ethnic differences in fetal growth were noted. SA fetuses had overall 
smaller measures of head and abdomen circumferences, but with 
disproportionately smaller abdominal circumference compared to WC, 
signifying early evidence of a head sparing growth restricted pattern. 
v. SA fetuses of GDM mothers showed early evidence of increased abdominal 
adiposity at 20 weeks with smaller measures of other fat free mass and skeletal 
growth compared to non-GDM controls 
vi. SA had higher cortisol awakening responses compared to WC. First trimester 
waking cortisol was an independent predictor of glycaemia in the third trimester. 
Despite significantly lower BMI, SA had similar glucocorticoid (GC) excretion 
to WC. Urinary GC excretion was independently predicted by maternal adiposity 
and not BMI in SA. 
Conclusion: This research addresses important gaps in the literature in gestational 
diabetes in SA. There are important ethnic differences in the impact of maternal 
diabetes and gestational diabetes on BW and fetal growth, and evidence of early 
26 
 
increase in adiposity at the expense of lean body mass in SA. This research provides 
novel evidence to support the argument for ethnicity tailored management of GDM. 
Our research also provides novel evidence for disordered HPA activity as a possible 
mechanism for the increased glycemic risk in SA. Larger randomized prospective 
studies incorporating offspring outcomes in relation to HPA are needed. 
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1.2 Gestational Diabetes Mellitus and ethnicity: 
GDM is defined as glucose intolerance first diagnosed in pregnancy [3]. It can be 
regarded as a pre-diabetes state, which is unmasked by the relative diabetogenic 
hormonal milieu of pregnancy. Normal pregnancy is associated with about 60% 
decrease in insulin sensitivity, exaggerating the risk of clinical 
hyperglycemia/gestational diabetes in women with pre-existing undiagnosed metabolic 
dysfunction [4]. 
The prevalence of GDM is increasing at an alarming rate globally in line with the 
increase in prevalence of type 2 diabetes (T2D) [5, 6]. The prevalence of GDM varies 
between 2-22% in population based studies [7] depending on the screening criteria used 
and the population characteristics. 
GDM increases the future risk of T2D by 7-8 fold in mothers and 2-4 fold in the 
offspring [8]. GDM has also been associated with offspring risks such as macrosomia, 
neonatal jaundice, increased C-Section rates, neonatal hypoglycaemia and shoulder 
dystocia [9]. There is strong evidence to show that treatment of mild GDM reduces 
offspring risk [10, 11].  
While GDM has been associated with various traditional risk factors such as obesity and 
family history of T2D, ethnicity has been regarded as one of the independent risk factors 
in GDM and has several implications in GDM, in particular in South Asians (SA). 
1. Risk of GDM: The prevalence of GDM vary widely with ethnicity [12]. Using 
the same criteria, the prevalence is more than double in South Asians (SA) 
compared to White Caucasians (WC) despite lower BMIs in SA [13, 14]. While 
the incidence of GDM is increasing globally, this increase is disproportionately 
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higher in SA compared to WC [15], paralleling the increase in T2D in SA. It is 
not entirely clear why SA are at higher risk of GDM than WC. Several theories 
have been postulated as discussed in the next section. 
2. Diagnosis of GDM: Currently GDM is diagnosed between 24-28 weeks of 
pregnancy using various criteria across the world, with little consensus. The 
different criteria that have evolved since the 1960’s are purely based on studies 
in WC. How these criteria perform in different ethnic groups especially SA is 
unclear. Some groups have called for the use of ethnic specific cut offs in the 
diagnosis of GDM [16, 17]. 
3. The effect of GDM on birth weight (BW): It is well known that GDM increases 
the risk of macrosomia[9]. Large for gestational age (LGA)/macrosomia has 
been used to derive glycaemic cut offs for defining GDM, assuming that the risk 
of LGA/macrosomia are uniform across ethnic groups [9]. However it has been 
shown that the effect of GDM may not be uniform across different populations. 
Studies among Blacks and WC show that the effect of GDM on BW is 
significantly modulated by ethnicity [18]. Literature comparing the effects of 
GDM on BW in SA and WC is sparse. If proven this further strengthens the 
argument for having ethnic specific diagnostic criteria for GDM. 
4. Post-partum screening and risk of future GDM: The risk of post-partum diabetes 
and methods of post-partum screening practices vary significantly across 
populations. It has been reported that the prevalence of post-partum T2D after 
GDM varies with ethnicity. Blacks had higher post-partum T2D rates compared 
to WC, despite having a lower prevalence of GDM [19]. SA have up to a two 
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fold increased risk of developing T2D following GDM after adjusting for 
potential confounders [2, 20]. However characterisation of the type of postnatal 
abnormalities and applicability pf various postnatal screening strategies in the 
two ethnic groups has not been studied previously. Ethnicity tailored postnatal 
testing strategies may be indicated if these differences were observed. 
1.3 Increased metabolic risk in SA and theories 
South Asians (SA) are a diverse population originating from the Indian subcontinent, 
including India, Bangladesh, Nepal, Pakistan and Sri Lanka. According to the 2011 UK 
Census, South Asians were UKs largest ethnic minority and constituted around 4.9% of 
the population of UK and Wales.  
It is well known that SA have disproportionately higher risk of gestational diabetes, type 
2 diabetes, pre-diabetes, premature cardiovascular mortality and morbidity compared to 
WC. In the UK, the prevalence for T2D in SA is 4-6 times higher and develops 5-10 
years earlier compared to WC [21-25]. Coronary heart disease [26] and stroke are more 
prevalent in SA with a 40-50% higher mortality than in WC [27, 28], in part secondary 
to the higher prevalence of diabetes. After adjusting for age, BMI, family history and 
smoking status, the hazard ratios for T2D in SA vs WC were over 4.07 for Bangladeshi 
women, 2.15 for Pakistani women and 1.71 for Indian women [29]. This adverse risk is 
also seen in pregnancy, which has metabolic implications both for the mother and 
offspring. The prevalence of GDM, which is a pre-diabetes state, using the same criteria 
are more than double in SA compared to WC despite lower BMIs in SA [13]. 
The reasons for this wide disparity are far from clear, although socio-economic and 
cultural influences on health have been implicated. A few studies using self-reported 
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physical activity reported lower activity in SA, compared to other ethnic groups.[30-32]. 
However objective evidence for this, using activity monitors is lacking in SA. Others 
reporting dietary trends in India in relation to insulin resistance report higher intakes of 
carbohydrates, saturated fatty acids, n6-poly-unsaturated fatty acids (PUFA) and lower 
n3 PUFA and fibre compared to other populations [33, 34].  
Novel risk factors, including inflammatory markers such as highly sensitive-C-reactive 
protein, adipokines (e.g adiponectin and leptin), inflammatory cytokines like tumor 
necrosis factor (TNF) alpha, Interleukin (IL-6), and prothrombotic plasminogen 
activator inhibitor (PAI-1) may be related to the excess coronary heart disease [26] 
mortality rates in South Asians, but unfortunately have not been examined prospectively 
in South Asians [35-37].  Lipoprotein(a), has been reported in one study to confer an 
increased genetic predisposition to pre-mature CHD [37].  
While above factors could play a role in adult metabolic risk, this risk is evident in early 
childhood and even at birth. Studies conducted in the UK and in the US report the 
incidence of T2D in children and adolescents to be at least 3 fold higher in SA compared 
to WC [38, 39], associated with increased prevalence of childhood obesity as seen in the 
reports of the National Child Measurement program [40]. SA children have higher % of 
body fat and are more insulin resistant for any given body mass than matched WC 
controls [41, 42]. Yajnik and his colleagues from the Pune Maternal Nutrition Study 
(PMNS) coined the term ‘thin-fat Indian baby’ to depict increased abdominal adiposity 
seen even at birth despite smaller size [43, 44]. It is believed that this pattern of central 
obesity that is closely linked to future adult metabolic risk is determined at birth.  
Several theories have evolved to explain this high risk in SA seen at birth and early life. 
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1. Thrifty genotype theory:  In 1962 James Neel described a “thrifty genotype” that 
modified insulin regulation and glucose and fat storage to provide a survival 
advantage during periods of famine in the hunter-gatherer days [45]. With 
calorie abundance, this genetic disposition became maladaptive resulting in 
adverse metabolic risk. However, it is an improbable assumption that South 
Asians would have been more vulnerable than other races. 
2. Thrifty phenotype theory: In 1992 Barker and Hales reported that low birth 
weight (LBW) and thinness at birth was associated with high risk of T2D, 
proposing that intra-uterine nutritional insults induce foetal adaptations to confer 
a survival advantage in the short term, which became maladaptive when nutrition 
improved thereafter [46].  The 1998 Dutch Winter hunger study reported a high 
incidence of glucose intolerance in adults who were exposed to malnutrition in 
utero during the famine [47]. In 1999, Yajnik and Fall demonstrated that children 
who were smaller at birth were more insulin resistant with greater adiposity. 
[48]. In the majority of the studies low birth weight is used as a marker of under 
nutrition.  India has both the largest number of diabetics in the world and this 
could be related to the fact that Indian babies are amongst the smallest [49]. 
3. Fetal Insulin hypotheisis: In 1999, Hattersley proposed the theory that the same 
underlying genetic factors result in both the phenotype of a small baby and an 
adult with insulin resistance [50]. The association seen between fetal thinness 
and insulin resistance is thus explained as two manifestations of the same 
underlying cause. Although monogenic diabetes supports this theory this is 
relative rare and cannot explain the epidemic of T2D in SA. Considering the 
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predominant role of adulthood obesity in combination with LBW, a gene-
environment interaction in the peri-conceptional period is more a likely 
explanation. 
4. Thrifty Epigenotype: Another possibility is that of a relatively recent heritable 
modification of the Asian Indian epigenome or “thrifty epigenotype,” induced by 
a suboptimal intrauterine environment that could “program” the offspring for 
adult health outcomes [51]. These refer to changes in DNA other than gene 
sequence changes. Methylation of the CpG islands of DNA is a major epigenetic 
mechanism of gene silencing. The importance of methyl donors in nutritional 
programming is well studied in animals. Feeding Agouti mice with a methylating 
cocktail (B12 + Folate + Betaine + Choline) resulted in methylation of various 
candidate genes such as gluco-corticoid receptor and PPAR-γ genes involved in 
insulin and energy metabolism [52]. Another sheep model with periconceptional 
deficiency of methyl donors (methionine, vitamin B12 and folate) resulted in the 
methylation of a number of genes in the offspring leading to insulin resistance 
and obesity [53]. It has been shown that SA especially Indians have a high 
prevalence of B12 deficiency compared to WC, with studies reporting mean B12 
levels in SA nearly half of that in WC [54]. The Pune maternal nutrition study of 
675 women was the first clinical study to demonstrate the link between maternal 
vitamin B12 & folate status and offspring insulin resistance at 6 years [55]. It 
can therefore be hypothesized that SA have an altered epigenome at birth owing 
to a deficiency in various methyl donors especially Vitamin B12.  
5. Altered set points of regulatory systems: Hypothalamic-pituitary-adrenal axis 
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(HPA) hyperactivity and increased activity of 11 beta-hydroxy-steroid-
dehydrogenase-1 enzyme (HSD1) enzyme in adipose tissue resulting in 
hypercortisolemia has been linked to metabolic syndrome, diabetes and obesity 
[56, 57]. Exogenous maternal steroid administration during pregnancy has been 
linked to low BW in animal and human studies [58] and could be a possible 
explanation of the low birth size in SA. Variation in HPA and HSD1 activity has 
been described in different ethnic groups [59]. Reynolds reported lower 0900 
cortisol in SA men living in the UK compared to their WC counterparts [60]. 
However detailed HPA behaviour in SA has not been studied before in relation 
to GDM risk. 
In this study we will focus on the ethnic differences in GDM risk in particular between 
SA and WC. We will aim to study ethnic differences in applicability of different GDM 
diagnostic criteria, postnatal abnormalities after GDM, effects of GDM on foetal size 
and birth weight between SA and WC, and the role of the HPA in this risk in both ethnic 
groups. 
 34 
2 Chapter 2: Diagnosis of GDM 
2.1 Abstract 
Background: There is intense debate surrounding the various defining criteria for 
gestational diabetes. There is reluctance worldwide to adopt the International 
Association of the diabetes and pregnancy study groups (IADPSG) guidelines 
despite endorsement from the WHO. The National Institute for Health and Care 
Excellence (NICE) 2015 guidelines recommend new criteria based on cost-
effectiveness analysis using observational data. Both these criteria recommend lower 
Fasting Plasma Glucose (FPG) thresholds than current practice. Our aim was to 
compare the performance of IADPSG and NICE-2015 criteria in a risk-factor based 
selectively screened population consisting of WC and SA. 
Methods: A retrospective analysis was performed for 14477 women undergoing 
antenatal oral-glucose-tolerance-test (OGTT) (2010-2012) across three UK centres 
that used NICE recommended risk-factor based selective screening. The IADPSG, 
NICE-2015 and the mWHO1999 diagnostic criteria were applied to this population 
and the outcomes assessed in the two ethnic groups. 
Results: The prevalence of GDM was similar by NICE (10.5%) and IADPSG 
(10.6%). Both detected older women with higher BMI, higher multiparty and 
stillbirth rates compared to controls and had higher risk of large-for-gestational-age 
(LGA) infants despite adjustment for maternal characteristics including body-mass-
index (BMI). Maternal BMI was a significant predictor of C-Section risk, in the 
IADPSG group. CS rates in the NICE group were comparable to controls. SA have 
higher OR of being detected by the IADPSG criteria compared to WC. 
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Conclusion: Both new criteria diagnose women with higher metabolic risk and 
adverse offspring outcome, with similar increases in prevalence of GDM. Maternal 
BMI appears to be an important contributor of adverse pregnancy outcome, 
especially CS. It is unclear if treating mild maternal hyperglycaemia in these obese 
women will reduce offspring risk. Until further interventional evidence is available, 
the change in practice leading to increased incidence of mild GDM cannot be 
justified. 
  
 36 
2.2 Introduction 
2.2.1 History and evolution of various criteria for GDM 
Gestational Diabetes Mellitus is typically described as a state of glucose intolerance 
first recognised in pregnancy. The incidence of GDM is increasing rapidly in line 
with the increase in prevalence of type 2 diabetes (T2D) [5, 6]. The reported rates 
vary between 2-22% in population based studies [7] depending on the screening 
criteria used. It is associated with a multitude of maternal and offspring 
complications. The short-term risks include macrosomia, neonatal jaundice, neonatal 
hypoglycaemia and shoulder dystocia in the offspring [9] and preeclampsia [61] and 
higher likelihood of CS deliveries for the mother [62] [9]. In the long-term, the 
diagnosis of GDM is associated with at least 7 fold higher lifetime risk of T2D in 
the mothers and 2-4 fold higher risk of pre-diabetes and T2D in the offspring [8, 63, 
64]. There have been two well-designed multi-centre randomised controlled trials, 
which have demonstrated proven benefit of treatment in reducing short-term adverse 
outcomes in GDM [10, 11]. However, there is still intense debate on what should be 
the screening and diagnostic strategy for GDM with little consensus across the 
world. 
Historically O’Sullivan first defined GDM criteria in the 1964 using a 100g OGTT 
in a landmark study of 752 White Caucasian (WC) women in the second and third 
trimester. This criteria became the standard for GDM detection for the next decades 
although these threshold values were based on the predictive ability for subsequent 
development of maternal diabetes in the non-pregnant state among a second cohort 
of 1,013 women [65]. The O’Sullivan’s criteria was subsequently modified to 
convert the blood to plasma glucose values and adopted by the American NDDG 
group in 1979 [66]. However in 1982, Carpenter and Coustan following a study in 
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381 predominantly WC women recommended slightly lower cut offs to account for 
the change in the enzymatic method used to measure glucose in plasma since the 
1980s [67]. The evolution of various criteria for GDM diagnosis is shown in the 
table 1. 
 The WHO in 1985 for the first time recommended that a 75g OGTT [68].  
 The criteria for GDM diagnosis remained unchanged till this was further 
clarified in the fourth international workshop conference on GDM in 1998 
[3]. For the first time there was mention of risk stratification and selective 
screening for high-risk women who included ethnic minority women such as 
SA. They recommended the Carpenter-Coustan criteria. They also 
recommended criteria for 75g OGTT based on a large study by Sachs in a 
high risk population of 3505 predominantly WC women in Los Angeles and 
the recommendation of the European association for the Study of Diabetes 
based on observation in diverse European women [69].  
 Prior to HAPO other countries recommended slight variations of the NDDG 
criteria or the WHO criteria.  
 WHO (1999) recommended using a 75g OGTT to diagnose GDM in line 
with non-pregnant adults using cut offs to define GDM as either diabetes or 
IGT in pregnancy. It was acknowledged that the role of IFG was not very 
clear [70].  
 The HAPO was a landmark trial of 23,316 women across 9 countries 
between July 2000 and April 2006 [71]. 29.0% of women were termed 
“Asian or oriental” origin, however these participants were South East Asian 
from Honk Kong, Singapore and Thailand. There was no SA representation 
from India, Pakistan or Bangladesh where the prevalence rates are 
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disproportionately high. The HAPO study demonstrated an increased risk of 
macrosomia and increased cord c-peptide with increasing levels of 
glycaemia with no clear threshold at which risk escalates. The mean glucose 
values in this predominantly WC cohort were 4.5, 7.4 and 6.2 mmol/l at 
Fasting 1 and 2h respectively. The IADPSG met in 2008 to translate the 
HAPO study results to GDM criteria. It was decided that the diagnostic 
threshold would be the level of glycaemia at which the OR of adverse 
outcome such as LGA, increased cord C-Peptide and increased offspring 
body fat was 1.75. These levels corresponded to the IADPSG recommended 
criteria of GDM of FPG, 1hPG or 2hPG of 5.1, 10.0 or 8.5 respectively. 
 Following publication of the HAPO results the American diabetes 
Association (ADA), Australasian Diabetes in pregnancy society (ADIPS) 
and the WHO adopted the IADPSG criteria [72-74].  
 The ADA later reverted back to its original criteria due to lack of evidence of 
on reduction of C-Section rates [75].  
 In Feb 2015, NICE UK 2015 proposed new GDM diagnostic criteria using 
75g OGTT [76] (FPG: ≥5.6 and 2-hour: ≥7.8 mmol/l, one of two required for 
diagnosis) following a risk factor based selective screening process The 
recommendation was based on a health economic analysis that reported 
better cost-effectiveness for this new criteria. Their evidence was derived 
from routine observational data sets comprising of over 40,000 pregnant 
women across 14 centres, which included the HAPO centres in the UK and 
Australia, along with other centres in the UK. Majority of the centres used 
risk factor based selective screening with just over 12,000 women being 
screened by a universal screening process. NICE rejected the IADPSG 
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criteria deeming it not cost-effective based on health economic modelling in 
a subset (n=18,974) of these women for whom FPG, 1hPG and 2hPG values 
were available.  
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Table 1: Evolution of various GDM screening and diagnostic criteria
Criteria Recommendation Criteria 
O’Sullivan – (1964) 
Study of 752 WC women 
50g Glucose challenge followed by 100g OGTT for those 
with a 1hPG ≥7.8mmol/l. Universal screening 
FPG ≥ 5.3, 1hPG ≥10, 2hPG ≥ 8.6 or 3hPG ≥ 7.7 mmol/L (2 
or more values) 
NDDG modification of O’Sullivan (1979) (to obtain plasma 
G from blood G values) 
 50g G challenge followed by 100g OGTT for those with a 
1hPG ≥7.8mmol/l. Universal  screening 
FPG ≥ 5.8, 1hPG ≥10.6, 2hPG ≥ 9.2 or 3hPG ≥ 8.0 mmol/L 
(2 or more values) 
Carpenter Couston (1982): Study of 381 WC women. 50g G challenge followed by 100g OGTT for those with a 
1hPG ≥7.8mmol/l. Universal  screening 
FPG ≥ 5.3, 1hPG ≥10, 2hPG ≥8.6 or 3hPG ≥ 7.8 mmol/L (2 
or more values) 
Second International Workshop on Gestational Diabetes 
Mellitus (1984) 
Recommended the NDDG criteria. Universal screening.[77] 
WHO (1985) Recommended 75g OGTT as in non-pregnant. Selective 
screening 
FPG ≥ 7 or 2hPG ≥ 7.8 
Fourth international workshop conference on GDM (1998) -Risk stratification  
-100g OGTT or 75gOGTT 
- Carpenter Coustan criteria for 100gOGTT 
- FPG≥5.3, 1hPG≥10 or 2hPG≥8.6 mmol for 75gOGTT  
International Association of Diabetes and Pregnancy Study Groups (IADPSG) formed in 1998 
ADIPS (1998)  A 50g G challenge and a 75g OGTT for those with a 1hPG 
≥7.8. Universal screening 
FPG ≥ 5.5 and 2hPG≥8.0mmol/l 
New Zealand  Same as above FPG ≥ 5.5 and 2hPG≥9.0mmol/l 
CDA  Same as above  FPG ≥ 5.3, 1hPG≥10.6, 2hPG≥8.9mmol/l (Any 2 or more) 
WHO (1999) 75g OGTT in line with non-pregnant diagnosis of IGT. 
Selective screening 
FPG ≥ 7 or 2hPG ≥ 7.8 
HAPO trial of 23,316 women across 9 countries between July 2000 and April 2006.  
ADA (2004) Universal screening with 100 or 75gOGTT Carpenter Coustan criteria for 100gOGTT 
- FPG≥5.3, 1hPG≥10 or 2hPG≥8.6 mmol for 75gOGTT 
IADPSG (2008) Universal screening with 75gOGTT FPG, 1hPG or 2hPG≥5.1, 10.0 or 8.5 respectively 
NICE (2008) Selective screening with 75gOGTT- As per WHO - 1999 Same as WHO 1999 
ADA (2011) Adopted IADPSG 
ADIPS (2013) Adopted IADPSG 
WHO (2013) Adopted IADPSG 
CDA (2013) 50 g GCT followed by a 75 g OGTT using the glucose 
thresholds that result in an OR of 2.00.   Universal screening 
FPG ≥5.3 mmol/L, 1hPG ≥10.6 mmol/L, 2hPG ≥9.0 mmol/L 
(any 1) or 1-step 75 g OGTT IADPSG recommended criteria.  
ADA (2014) Recommends either 2 step using 50gOGTT -NDDG / or 
universal screening with IADPSG 
NDDG or IADPSG. 
NICE [78] Selective screening using risk factors. Diagnosis by 75g 
OGTT 
FPG ≥5.6 mmol/L or 2hPG ≥7.8 mmol/l 
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2.2.2 Applicability of GDM screening criteria among various ethnic groups 
The decision to adopt the IADPSG criteria globally and in particular in SA has been 
contentious for several reasons.  
1. Firstly the IADPSG is associated with significantly increased prevalence. 
The expected increase is to up to 17.8% varying across populations between 
9.3-25% (22). This is thought to be secondary to the lowering of the FPG cut 
off in those countries where the WHO-1999 criteria is used and to the lack of 
the initial 50 g glucose challenge in regions using the Carpenter-Coustan 
criteria. In countries like India where the previous WHO criteria and the 2 
step Carpenter and Coustan [79] criteria are prevalent, the impact of 
changing to IADPSG may be significant. Studies have reported upto a three 
times increase in the prevalence of GDM by the IADPSG criteria in 
Asians[80]. 
2. Secondly, without including SA in the HAPO study it is impossible to say 
whether the odds of LGA in SA are comparable to WC at a particular 
glycaemic level. Considering that the prevalence of LGA in SA is far lower 
than WC, the corresponding level of glycaemia to result in the odds ratio 
(OR) of LGA of 1.75 could in fact be higher. Also, it has been shown that 
the effect of glycaemia on birth weight varies with ethnic groups [18, 81]. 
One recent study that compared the effect of the IADPSG criteria on a large 
population including SA minority in fact recommended lower GDM 
diagnostic thresholds for SA than in WC[82].  
3. Thirdly, there is evidence from the DECODE study that SA have a greater 
proportion 2hPG abnormalities compared to FPG abnormalities and it is 
possible that raising the 2hPG cut off might miss a significant proportion of 
 42 
the SA minority group [83]. In the HAPO study 55% of women were 
diagnosed based on FPG alone, however this was as low as 24-26% in 
Bangkok and Hong Kong, and up to 47% in Singapore reflecting ethnic 
differences in the prevalence of fasting and post-prandial hyperglycaemia. 
The highest rates of diagnosis by FPG were in Barbados and America (74 
and 73%). Although lowering the FPG cut off to 5.1 is expected to identify 
women who are likely to be missed by the increased 2hPG cut off of 
8.5mmol/l, this has not been assessed systematically in mixed ethnic 
populations.  
4. Fourthly, it is now increasingly recognised that maternal obesity is a more 
significant and independent player for LGA and C-Section rates than 
maternal glucose except at the highest glucose category [71, 84, 85]. In fact 
75% of LGA in the HAPO study were born to mothers without with normal 
glucose tolerance. The long-term risks of obesity and glucose intolerance in 
offspring associated with GDM were lost when maternal BMI is factored 
into the analysis [86]. With significantly lower prevalence of obesity in SA, 
it is conceivable that the OR of foetal outcome, especially LGA in the 
different glycaemic categories would be very different. 
5. Lastly, evidence of treatment benefit in this newly diagnosed additional 
population with mild fasting hyperglycaemia is lacking. Two intervention 
studies, the ACHOIS and MFMU trials published in 2005 and 2009 showed 
the benefit of treating mild GDM, using 75g OGTT [10] and 100g OGTT 
[11] respectively. It is important to note that neither of these intervention 
studies included the same outcomes used to define the IADPSG criteria as 
their composite primary outcome, except the C-peptide level in the MFMU 
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study [11]. The ACHOIS trial screened women using either risk factor based 
selective screening or 50g glucose challenge test (GCT) to select women 
with a 1hPG ≥ 7.8mmol/l for the 75g OGTT. They defined mild GDM as 
FPG <7.8mmol/L with 2hPG between 7.8 & 11.1mmol/l on 75g OGTT. 95% 
of women in the ACHOIS study had a fasting plasma glucose (FPG) levels 
between 3.4mmol to 6.2mmol, with median (IQR) 2-hour glucose value of 
8.6 (8.1-9.3) mmol/l after a 75g OGTT [10]. The MFMU trial used an initial 
screening test of 50g GCT to select women with 1hPG between 7.5 and 
11.1mmol/l to undergo a subsequent 100g OGTT. Mild GDM was defined as 
FPG<5.3mmol/l with one of 3 other thresholds that include 1hPG, 2hPG, and 
3hPG values greater than 10.0, 8.6 and 7.8mmol/l respectively. In the 
MFMU trial 95% of the women in the intervention arm had a FPG between 
4.5 and 5.1mmol/l with a 2-hour value ranging between 7.2 and 12.1mmol/l 
after a 100g OGTT [11]. Therefore, while there was some overlap in the 
glycaemic ranges with the proposed IADPSG criteria in both these trials, a 
direct extrapolation of the results from the available interventional studies is 
difficult given the differences in screening methods and selection criteria 
used. Again both these trials were conducted in a predominantly WC 
population. 
With both the NICE and IADPSG criteria recommending lower FPG thresholds than 
the prevalent mWHO99 criteria there is increased pressure among care providers to 
adopt a change in practice [87]. If universal screening is followed, the incidence of 
GDM is expected to increase to up to 17.8% with the new IADPSG criteria [88], 
identifying a larger proportion of women with mild fasting glucose abnormalities. 
However, many countries and around 90% of the units in the UK still use risk factor 
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based selective screening, with a majority using the WHO / mWHO-99 criteria for 
diagnosis with a 75g OGTT [89]. Only 4% of UK centres adopted the IADPSG 
criteria [89].  
Meek et al were the first to compare the likely impact of the NICE and IADPSG 
criteria in a retrospective cohort. The centre used a random blood glucose in early 
pregnancy, and subsequent glucose challenge test (GCT) at 26-28 weeks for 
screening followed by a diagnostic 75gOGTT at 26-28 weeks [90]. They reported 
the highest risk of LGA and CS in the group diagnosed by IADPSG and NICE 
criteria compared to control women who did not have OGTT. While this study 
added additional critical evidence for the diagnosis of GDM, this may not be 
applicable to the UK and other countries that follow risk factor based selective 
screening and not a GCT. The impact of the new NICE guidelines should ideally be 
studied on a selectively screened population, on which the evidence for the guideline 
is largely based.  
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2.3 Hypotheses and research questions 
We hypothesised that moving to the new IADPSG criteria is likely to preferentially 
miss a larger number of SA with adverse foetal outcome compared to WC. 
2.4 Aims  
Our aim was to compare between SA and WC the impact of changing to the 
IADPSG and new NICE criteria in a risk factor based selectively screened multi-
ethnic in UK.  
2.5 Objectives 
 Compare the prevalence of GDM by various criteria 
 Compare short-term adverse pregnancy outcomes by various criteria 
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2.7 Methods 
2.7.1 Subjects: 
This was a retrospective study of all pregnant women who attended for antenatal 
OGTT across three National Health Service (NHS) hospitals in the West Midlands 
(Coventry, Nuneaton and Warwick) between Jan 2010 and Dec 2012. OGTT results 
were collected from the pathology database of Warwickshire. Maternal and 
offspring data were collected for these women from the Perinatal Institute database 
for each trust. The maternal, offspring and pathology databases were cleaned and 
merged to obtain data for all singleton pregnancies during this period. For the 
purpose of this study, ethnicity was grouped into South Asians (SA -Indian, 
Bangladeshi, Pakistani, Sri Lankan, Nepali), White Caucasian (WC - British / 
European) and others (Chinese, Black, Middle Eastern, Mixed).  
2.7.2 Data cleaning and merging 
 
 
 
 
 
 
 
 
        
Original OGTT Dataset (all OGTTs between Jan 2010 – 
Dec 2012 across three hospitals) 
n = 30,068 
 
Antenatal OGTT n=14477. Complete fasting and 2hPG 
available for n=14371 
Biochemistry database Maternity database – Perinatal Institute database  
(GEH / UHCW / Warwick) 
Maternal database 
2010, 2011, 2012, 197 
maternal variables per centre. 
Offspring database 
2010, 2011, 2012: 
39 variables 
Mother and baby data merged separately for every 
year for each centre, multiple pregnancy excluded 
Total deliveries 2010-2012: 
Warwick – 8624, UHCW – 15567, GEH - 7032 
Laboratory database and maternity database merged separately for each year 
Final database with maternal and offspring outcome data n=8785 
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2.7.3 GDM screening and criteria  
All these centres used the selective screening based on at least one of the following 
risk factors recommended by NICE: BMI≥30, first-degree relative with diabetes, 
previous GDM, previous unexplained stillbirth, previous baby with birth weight ≥ 
4.5 kg or women of ethnic minority origin. During this period, the centres used 
modified WHO-1999 criteria (mWHO-99) for the clinical diagnosis of GDM 
following a 75g OGTT: FPG ≥6.1 and/or 2hPG ≥7.8mmol/l, one of two readings 
sufficient for diagnosis. Treatment was based on the mWHO-99 criteria. 
2.7.4 Statistical analysis 
The new NICE criteria (FPG ≥5.6 or 2hPG ≥7.8mmol/l), mWHO-99 and the 
modified IADPSG criteria (FPG ≥5.1 or 2hPG ≥8.5mmol/l) were applied to this 
population. Several subgroups were identified as shown in the results section. 
Maternal characteristics and offspring outcomes were compared across the groups. 
Student t test, chi-square test and fisher exact test were used to compare means and 
proportions between any two groups. A significance level of p ≤ 0.001 was 
considered significant, with p≤0.01 being considered a trend when making multiple 
comparisons. Logistic regression was used to assess the predictors of LGA and CS. 
SPSS version 22.0 was used for analysis. 
2.7.5 Laboratory analysis 
Venous samples were used for glucose testing. Venous blood was collected using 
fluoride oxalate tubes and the plasma glucose is analyzed using a hexokinase 
method in our laboratory accredited by UKAS. 
 
 48 
2.7.6 Definitions  
Macrosomia was defined was birth weight >4000g. Multiparty was defined as 
having had 2 or more live births beyond 24 weeks gestation. Pre-eclampsia was 
defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 
mmHg on two or more occasions with proteinuria ≥1+ on dipstick. LGA and SGA 
were defined as BW ≥90th and ≤ 10th centile for gestational age respectively. WHO 
centile calculator using mean BW of 3,542 g (SD 437 g) at 40 weeks was used and 
available from the link below. 
www.who.int/reproductivehealth/topics/best_practices/weight_percentiles_calculato
r.xls [91-93].   
2.8 Results 
Of the 14,477 pregnancies during this period, both FPG and 2hPG values were 
available for 14,371. Of these 8785 women had maternal and offspring data. The 
baseline maternal and offspring characteristics of all women undergoing OGTT split 
by ethnicity are shown in Table 2.  
The incidence of GDM with the mWHO-99 criteria was 9.4% (1347/14371). The 
incidence with the IADPSG and new NICE would have been 10.6% (1525/14371) 
and 10.5% (1505/14371), respectively. Fig 1 shows the control population as well as 
the relative numbers of women diagnosed by each criterion.  
 
In the WHO group, 7.1% of women were diagnosed by FPG alone, 81.6% by 2hPG 
alone, and 11.3% were diagnosed by both FPG and 2hPG readings. In the IADPSG 
group 52.6% of diagnosis was based on FPG alone, 26.2% on 2hPG alone and 
21.2% on both abnormal readings. In the NICE group, these figures were 15.8%, 
65.9% and 18.3% respectively. 
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Out of the 1347 GDM women diagnosed by mWHO-99, the IADPSG criteria will 
miss 440 women (group 1) but diagnoses an additional 618 women (group 3 and 4). 
NICE diagnoses an additional 158 (group 3), in addition to the 1347 GDM women 
by the mWHO-99 criteria (total n=1505) but will miss 460 women diagnosed by 
IADPSG alone (group 4). We studied the maternal and offspring characteristics of 
women in the IADPSG (group 3+4), NICE (group 3) in comparison to the currently 
used mWHO-99 (group1) and controls to assess the impact of changing from the 
current mWHO-99. We also compared the untreated groups by NICE (group 3) with 
the IADPSG alone (group 4). 
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Table 2: Baseline maternal and offspring characteristics of the whole cohort of women undergoing antenatal OGTT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P* values represent differences between SA and WC. 
  
 Total (n=14477) SA (n=1209) WC (n=6060) P* 
Age in years: Mean(SD) 30.37(5.89) 31.01(4.7) 30.11(6.20) <0.0001 
Height in cm:  Mean(SD) 163.81(7.49) 159.78 (6.39) 164.78 (7.25) <0.0001 
BMI (Kg/cm2):   Mean(SD) 28.53 (6.91) 25.26 (5.3) 29.52 (7.13) <0.0001 
Multiparity (≥2): % (n) 24.9 (2170/8708) 27.0 (324/1202) 23.4 (1412/6044) 0.008 
Smoking: % (n) 13.8 (1202/8712) 2.1 (25/1209) 17.9 (1083/6040) <0.0001 
FPG in mmol/l:  Mean(SD) 4.41(0.56) 4.48 (0.65) 4.41(0.52) <0.0001 
2hPG in mmol/l:  Mean(SD) 5.78(1.49) 5.85 (1.64) 5.78 (1.53) 0.142 
Pre-eclampsia: % (n) 6.7 (203/3024) 9.1 (25/232) 5.5 (142/2566) 0.028 
Still birth 0.3 (24/ 6914) 0.6 (6/1049) 0.3 (14/4584) 0.405 
Birth weight in grams:  Mean(SD) 3360.70 (632.1) 3092.09(580.10) 3431.25 (630.98) <0.0001 
Gestational age (days):  Mean(SD) 276.11(13.59) 274.39(13.54) 276.39(13.56) <0.0001 
Macrosomia: % (n) 13.6  (939/6890) 4.3 (45/1049) 16.5 (752/4561) <0.0001 
LGA: % (n) 12.2 (757/6208) 4.4 (43/984) 15.0 (612/4076) <0.0001 
SGA: % (n) 13.2 (933/7079) 25.1 (267/1062) 10.3  (487/4723 <0.0001 
Congenital Anomalies: % (n) 1.9 (127/6680) 2.0 (2/1018) 1.9 (85/4435) 0.920 
C-Section: % (n) 34.5 (2384/6903) 35.3 (370/1047) 33.9 (1552/4578) 0.376 
Special care: % (n) 4.5 (81/1801) 2.2 (3/134) 4.7 (74/1559) 0.181 
1 min APGAR score: <7 % (n) 6.8 (468/6861) 4.4 (46/1043) 7.2 (325/4544) 0.001 
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Fig 1: Representation of populations detected by IADPSG, NICE and mWHO-
99 criteria.  
 
 
 
 
 
  
1 2 3 4 
 
1: mWHO-99 positive-NICE positive-IADPSG negative (2HPG 7.8-8.4 and FPG < 5.1mmol/l): n=440 
(3.06%), 100% treatment 
2: mWHO-99 positive-NICE positive-IADPSG positive (2HPG ≥8.5 or FPG ≥ 6.1mmol/l): n=907 (6.3%), 
100% treatment 
3: mWHO-99 negative-NICE positive-IADPSG positive (FPG 5.6-6.0 and 2hPG <7.8mmol/l): n=158 
(1.1%) , 0% treatment  
4: IADPSG positive-NICE negative-mWHO-99 negative (FPG 5.1-5.5 and 2hPG<7.8mmol/l): n = 460 
(3.2%) , 0% treatment 
Control group. Risk factor positive but GDM negative by all criteria (FPG<5.1 and 2hPG<7.8mmol/l):  
n=12406 (86.3%), 0% treatment 
Total population represents all women undergoing antenatal OGTT: n=14371 
Control 
 52 
2.8.1 Comparison of mWHO-99, IADPSG and NICE criteria 
Table 3 shows the key maternal and offspring outcomes in the various subgroups 
and the control population. Additional women who were detected with the IADPSG 
(group 3&4) and NICE criteria (group 3) had significantly higher BMI and rates of 
multiparity than controls and mWHO-99 groups (group 1). The offspring in both 
groups also had significantly higher crude birth weight, rates of macrosomia and 
LGA. CS rates in the untreated IADPSG group (group 3&4) were higher than that of 
the controls but similar to that of the treated GDM women (group 1). CS rates in the 
NICE group (group 3) were no higher than that in controls and mWHO-99 groups. 
Both NICE (group 3) and IADPSG (group 3&4) groups had significantly higher still 
birth rates compared to controls and the treated mWHO-99 groups, with the highest 
rates seen in the NICE group (4.1%, 3/73).  
2.8.2 Comparison of NICE and IADPSG criteria  
There were no significant differences in maternal or offspring risk characteristics 
between additional women diagnosed by NICE (group 3) (FPG 5.6-6.0 and 2hPG 
<7.8mmol/l) and IADPSG (group 4) (FPG 5.1-5.5 and 2hPG <7.8mmol/l) (table 2). 
Still birth rates were the higher in the additional women diagnosed by NICE (group 
3) compared to the IADPSG group (group 4).  
2.8.3 Risk of LGA and CS 
Women in the IADPSG women (group 3&4) had significantly higher odds of CS 
and LGA rates compared to controls (table 4). The differences in rates of LGA 
persisted even after the adjustment for maternal age, smoking, parity, ethnicity and 
BMI. However, the differences in CS rates became non significant after the 
adjustment for maternal BMI. Although there were higher overall CS rates, there 
were no differences in the rates of emergency CS between the groups (group 3&4 vs 
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control: 7.4 vs 8.2%, p=0.486). Similar observations were seen in additional GDM 
women diagnosed by NICE (group 3; n=158) for LGA, however there were no 
differences in CS risk between controls and the NICE in any of the models. The 
odds of LGA and CS in the IADPSG group was no different from that in the NICE 
group both in adjusted and unadjusted models (table 5) 
2.8.4 Impact of the newer criteria on SA  
There were no significant differences in the ethnic composition of women detected 
by any criteria. The proportion of SA women in the mWHO-99 group (group 1&2) 
was significantly higher than in the control group. However there were no 
significant differences in ethnic composition between any other groups. 
SA were more likely than WC (OR: 1.862 (1.152, 3.012), p = 0.011) to be in the 
IADPSG group (group 3&4) than in the WHO group (group 1) after adjustment for 
maternal BMI, smoking, parity and age. In the unadjusted model, ethnicity did not 
predict the risk of being in either groups (Table 6).  
Ethnicity was not an independent predictor of being diagnosed by the new NICE 
criteria, i.e of being in group 3 compared to group 1 either in the adjusted or 
unadjusted model.
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Table 3: Comparison of maternal characteristics and pregnancy outcomes by mWHO-1999, IADPSG and NICE Criteria. 
P* Comparison between control and respective groups, P** comparison between group 1 and group (3&4), P***comparison between group 3 and group (1&2) 
P¥ comparison between group 3 and group 4
 
Normal (0% 
treatment) 
n=12406 
mWHO1999  positive -
IADPSG negative (group 1) 
(100% treatment) n=440 
IADPSG Positive -mWHO1999  
negative  
(group 3+4) (0% treatment) (n=618) 
mWHO1999 positive-
NICE positive (100% 
treatment) (group 1 +2) 
n= 1347 
mWHO1999  negative-NICE positive 
(0% treatment) (group 3) n= 158 
IADPSG positive-NICE Negative (group 4) 
(0% treatment) (n=460) 
Mean or % Mean or % 
P* (vs 
control) 
Mean or % 
P* (vs 
control) 
P** (vs 
group 1) 
Mean or % 
P*(vs 
control) 
Mean or % 
P* (vs 
control) 
P*** (vs 
group 1+ 
2) 
Mean or % P* 
P¥   (vs  group3 
) 
Maternal Age 30.10 (5.89) 31.78 (5.58) <0.0001 31.54 (5.67) <0.0001 0.579 
32.28 
(5.63) 
<0.0001 
31.66 (6.15) 0.028 0.365  31.52 (5.56) <0.0001 0.85 
Height cm 163.91 (7.63) 161.89 (7.79) <0.0001 
164.30 
(6.74) 
0.218 <0.0001 
162.53 
(6.76) 
<0.0001 
162.99 (6.96) 0.207 0.561 164.60 (6.66) 0.048 0.05 
BMI in Kg/cm2 28.15 (6.91) 28.16 (7.25) 0.985 32.85 (7.19) <0.0001 <0.0001 29.62 (7.04) <0.0001 34.05 (7.11) <0.0001 <0.0001 32.59 (7.20) <0.0001 0.09 
Multiparty 
24.3 
(1802/7403) 
23.4 (62/265) 0.724 
33.6 
(160/476) 
<0.0001 0.004 
25.3(204/80
5) 
0.675 42.5 (37/87) <0.0001 0.001 31.6 (123/389) 0.001 0.05 
FPG 4.9 (0.4) 4.5 (0.4) <0.0001 5.4 (0.2) <0.0001 <0.0001 5.2 (1.3) <0.0001 5.7 (0.1) <0.0001 <0.0001 5.3 (0.1) <0.0001 <0.0001 
2hPG 5.4 (1.1) 8.0 (0.2) <0.0001 6.0 (1.1) <0.0001 <0.0001 8.9 (1.7) <0.0001 5.9 (1.1) <0.0001 <0.0001 6.0 (1.1) <0.0001 1.000 
Smoking at booking 
14.2 
(1054/7403) 
8.2 (22/265) 
 
0.006 
15.1 
(72/476) 
0.586 0.007 9.5 (76/803) <0.0001 20.7 (18/87) 0.086 0.001 13.9 (54/389) 0.845 0.11 
Ethnicity % (SA; 
WC; others) 
13.4; 69.7; 16.9 
(7404) 
15.5; 67.4; 17.0 
(264) 
0.598 
14.9; 68.6; 
16.6 (477) 
0.674 0.950 
16.8; 66.4; 
16.8 (804) 
0.032 
18.4; 69.0; 
12.6 (87) 
0.292 0.601 
14.1; 68.5; 17.4 
(390) 
0.872 0.39 
Pre-eclampsia 6.4 (161/2533) 6.1 (5/82) 0.925 9.3 (19/205) 0.106 0.381 8.4 (25/296) 0.213 10.0 (3/10) 0.446 0.772 9.1 (16/175) 0.149 0.88 
Still birth 0.3 (17/5877) 0 (0/194) 1.000 1.2 (5/413) 0.012 0.049 0.3 (2/620) 0.702 4.1 (3/73) 0.002 0.01 0.6 (2/340) 0.271 0.041 
BW in g 
3366.12 
(625.18) 
3147.09 (625.30) <0.0001 
3542.36 
(700.30) 
<0.0001 <0.0001 
3199.86 
(611.618) 
<0.0001 3463.54 
(897.62) 
0.416 0.017 3559.05 (651.34) <0.0001 0.39 
Gestational age in 
days 
276.9(13.31) 269.70 (14.46) <0.0001 
274.31(14.9
3) 
<0.0001 <0.0001 
269.09 
(13.479) 
<0.0001 270.31 (19.16) 0.002 0.564 275.2 (13.69) 0.012 0.03 
Macrosomia 
(>4000g) 
13.7 (800/5858) 5.2 (10/191) 0.001 
24.3 
(100/412) 
<0.0001 <0.0001 7.0 (43/616) <0.0001 26.4 (19/72) 0.003 <0.0001 23.8 (81/340) <0.0001 0.65 
LGA 10.9 (570/5213) 11.1 (21/190) 0.959 
27.1 
(102/377) 
<0.0001 <0.0001 
14.2 
(87/614) 
0.017 26.1 (18/69) <0.0001 0.009 27.3 (84/308) <0.0001 0.84 
SGA 13.6 (822/6030) 17.2 (33/192) 0.159 8.0 (34/423) 0.001 0.001 
12.8 
(79/619) 
0.547 8.1 (6/74) 0.168 0.249 8.0 (28/249) 0.003 0.98 
Congenital 
anomalies 
1.9 (108/5)693 1.1 (2/183) 0.483 2.3 (9/393) 0.583 0.328 2.0 (12/586) 0.795 4.5 (3/67) 0.126 0.209 1.8 (6/326) 0.942 0.19 
CS 
33.3 
(1954/5870) 
39.1 (75/192) 0.09 
40.0 
(165/413) 
<0.006 0.835 
42.5 
(262/616) 
<0.0001 41.1 (30/73) 0.16 0.81 39.7 (135/340) 0.015 0.83 
Special Care 4.7 (72/1534) 2.2 (1/46) 0.422 4.5 (5/111) 0.927 0.488 4.3 (7/162) 0.842 6.3 (1/16) 0.765 0.72 4.2 (4/95) 0.828 0.72 
1 min APGAR  <7 6.7 (391/5839) 6.3 (12/189) 0.851 8.6 (35/371) 0.137 0.339 7.4 0.538 8.5 (6/71) 0.557 0.74 8.7 (29/335) 0.166 0.96 
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Table 4: Risk of LGA and CS in IADPSG (group 3&4) and NICE (group 3) groups compared to controls  
 
 
 
 
Table shows OR of LGA and CS in the 
IADPSG and the NICE group compared 
to women in the control group 
 
 
 
Table 5: Risk of LGA and CS in IADPSG (group 4) compared to NICE groups (group 3) 
 
 
All OR are in comparison to controls. 
aUnadjusted,  bAdjusted for age, ethnicity, 
parity, smoking, cModel 2+ BMI, *All 
models include offspring sex for LGA 
analysis 
 
 
 
 
Table 6: Predictors of being in group (3 & 4) vs being in group 1  
aUnadjusted model, bMultivariable 
regression after adjustment for age, parity, 
smoking, BMI and ethnicity in the same 
model.
 Control IADPSG  NICE  
  OR (CI) p OR (CI) p 
LGA* 1.00 (Ref) 2.989a (2.340, 3.818) <0.0001 2.889 (1.668, 5.003) <0.0001 
 3.056b (2.374, 3.934) <0.0001 3.123 (1.770, 5.513) <0.0001 
 2.989c (2.340, 3.818) <0.0001 2.677 (1.508, 4.751)   0.001 
CS 1.00 (Ref) 1.333a (1.087, 1.636) 0.006 1.398 (0.874, 2.236) 0.162 
 1.262b (1.025, 1.555) 0.029 1.352 (0.838, 2.180) 0.217 
 1.134c (0.917, 1.402) 0.245 1.198 (0.740, 1.937) 0.463 
 NICE IADPSG  
 OR (CI) OR (CI) p 
LGA* 1.00 (Ref) 1.043 (0.573, 1.897)a 0.892 
 0.963 (0.519, 1.790)b 0.906 
 0.985 (0.529, 1.834)c 0.985 
CS 1.00 (Ref) 0.944 (0.564, 1.579)a 0.826 
 0.917 (0.543, 1.548)b 0.745 
 0.929 (0.550, 1.570)c 0.783 
 OR (CI)a p OR (CI)b p 
SA (WC ref) 0.943 (1.443, 0.616) 0.786 1.862 (1.152, 3.012) 0.011 
BMI 1.117 (1.086, 1.149) <0.0001 1.128 (1.094, 1.163) <0.0001 
 Age 0.988 (0.960, 1.017) 0.410 1.005 (0.972, 1.038) 0.785 
 Parity 0.663 (0.456, 0.964) 0.031 0.744 (0.496, 1.116) 0.153 
Smoking 0.592 (0.353, 0.992) 0.047 0.591 (0.335, 1.041) 0.068 
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2.9 Discussion 
Our study reports the impact of the new NICE and IADPSG criteria on a large risk 
factor based selectively screened multi-ethnic British population. Considering that 
the majority of UK centres still practice risk factor based selective screening and use 
the mWHO-99 criteria [76, 89], our data provides crucial evidence for UK and other 
centres that follow the same. Compared to the mWHO-99 criteria, the NICE criteria 
detect an additional cohort of 158 women with isolated mild fasting hyperglycaemia. 
(Group 3: FPG 5.6-6.0mmol/l, and 2hPG<7.8mmol/l) The IADPSG detects a larger 
cohort of 618 women with isolated mild fasting hyperglycaemia (group 3&4: FPG 
5.1-6.0 & 2hPG<7.8) at the expense of missing 440 women with mild 2-hPG 
abnormalities (group 1: 2hPG: 7.8-8.4 mmol/L & FPG <5.1mmol/l) Both the criteria 
resulted in similar increases in the incidence of GDM compared to the mWHO-99 
criteria. 
2.9.1 Impact of changing to NICE or IADPSG   
Both NICE (group3) and IADPSG (group 3&4) groups diagnosed additional women 
with mild fasting hyperglycaemia with characteristics of higher maternal metabolic 
risk (higher BMI and multiparity) and higher rates of adverse pregnancy outcomes 
(LGA, still births) compared to controls and the currently practiced mWHO-99 
group.  
Women in the IADPSG but not the NICE group had a significantly higher risk of CS 
compared to controls. Despite higher overall CS rates, the proportion of emergency 
CS in the IADPSG group was similar to that in controls. Both the groups had similar 
CS rates to treated women in the mWHO-99 groups (group 1) despite not being 
labelled as GDM in routine care.  
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A comparison of the untreated NICE (group 3) and IADPSG (group4) groups 
revealed no differences in maternal characteristics, LGA or CS risk (table 3, table 6), 
with the exception of higher still birth rates in NICE group. However, the overall 
numbers of stillbirths were small to make any meaningful conclusions. The 
Cambridge study reported higher rates of LGA and CS in the IADPSG group when 
compared to the NICE group [90]. However it must be remembered that they 
compared untreated women in IADPSG group with the treated women in the NICE 
positive/IADPSG negative group, making treatment differences a likely explanation 
for their results.   
The higher risk of CS and LGA with the IADPSG criteria were reported in two other 
observational studies in the UK: The ATLANTIC-DIP study using universal 
screening and a more recent retrospective study from Cambridge using 50gGCT 
screening [90, 94]. Other studies comparing the IADPSG to the Carpenter-Coustan 
criteria in the setting of a 50g GCT based screening [95-97] also depicted higher CS 
rates in the IADPSG group, but LGA rates were similar to non-GDM controls. The 
variation in these results is likely due to the differences in screening and hence 
detection of a different control population, against which these criteria were 
compared.  
2.9.2 Predictors of higher CS and LGA risk 
The higher LGA risk in both groups, persisted despite adjustment for maternal 
characteristics including BMI (table 4). It is difficult to say if this risk is entirely 
mediated by glycaemic differences or by the altered metabolic milieu of an obese 
pregnancy such as higher circulating free fatty acids which have been shown to 
independently correlate with LGA risk [98]. In our study, the difference in mean 
glycaemia between controls and the IADPSG group was 0.5 mmol/l with FPG and 
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0.6 mmol/l with 2hPG, which although statistically significant, could be argued not 
to be clinically significant to contribute to a three fold higher risk of LGA. 
From our data, it also appears that the risk of CS in the IADPSG group is largely 
mediated by BMI. The higher risk of CS in the IADPSG group was no longer 
significant after adjustment for maternal BMI, signifying that maternal BMI played 
an important role in determining this risk (table 4). The higher rates of primary, as 
well as repeat CS in obese women has been reported previously, with obese women 
having difficulty completing the second stage of labour owing to soft tissue dystocia 
[99]. Our results are also in agreement with the HAPO post hoc analysis and other 
studies where maternal obesity has been shown to be a more significant predictor of 
CS rates than maternal glucose except in women with the highest degree of 
hyperglycaemia [71, 84, 85, 90, 100].  
Despite detection of a higher risk cohort with more adverse offspring outcome, the 
question of whether treatment of glycaemia in the IADPSG or NICE group would 
indeed improve outcomes such as LGA or CS still remains unanswered. Two non-
randomised observational studies observed a reduction in LGA rates with treatment 
in the IADPSG group, however only one study showed a reduction in CS rates [101, 
102]. Both these trials compared the IADPSG groups (using universal screening) 
with the Carpenter-Coustan criteria, which uses a 50g GCT screening strategy, 
hence making it difficult to make direct comparisons. In fact women in the above 
studies had far lower BMI than seen in our study, owing to the risk factor based 
selective screening used in our study.  Evidence form the MFMU trial showed that 
women who benefited from intervention in GDM gained significantly less weight in 
pregnancy than those in the control arm [11]. Hence it is conceivable that the benefit 
of treatment came from weight lowering rather than glucose lowering effects of the 
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intervention. While it may be prudent to risk stratify and intervene on women with 
high BMI to reduce these risks, the available intervention trials on the overweight 
and obese pregnant women have failed to show a benefit in reduction of perinatal 
risk, especially LGA [103, 104].  
2.9.3 Effect of IADPSG and NICE on SA ethnicity 
Contrary to our hypothesis SA were not more likely to be missed by the higher 
2hPG cut off of the IADPSG group. The ethnic compositions of all groups were 
similar. Again BMI but not ethnicity was the most important predictor of being 
detected by the IADPSG criteria in univariate linear regression analysis (table 6). 
After adjustment for BMI, SA had a higher OR of being in the IADPSG group 
(group 4&5) compared to group 1, indicating that BMI was the main driver for mild 
FPG abnormalities in the WC ethnic group. It is possible that our selective screening 
strategy influenced the lack of ethnic differences between the groups and that a more 
significant ethnic difference might have been more apparent in a universally 
screened population. Only one other study compared the impact of the IADPSG 
criteria on a mixed ethnic group. Our results are in agreement with another study 
that reported that SA minority was an independent predictor of being diagnosed by 
the IADPSG criteria [86]. Some studies have reported up to a threefold increase in 
the prevalence in GDM using the new IADPSG criteria compared to the prevalent 
criteria in Asians [80] 
In summary, further randomised interventional trials are therefore needed to 
investigate the real benefit of detection and treatment of mild fasting 
hyperglycaemia (whether by NICE or IADPSG) in reducing offspring risks. Such 
trials should not only include the cost effectiveness of treating GDM with respect to 
short-term adverse outcomes but also incorporate the increase in CS rates, which is 
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likely to accompany a diagnosis of GDM. We therefore believe that without such 
evidence to support the detection of milder forms of hyperglycaemia, the change in 
diagnostic criteria cannot be supported purely based on adverse offspring outcome 
in observational studies.  
Our study has important limitations: it is retrospective in nature, lacks data on 
glycemic control or treatment during pregnancy and 1hPG values in the IADPSG 
criteria were not available. The key strength of our study is the real life data from a 
large multi-ethnic population in which the NICE recommended selective screening 
criteria were used. The selective screening method and our diagnostic criteria for 
GDM (mWHO-99) is still widely used in the UK and other centers across the world, 
making it more relevant to current practice. 
2.10 Future directions and gaps in the evidence 
 Prospective studies are needed to assess the risk of adverse offspring 
outcome using various criteria in SA 
 Prospective randomised interventional studies are needed both in SA and 
WC to assess the real benefit of treating GDM based on the IADPSG criteria 
 Above studies should incorporate cost effectiveness analysis 
 GDM diagnostic criteria should be evaluated in the light of screening 
strategies. Studies are needed to assess the impact of different GDM criteria 
in universal vs selective screening settings. 
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3 Postnatal screening in GDM 
3.1 Abstract 
Background: The ideal test for postnatal screening after gestational diabetes mellitus 
is still under debate. Most international guidelines continue to recommend a 
postnatal oral glucose tolerance test (OGTT). In contrast, the new National Institute 
of health and Care Excellence (NICE), UK guidance recommends fasting plasma 
glucose (FPG) or HbA1c but not an OGTT for postnatal testing. Our aim was to 
compare the performance of FPG (using both the WHO and ADA definitions of 
IFG) with OGTT and the uptake rates of OGTT with HbA1c in SA and WC.  
Research Design and Methods: Multicentre retrospective study of 1289 women with 
GDM referred for postnatal OGTT between 2008 and 2012. Subsequent data was 
collected from one centre for 339 women referred for postnatal HbA1c between Dec 
2013 and Dec 2014. Sensitivity and ROC analysis was performed. 
Results: 630 (48.8%) attended postnatal OGTT. FPG at the cut point of 6.1mmol/l 
(WHO criteria for impaired fasting glycaemia - IFG) would miss 88% of IGT and 
16.7% of diabetes. The ADA criteria for IFG (FPG of ≥5.6 mmol/l) would detect 
100% diabetes in both ethnic groups but would still miss 64% IGT. The uptake 
improved to 62.8% with subsequent use of postnatal HbA1c.  
Conclusion: FPG at the ADA threshold of ≥5.6 mmol/l has high sensitivity to detect 
persisting postnatal diabetes even in SA ethnic minority groups. Postnatal HbA1c 
shows promising increase in uptake compared to OGTT. The new NICE 
recommendation for postnatal screening is therefore a welcome change to improve 
care of these high-risk women.  
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3.2 Introduction 
3.2.1 Risk of post-natal diabetes – summary of literature and variation with 
ethnicity 
Gestational Diabetes is a recognised ‘pre-diabetes’ state associated with a 7-8 fold 
higher lifetime risk of developing type 2 diabetes compared to those without GDM 
[8]. The risk of developing type 2 diabetes (T2D) increases rapidly within the first 5 
years of index delivery, the incidence of which can range from 2.5 to 16.7% in the 
first year after delivery [105]. This risk is higher in South Asians (SA) who have up 
to a 5-fold higher risk of T2D compared to White Caucasians (WC) [106].  
Literature comparing the risks of postnatal T2D incidence between SA and WC is 
sparse. A systematic review of 20 studies compared the relative risk (RR) of 
developing diabetes post GDM across different nationalities [8]. (Table 1). The RR 
of T2D in India was significantly higher than the pooled RR (22.7 (10.09, 51.08) vs 
7.43 (4.79, 11.51)).  
Table 1: Relative risk of postnatal diabetes following GDM. 
 
Table 1: Forest plot shows the Relative risk of postnatal diabetes following a GDM pregnancy across 
the world. Reproduced with permission from a systematic review by Bellamy et al [8] 
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Table 2: Summary of literature comparing the risk of post-partum T2D after 
GDM between SA and WC: 
 
Study Time of follow up post GDM Results 
Bellamy et al [8]  Systematic review of varying 
time periods post GDM 
RR: India: 22.7 (10.09, 51.08), Cumulative: 
7.43 (4.79, 11.51)  
Sinha et al [106] 6-12 weeks post partum Incidence: 7% in WC, 5% in Black, 35% in 
SA  
Mukerji et al [2] Median FU period 7.6 years post 
GDM 
Cumulative incidence of diabetes was 16.5% 
for Chinese, 31.8% for SA and 25.7% for WC 
Krishnaveni et al [79] 5 years follow up  Incidence of Diabetes: GDM vs control. 37% 
versus 2% 
 
Figure 1: Cumulative incidence of diabetes following GDM: 
 
A summary of other literature comparing the risk of post-partum diabetes after 
GDM is shown in table 2. All other studies apart from the systematic review 
reported incidence rates and not relative risk. However the incidence of post-partum 
T2D was significantly higher in SA compared to WC. Figure 1 shows the 
cumulative incidence of T2D in women with and without GDM, across SA, Chinese 
and WC ethnicities. This study reported that although the overall incidence of T2D 
Figure 1 shows the 
cumulative incidence of 
diabetes following a 
diagnosis of GDM between 
SA, WC, and Chinese 
ethnic groups. 
Reproduced with 
permission from Mukerji et 
al [2]  
  
 
 64 
was higher in SA in both categories, the presence of GDM conferred a 13 fold 
higher risk in WC compared to 9-10 fold risk in SA [2]. 
In summary, postnatal screening in women with GDM provides a unique 
opportunity for early detection of diabetes, intervention to prevent T2D and for 
timely pre-conception care for subsequent pregnancies. This assumes greater 
importance in SA who have a significantly higher risk of postnatal diabetes 
compared to WC.  
3.2.2 Poor uptake of postnatal screening: 
Postnatal testing following GDM is poor with uptake rates of OGTT being between 
23 and 58% [107]. This is in sharp contrast to high uptake (94%) of other postnatal 
screening programs such as cervical screening done at similar time interval post-
delivery [108]. A few studies have examined the impact of ethnicity on postnatal 
uptake rates [109-111] (table 3). All the three studies show that SA and non-WC 
ethnicity was associated with higher rates of uptake for postnatal testing.  
Table 3: Summary of relevant studies comparing uptake of postnatal screening 
between ethnic groups. 
 
Studies Type of 
test 
Sample 
size 
Uptake rates by ethnicity 
Lawrence et al FPG 
(79.1%) or 
OGTT 
(18.2%), 
both 
(2.7%). 
 
n = 11,825,  
 
Whole cohort 50.2% 
WC 47.7%; SA 59.0%; Black 27.2%; Hispanic 51.1%; Others 
47.8 % 
Ferrara et al OGTT or 
FPG 
n = 14,448  
 
Whole cohort:  38.2 % 
WC 33.2%; SA 45.5%; Black 26.1%; Hispanic, 40.5%; 
Other/Unknown, 34.1% 
Kwong et al FPG 
(4.8%) or 
OGTT 
(95.2%) 
n = 909 Overall 48.2 % 
WC 46.7%; Non-Caucasian 50.1%. 
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3.2.3 Various postnatal screening strategies  
 
OGTT, FPG and HbA1c are three tests that have been used for postnatal screening 
following GDM. The Fifth International Workshop Conference on GDM [112], 
Australasian Diabetes in Pregnancy Society (ADIPS) [73] and the Canadian 
Diabetes Association [113] recommend an OGTT as the gold standard at 6 weeks 
post-partum. The ADA guidelines recommend “post-partum screening at 6-12 
weeks using non-pregnancy OGTT criteria” to detect diabetes and specifically 
mention not to do HbA1c due to the potential effects of antepartum treatment [114]. 
The American College of Obstetrics and Gynaecology (ACOG) guidelines are 
ambiguous and recommend either a FPG or OGTT at 6 weeks [62]. Although most 
international guidelines recommend an OGTT as the postnatal test of choice 
following GDM, there is considerable debate about replacing this with either FPG or 
HbA1c, due to poor uptake, cost, complexity and question of the real rationale for a 
OGTT [115, 116]. The latest NICE guidelines now categorically and unambiguously 
recommend either FPG or HbA1c but not an OGTT for postnatal screening[117]. 
The lack of consensus among recommendation is also reflected in clinical practice. 
A survey of ACOG fellows reported that only 50·8% of obstetricians used an OGTT 
for postnatal screening with 27·4% using FPG and the remaining relying on other 
tests [118]. Similarly, only 54% of practitioners in North Carolina reported using 
OGTT of the 27% of respondents who performed any form of postnatal screening 
for GDM [119]. A cross sectional survey of Australian women with a recent history 
of GDM women revealed use of various postnatal screening tests nationally, i.e. 
OGTT (56·4%), FPG (32·6%), capillary blood glucose (23.5%), random plasma 
glucose (6.1%), and HbA1c (2·4%) [120]. 
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While there is no doubt that FPG or HbA1c are one-step alternatives to a 
cumbersome and more expensive OGTT, it is not known whether using these tests 
to simplify postnatal screening would indeed improve uptake. Several studies also 
depict poor sensitivity of FPG to detect overall postnatal abnormalities [107]. This 
could especially be a problem in SA who are known to have a higher prevalence of 
postprandial abnormalities compared to WC [121]. Only a few studies have 
examined the sensitivity of the lowered definition of normal FPG of 5.6mmol/l to 
detect diabetes and IGT in populations with SA and other ethnic minority groups 
[122]. 
3.3 Aims and objectives 
The primary aim of this study is to compare the performance of FPG (according to 
WHO and ADA IFG criteria) with that of OGTT in the postnatal period, in a multi-
ethnic British population. We also assessed the change in uptake rates with postnatal 
HbA1c compared to OGTT in a sequential retrospective observational cohort study. 
3.4 Methods 
3.4.1 Subjects  
Routine clinical data from two independent cohorts of pregnant women were 
collected from across three NHS hospitals in the West Midlands (Coventry, 
Nuneaton and Warwick). A total of 14,477 pregnant women underwent OGTT as a 
part of their antenatal testing for GDM between 2009 and 2012. Of these, 8.9% of 
the women (n=1289) were diagnosed with GDM (OGTT cohort). Women in the 
OGTT cohort were requested to attend postnatal OGTT around 6 weeks postpartum.  
The second cohort (HbA1c cohort) contained 339 women with history of GDM, 
who delivered between Nov 2013 and Dec 2014. These women were recommended 
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to undergo a postnatal HbA1c instead of OGTT, following a change in clinical 
practice in one of the hospitals (Coventry). 
3.4.2 GDM screening and diagnostic criteria 
All these centres used the selective screening based on the risk factors recommended 
by NICE: BMI ≥ 30Kg/cm2, first-degree relative with diabetes, previous GDM, 
previous unexplained stillbirth, previous macrosomia (≥ 4.5 kg) or women of ethnic 
minority origin. Women meeting any one of the above criteria underwent a 75 g 
OGTT between 26-28 weeks. During this period all centres used the modified WHO 
1999 criteria for the diagnosis of GDM following a 75g OGTT: FPG ≥6.1mmol/l 
and/or 2-hour plasma glucose (2hPG) ≥7.8mmol/l. Obstetric and neonatal 
characteristics were obtained for all women undergoing an OGTT. BMI was 
measured at the booking visit.  
3.4.3 Definitions 
For the purpose of this study, ethnicity was grouped into South Asians (SA -Indian, 
Bangladeshi, Pakistani, Sri Lankan and Nepali), White Caucasian (WC - British / 
European) and Other (Chinese, Black, Middle Eastern, Mixed).  
Multiparity was defined as ≥2 live previous pregnancies that progressed beyond 24 
weeks gestation. Macrosomia was defined as BW≥4000g. 
3.4.4 Definitions of postnatal glucose abnormalities 
 Impaired glucose tolerance (IGT) was defined as a 2hPG ≥7.8 but <11.1mmol/l, 
with FPG <7.0mmol/l. IFG was defined either as FPG ≥5.6 or ≥6.1mmol/L as per 
the ADA and WHO definitions, respectively with 2hPG <11.1mmol/L. Isolated IFG 
(iIFG) was defined as IFG with normal 2hPG (<7.8mmol/L). Isolated IGT (iIGT) 
was defined as IGT with a normal FPG (ADA <5.6 or WHO <6.1mmol/L). Diabetes 
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was defined as either FPG ≥ 7.0 or 2hPG ≥ 11.1 mmol/l or both. We applied both 
the WHO and the ADA cut points for IFG to evaluate the performance of FPG 
compared to OGTT to detect postnatal abnormalities.  
3.4.5 Statistical methods 
Student’s t test and Chi square test were used to compare means and proportions 
respectively. Post hoc testing and Bonferroni adjustment was performed to enable 
comparisons between multiple groups. Receiver operating characteristics and 
sensitivity analysis were used to assess the performance of FPG to detect IGT and 
diabetes as diagnosed by OGTT. SPSS version 22.0 was used for analysis. 
3.5 Results 
3.5.1 Uptake rates with OGTT and HbA1c 
Baseline characteristics of the women who were invited for OGTT (OGTT cohort) 
are shown in table 4.  
630 (48.9%) women attended postnatal OGTT. 627 had full OGTT, 2 women had 
FPG >14mmol (hence OGTT was abandoned) and one had only FPG but did not 
complete the OGTT. The mean timing of postnatal OGTT was 9.39 ± 4.17 weeks 
post-delivery.  
 In Coventry, 213 (62.8%) women attended for postnatal HbA1c tests, compared to 
only 48.7% (381/783) for OGTT testing (p<0.0001).  The mean timing of post-
partum HbA1c testing was 16.21±9.65 weeks post-delivery. 
Comparisons of characteristics of women who attended and did not attend postnatal 
testing by OGTT and HbA1c are shown in the table 5. Women who failed to attend 
postnatal OGTT were younger and more likely to be smokers, multiparous and have 
macrosomic offspring compared to those who attended. There were no differences in 
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characteristics between women who attended and failed to attend postnatal HbA1c 
except a significantly higher proportion of SA compared to WC among the 
attenders. 
Table 4: Baseline characteristics of women invited for postnatal OGTT 
*Available data on variables in indicated by (n) for continuous variables and as a proportion for 
categorical variables. 
¥ 
  Post hoc testing revealed significant differences in proportions of WC and other minority ethnic 
groups only but not of SA.  
 
Table 5: Characteristics of women who attended and did not attend post-natal 
testing 
 
Baseline maternal characteristics obtained at booking and offspring birth weight of women who 
attended and failed to attend postnatal testing by both HbA1c and OGTT.  
* Data was available for 392 (62.2%) women. ¥ Data was available for 369 (55.9%) women.  
a BMI was available for 182 (85.4%) and 98 (77.7%) of women who attended and did not attend 
respectively 
b Height was available for 187 (87.7%) and 107 (84.9%) of  women who attended and did not attend 
respectively 
c Post-hoc testing revealed significant differences in the proportions of SA and WC only.  
Mean (SD) or % (n) for proportions 
Baseline characteristics Total n=1289 
Age in years  31.97 (5.50) (1288) 
BMI (kg/cm2) 29.64 (6.93) (n=761)* 
Height (cm) 162.45 (6.72) (n=761)* 
Multiparity (parity≥2) 26.3 (200/761) 
Smoking 9.2 (70/759) 
Macrosomia (>4 Kg) 9.2 (70/757) 
Ethnicity (WC; SA; others) 65.5; 27.2; 7.3  (n=1281)* 
 Mean (SD) or % (n) for proportions 
 OGTT cohort HbA1c cohort 
Attended 
(n=630) 
 
Not attended 
(n=659) 
 
P value Attended 
(n=213) 
 
Not attended 
(n= 126) 
 
P value 
Age 32.35 (5.25)  31.61 (5.7) 0.016 33.19 (5.09) 31.99 (6.18) 0.069 
BMI 29.64 (6.61)* 29.63 (7.26)
¥ 0.974 29.04 (6.79)a 29.66 (7.99)a 0.516 
Height 161.87 (7.02)* 163.07 (6.33)
¥ 0.013 161.96 (7.24)b 162.29 (6.03)b 0.671 
Smoking  4.9 (19/390) 13.8 (51/369) <0.0001 5.3 (11/207) 8.5 (10/118) 0.265 
Ethnicity    (WC; 
SA; others)  
64.4; 27.8; 7.8 
(627) 
66.5; 26.8; 6.7 
(654) 
0.654 43.5; 33.8; 22.7 
(207) 
58.7; 21.5; 19.8 
(121) 
0.02c 
Multiparity  
(Parity ≥ 2) 
21.0 (82/391) 31.9 (118/370) 0.001 46.4 (97/209) 49.2 (60/122) 0.626 
Macrosomia  
(≥4000g)  
5.9 (23/391) 12.8 (47/366) 0.001 8.6 (18/210) 8.0 (10/125) 0.855 
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3.5.2 Postnatal abnormalities with OGTT by ethnicity 
Table 6 shows the relative proportions of isolated FPG, isolated 2hPG and 
concomitant FPG and 2hPG abnormalities using both the ADA and WHO 
definitions of IFG.   
By WHO criteria of IFG: Seventy-eight (12.4%) had abnormal OGTT results. The 
overall prevalence of diabetes was 1.9%. iIGT was the most common abnormality 
accounting for 56.4% (44/78) of the abnormal results.  88% (44/50) of IGT and 
16.7% (2/12) of diabetes had normal FPG. On post-hoc testing, WC had 
significantly lower proportion of overall abnormalities (10% vs 19.2%, p<0.05) and 
isolated 2hPG abnormalities compared to the other minority ethnic group (5.0 vs 
15.4%, p<0.05). SA tended to have higher overall abnormalities (p=0.032) and also 
isolated 2hPG abnormalities (p = 0.02) compared to WC however on applying the 
Bonferroni correction this difference ceased to be significant. 
By ADA criteria of IFG: One hundred and fourteen (18.1%) had abnormal OGTT 
results. iIFG was the most common abnormality accounting for 45.6% (52/114) of 
the abnormal results. 64% (32/50) of women with IGT but none of those with 
diabetes had normal FPG. Again, WC had lower proportions of 2hPG abnormalities 
compared to the other minority ethnic group (3.2 vs 15.4%, p<0.05). SA tended to 
have higher overall abnormalities (p = 0.03) compared to WC but had similar 
proportion of 2hPG abnormalities to WC. 
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Table 6: Categories of postnatal abnormalities based on Fasting and 2hPG abnormalities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All categories also include diabetes (d) based on FPG, 2hPG values  
* Indicate significant difference between WC and other ethnic group in respective categories on post-hoc testing. 
 
  
Category of abnormality  Total population 
(629) 
 n (%) 
SA  
(174) 
n (%) 
WC  
(403) 
n (%) 
Others 
(52) 
n (%) 
p value 
WHO 
Normal 551 (87.6)  146 (83.9) 363 (90.0)* 42 (80.8)* 0.027 
Isolated FPG abnormalities   
(FPG≥6.1 & 2HPG<7.8) 
17 (2.7)  
(1d) 
4 (2.3)  
(0d) 
12 (3.0) 
(1d) 
1 (1.9)  
(0d) 
Isolated 2hPG abnormalities  
(2HPG≥7.8 & FPG<6.1) 
46 (7.3)  
(2d) 
18 (10.4)  
(0d) 
20 (5.0)* 
(2d) 
8 (15.4) * 
(0d) 
Both FPG and 2hPG abnormalities 
(2HPG≥7.8 & FPG≥6.1)  
15 (2.4)  
(9d) 
6 (3.4) 
(4d) 
8 (2.0) 
(5d) 
1 (1.9) 
(0d) 
ADA 
Normal 515 (81.9)  134 (77.1) 341 (84.6) 39 (75.0) 0.001 
Isolated FPG abnormalities  
(FPG≥5.6 & 2HPG<7.8) 
53 (8.4)  
(1 d) 
16 (9.2) (0d) 34 (8.4) (1d) 4 (7.7) (0d) 
Isolated 2hPG abnormalities  
(2HPG≥7.8 & FPG<5.6) 
32 (5.1) (0d) 
 
11 (6.3) (0d) 13 (3.2)* (0d) 8 (15.4)*  (0d) 
Both FPG and 2hPG abnormalities 
(2HPG≥7.8 & FPG≥5.6) 
29 (4.6)  
(11 d) 
13 (7.5) (4d) 15 (3.7) (7d) 1 (1.9) (0d) 
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Sensitivity analysis 
We conducted a ROC analysis to assess the ability of FPG to detect diabetes and 
IGT as defined by OGTT (figure 2). ROC analysis revealed that postnatal FPG was 
an excellent predictor of overall postnatal diabetes (AUC=0.983, CI: 0.966-1.00, 
p<0.0001) and in both SA and WC. FPG was a moderate predictor of IGT 
(AUC=0.697, CI: 0.620-0.773, p<0.0001). ROC curves with AUC for SA and WC 
are presented in figure 3 and 4 for IGT and diabetes respectively. 
The Sensitivity, specificity, positive predictive value (PPV) and negative predictive 
Value (NPV) of various postnatal FPG cut offs to predict postnatal IGT and diabetes 
are shown in table 7. FPG of 6.1mmol/l will miss up to 88% of IGT and 16.7% of 
diabetes. While FPG of 5.6mmol/l will detect 100% diabetes, it would miss 64% of 
IGT. Only 13% of women had a FPG≥5.6mmol/l. Therefore performing 
confirmatory OGTT only in those women with FPG ≥5.6mmol/l will reduce the 
need for OGTT by 87%. In order to obtain 100% sensitivity for detection of IGT, 
the FPG threshold will have to be lowered to 4 mmol/l, with over 98% of women 
needing a second confirmatory OGTT. 
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Table 7: Sensitivity analysis for various thresholds of FPG to detect IGT and diabetes 
 
Sensitivity, specificity, 
positive predictive value 
(PPV) and negative 
predictive value (NPV) 
of various thresholds of 
FPG to detect diabetes 
and IGT.  
* The proportion of women in the respective FPG ranges. 
 
Figure 2: Receiver operating characteristics curve for fasting plasma glucose concentrations to identify persistent postnatal glucose 
abnormalities  
                                                                                                    
a: FPG as a predictor of postnatal IGT        b: FPG as a predictor of postnatal  diabetes 
   AUC=0.697, CI: 0.620-0.773, p<0.0001                               AUC=0.983, CI: 0.966-1.00, p<0.00 
FPG threshold 
(mg/dl) 
 IGT Diabetes % meeting 
criteria* 
 Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV  
FPG ≥4.0 100.0 2.3 8.3 100.0 100.0 2.1 1.9 100.0 97.9 
FPG ≥4.5 94.0 24.3 9.9 97.9 100.0 22.9 2.5 100.0 77.5 
FPG ≥5.0 63.8 70.0 14.6 96.0 100.0 61.1 4.8 100.0 40 
FPG ≥5.6 36.0 90.8 25.7 94.1 100.0 88.7 14.6 100.0 13 
FPG ≥6.1 12.0 97.2 27.3 92.6 83.3 96.4 31.3 99.7 5.1 
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Figure 3: ROC curves for FPG to detect IGT by ethnicity 
                   
 
Figure 4: ROC curves for FPG to detect diabetes by ethnicity 
                                       
 
 
 
 
 
  a) WC: AUC: 0.705 (0.591, 0.819)   b) SA: AUC: 0.726 (0.610, 0.841)    c) Others: AUC: 0.623 (0.418, 0.829) 
                    p=0.002         p=0.001     p=0.256 
a) WC: AUC 0.983 (0.960, 1.000)                       b) SA: AUC 0.991 (0.974, 1.000) 
                    p<0.0001               p=0.001 
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3.6 Discussion 
3.6.1 Uptake rates with HbA1c and OGTT 
Our study involving a large multi-ethnic population of high-risk women with GDM 
showed that the uptake for OGTT was just under 50%, in agreement with world-
wide reported rates [107, 123]. Although reasons for the poor attendance for OGTT 
have not been not widely studied, time constraints of the OGTT were the most 
commonly cited reasons in surveys of GDM women [124]. It is possible that 
simplifying the postnatal test to a one-step FPG or HbA1c might improve uptake 
although direct evidence for this is lacking. The first 12-month data from one of our 
centres showed an encouraging increase in uptake with HbA1c. To our knowledge, 
we are the first to show that uptake rates for postnatal HbA1c were higher than that 
for OGTT. Women who failed to attend postnatal OGTT also had features of higher 
metabolic risk such as smoking, macrosomia and multiparity, despite a younger age. 
It was reassuring to note that unlike with postnatal OGTT, women who failed to 
attend HbA1c testing had similar metabolic risk characteristics to those who 
attended.  SA were more likely to attend postnatal HbA1c than WC. This is in 
agreement with previously summarised studies that non-WC ethnicity, especially 
SA were more likely to attend postnatal screening than WC. 
3.6.2 FPG as a postnatal test to detect diabetes 
Our study showed that FPG at the ADA definition of IFG of FPG≥5.6mmol/l had 
100% sensitivity to detect postnatal diabetes even in populations with SA and other 
ethnic minority groups. However, the NICE and WHO recommended definition of 
IFG at FPG ≥6.1mmol/l would miss 16.7% of diabetes. Whilst our data is in 
agreement with some studies reporting a high sensitivity of FPG at 5.6 mmol/l of 
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98-100% to detect diabetes [122, 125, 126], other studies have reported a lower 
performance of FPG [105, 127]. This variation in sensitivity is probably due to the 
variation in the screening and diagnostic criteria used to diagnose GDM, and hence 
in the population characteristics of the women screened. In our study about 4% of 
women with FPG between 5.6 and 7.0 mmol/l had 2hPG values diagnostic of 
diabetes (≥11.1mmol/l). Both the ADA and the WHO recommend that the diagnosis 
of diabetes in asymptomatic, high-risk population should not be based on a single 
test alone [128, 129]. Therefore we recommend that women with postnatal FPG ≥ 
5.6mmol/l, should have a confirmatory OGTT for diagnosis of diabetes. This will 
substantially reduce the need for OGTT by 87% (Table 7).  
3.6.3 FPG as a postnatal test to detect IGT 
On the other hand, despite the high sensitivity to detect diabetes, our study showed 
that FPG threshold of ≥5.6mmol/l and ≥6.1mmol/l would miss 64% and 88% of 
IGT, respectively. Such low sensitivity of FPG to detect IGT has been confirmed in 
other studies [107, 130]. In addition, our data also showed that iIGT was seen in a 
higher proportion of ethnic minority groups who were therefore more likely to be 
missed if FPG alone used for postnatal testing (Table 6). Older studies in non-
postnatal adults using a FPG cut off of ≥7.1mmol/l showed that 2hPG abnormalities 
were more common in SA than WC thereby limiting the utility of using FPG to 
detect concomitant IGT in SA at these thresholds [121]. Although SA had a greater 
proportion of 2hPG abnormalities this did not reach statistical significance probably 
owing to the small numbers in the groups.  
Do we really need to worry about missing isolated postnatal IGT following GDM? It 
has been argued that the real purpose of postnatal screening is to detect women with 
overt diabetes and not those “at risk of diabetes” such as IGT [115, 125]. The 
  
 
 77 
diagnosis of GDM already places these women in the category of those “at risk” of 
future diabetes thereby making postnatal detection of IGT redundant practice.  
On the contrary, it could be argued that a further risk stratification of GDM women 
in the postnatal period might help to identify a sub-group of women who may 
benefit more from lifestyle intervention and/or metformin. The post-hoc analysis of 
the DPP showed that both intensive lifestyle intervention and metformin therapy 
significantly reduced the risk of future diabetes risk in GDM women with postnatal 
IGT [131] compared to those without GDM. However this conclusion warrants 
closer inspection. Women in the DPP were at an average of 12 years post partum 
and did not have isolated IGT. Their mean FPG and HbA1c were 5.9 (SD: 0.5) 
mmol/l and 5.87 (SD: 0.5) % (29.7-51.6mmol/l), respectively, implying a significant 
overlap between IGT, IFG and pre-diabetes by HbA1c criteria. Therefore, this 
evidence cannot be extrapolated to assume direct benefit for isolated IGT in the 
immediate postpartum period. Additionally, such risk stratification can also be also 
performed using FPG or HbA1c. Thus both the ADA and the NICE guidance for the 
prevention of diabetes post GDM recommend metformin [132] and  intensive 
lifestyle intervention [132, 133] for women with IFG (FPG 5.6-6.9mmol/l) or pre-
diabetes using HbA1c (5.7-6.4%) (39 - 47 mmol/mol).  
Furthermore, the argument for detection of postnatal IGT for the purpose of 
intervention should be taken in context with the poor uptake of OGTT across the 
world. Not having any postnatal test would mean that a large number of women 
would miss the opportunity for postnatal risk stratification and hence engagement in 
any form of preventive intervention that has proven benefit. Therefore, we believe 
that persevering with a complex test with poor uptake rates for the sole purpose of 
detecting postnatal IGT is not justified.  
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The key strength of the study is the large sample size, and real-world evidence in a 
mixed ethnic population. Our study has important limitations. The newly proposed 
IADPSG or NICE criteria were not used for diagnosing GDM. Data from our study 
therefore cannot be extrapolated to populations where these criteria are already 
adopted for diagnosis GDM. However, several centres in Europe and most of the 
UK still follow the old WHO criteria for diagnosis [134] where our results will be 
relevant. Our study is observational and retrospective and therefore prone to missing 
data. Prospective randomised trials are needed to assess the real effect of FPG or 
HbA1c on uptake of postnatal screening and to inform the ideal timing of postnatal 
HbA1c in the context of antepartum treatment for GDM, postpartum anaemia and 
volume shifts during pregnancy.  
In conclusion, we welcome the new NICE recommendation to replace postnatal 
OGTT by FPG or HbA1c. Simplifying postnatal testing may improve uptake, enable 
further risk stratification and hence better engagement in further preventive 
strategies. However, the FPG threshold of ≥6.1mmol/l recommended by NICE 
should be lowered to the ADA defined threshold of ≥5.6mmol/l to improve 
detection of postnatal diabetes. FPG at this lowered cut off is a highly sensitive test 
to detect diabetes even in a population with SA.  
3.7 Future directions 
 Prospective randomised studies comparing the uptake rates of HbA1c and 
FPG with OGTT in a mixed ethnic population 
 Cost effectiveness analysis for long term follow up of women with GDM 
using HbA1C 
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 Exploring effectiveness of other interventions to improve uptake of postnatal 
testing – currently in the process of conducting a systematic review to apply 
for funding for Health-Technology-Appraisal (HTA) project. 
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4 Effect of maternal diabetes on offspring birth weight 
(BW) in SA and WC 
4.1 Abstract 
Background: Both gestational and pre-gestational diabetes are associated with 
adverse offspring outcomes particularly macrosomia, with a continuous relationship 
between glucose and birth weight (BW). This evidence from studies in White 
Caucasians (WC) is extrapolated to other ethnic groups, under the assumption that 
the relationship between maternal glycaemia and BW is uniform across ethnic 
groups. We compared the impact of maternal diabetes on BW between South Asians 
(SA) and WC. 
Methods: A Retrospective analysis was conducted for all SA and WC singleton, live 
births across Leicester from 1994-2002 (n=53,128). Ethnic specific BW z-scores 
and centiles were derived from this dataset. The increase in BW and the odds-ratio 
of large-for-gestational-age with maternal diabetes was compared between SA and 
WC using regression analyses with interaction terms.  
Results: SA had a higher prevalence of both GDM (SA vs WC: 2.9% vs 0.8%, 
p<0.0001) and pre-gestational diabetes (SA vs WC: 0.6% vs 0.4%, p<0.0001) than 
WC. Both gestational and pre-gestational diabetes were significant predictors of 
offspring BW and LGA after adjustment for confounding maternal characteristics. 
The increase in offspring BW with pre-gestational diabetes was 139.24g lower in 
SA compared to WC (p=0.034 for interaction). Similar results persisted with ethnic 
specific BW z-scores. (p=0.013 for interaction). The effect of maternal GDM on 
BW and LGA was similar across both ethnic groups. 
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Conclusion: The relationship between maternal diabetes and BW differs with 
ethnicity. The increase in BW with pre-gestational diabetes was significantly lower 
in SA. Our results emphasize the need for ethnic specific glycaemic targets in 
pregnancy. 
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4.2 Introduction 
The prevalence of diabetes among women of childbearing age and the incidence of 
gestational diabetes mellitus is increasing alongside the epidemic of type 2 diabetes 
(T2D) and obesity[5] [135] [12] [13]. This is especially higher in certain ethnic 
minority populations[136].  South Asians (SA) have a 2-4 fold higher risk of T2D 
and GDM compared to White Caucasians (WC) [12] [137] [138] [139]. While the 
prevalence of T2D doubled in the USA over 40 years[140], this has tripled in Indian 
populations in just 14 years[141]. Studies in the UK also show an alarming increase 
in the incidence of T2D in young people with a three-fold higher prevalence in SA 
compared to WC [38]. 
Poorly controlled maternal diabetes and GDM are known to be associated with a 
number of perinatal complications such as macrosomia, congenital malformations 
and increased perinatal mortality[9, 142] with evidence of a continuous relationship 
between maternal glucose and adverse offspring outcome[9, 143]. Most evidence for 
this risk comes from studies in WC[9, 142, 143]. In fact, the International 
Association of Diabetes and Pregnancy Study Groups (IADPSG) based the 
definition of GDM on glycaemic thresholds of increased risk of large for gestation 
age (LGA), increased cord C-Peptide and adiposity observed in the Hyperglycaemia 
and Adverse Pregnancy Outcomes (HAPO) study
11
. Despite their significantly 
higher metabolic risk, SA were poorly represented in the HAPO group, except for a 
cohort of South East Asian women from Singapore[9]. The IADPSG criteria to 
define GDM were therefore based on the questionable assumption that the effect of 
glucose on birth weight is uniform across different ethnic groups. Furthermore, 
similar glycaemic targets are set in pregnancy (both GDM and pre-gestational 
diabetes) for all ethnic groups under the same premise.  
  
 
 83 
 
However, there is emerging evidence that the magnitude of the impact of maternal 
glycaemia on offspring size may differ with ethnicity. Maternal diabetes results in a 
larger increase in birth weight (BW) and increased odds of LGA in Blacks despite 
their overall lower mean BW[18, 81, 144, 145] when compared to non-Hispanic 
Whites. While the odds of macrosomia in WC was 2.5 fold higher in mothers with 
diabetes compared to those without, the corresponding odds were 6 fold higher in 
Blacks[144], suggesting that ethnicity significantly modified the relationship 
between maternal glycaemia and BW.  
Conversely, despite higher levels of maternal glycaemia [146-148], SA offspring are 
amongst the smallest babies in the world [13, 149-151]. A few studies have 
compared the impact of GDM on BW between SA and WC with conflicting results. 
Table 1 shows a summary of all the relevant studies comparing the impact of 
maternal diabetes on BW across ethnic groups. These studies lacked appropriate 
adjustment for maternal characteristics [148, 152], failed to use ethnic specific BW 
centiles [137, 145, 149] or included a heterogeneous ‘Asian’ population that 
included both SA and South East Asians [14, 15, 137]. Only one study examined the 
effects of pre-gestational diabetes on offspring BW in SA and WC, but used the 
same population centiles for both ethnic groups and included a heterogeneous Asian 
population[149].  
Our aim was to compare the impact of both pre-gestational diabetes and GDM on 
offspring BW between SA and WC in a large population based, bi-ethnic pregnancy 
cohort from Leicestershire, UK
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Table 1: Summary of literature comparing the impact of maternal diabetes on offspring birth weight
 Subjects Maternal 
diabetes  
type 
Key results Confounding variables adjusted for SA 
included 
Ethnic 
centiles 
Contr
ols 
Xiang [153]  29,544 women (9 ethnic 
groups) 
GDM LGA in Asians*: RR: 1.24 (0.98, 1.58), p =0.07 (WC reference) 
*Heterogeneous group including SA 
Maternal age, education, insurance type, presence of comorbidity, 
pre-eclampsia/eclampsia, anti-hyperglycemic drug use, smoking, 
BMI, gestational weight gain. 
Yes*  Yes No 
Hedderson[14]  n =7648 (SA & WC) GDM Odds of LGA in Asian* 1.19 (0.98, 1.46) (Ref WC) 
*Heterogeneous group including SA 
Parity, age, gestational age, education, BMI, sex, medication Yes* Yes No 
Mocarski[145]  536,084, 4 Ethnic groups  GDM Adjusted OR of macrosomia SA: 1.1 (0.9, 1.2), WC: 1.1 (1.0, 1.2). Maternal age, being foreign born, insurance, education, parity, 
tobacco use during pregnancy, and pre-pregnancy weight. 
Yes No Yes 
Makgoba [154]  130 549 (SA, Blacks WC) GDM Prevalence of LGA in SA vs WC 9.2% vs 18.8% (p<0.001) None. (Adjustment made only for analysis of effects of BMI) Yes No Yes 
Rosenberg[149]  329 988 (4 ethnic groups) GDM and pre-
gestational 
Diabetes 
Adjusted OR for low birth weight (LBW) in Asian* vs WC: 
Pregestational 2.28 (1.42, 3.68) vs 1.59 (1.01, 2.05)  
GDM: 1.17 (0.99, 1.39) vs 1.06 (0.87, 1.28). Only LBW was 
reported. *Heterogeneous group including SA 
Maternal age, marital status, mothers education, birth place, 
prenatal care, parity, social risk, pre-pregnancy weight, pregnancy 
weight gain, hypertension and pre-eclampsia 
Yes No Yes 
Dunne[152]  312 WC and 128 Indo-Asian GDM, T2DM, 
T1DM 
Prevalence of 25% LGA in SA vs 37% in WC. No OR/RR reported. None Yes No No 
Nguyen [137]  32,193 – North California GDM OR for LGA in Asian* compared to WC 0.40 (0.33, 0.48). 
*Heterogeneous group including SA 
Maternal age, obesity, education, prenatal care, nulliparity and 
hypertension.  
Yes No No 
Wong[148]  5 Ethnic groups (n=869) GDM Prevalence of LGA: SA vs WC- 11.0 vs 13.9 (p: non significant) None Yes Yes No 
Dalfra[155]  Native Italian and immigrant  GDM Adjusted OR for LGA. Immigrants vs Native Italian 1.63 (0.97, 
2.74), p=0.06 
Age, pre-pregnancy BMI, Insulin therapy, Weight gain in 
pregnancy, 
No Yes No 
Homko [156]  103 African and 36 Latino GDM Higher risk of macrosomia in Latino compared to African (RR = 
2.68) 
BMI, weight gain, Glycaemic control, therapy. No No No 
Kieffer[144]  Blacks and Whites: 
111,044 infants of diabetic 
mothers and 
5,008,970 infants of non-
diabetic mothers 
GDM and T2D 
and T1D 
Offspring weight gain with maternal diabetes: Black vs Whites: 220g 
vs 96g, adjusted OR of macrosomia: Blacks: 3.24 (95% CI 3.09–
3.38), WC: 1.66 (95% CI 1.63–1.68). 
Gestational age, maternal hypertension status, prenatal 
care use, and maternal socio-demographic characteristics. No BMI 
adjustment. 
No No Yes 
Hunt [18]  92,233 NHB and 151,957 
NHW births 
GDM and pre-
gestational 
Diabetes 
Adjusted RR for LGA: GDM: NHW vs NHB: 1.21 (1.15, 1.29) vs 
1.94 (1.77, 2.13). Pre-gestational diabetes: NHW vs NHB: 1.61 
(1.48, 1.76) vs 2.22 (1.98, 2.49) 
Maternal age, offspring sex, BMI, maternal tobacco use, 
hypertension status, education and prenatal care 
No No Yes 
Sandana[81]  1190 WC and 865 Blacks GDM and IGT Adjusted OR for LGA: WC vs Blacks: 1.4 (0.7–2.7) vs 1.6 (0.6–4.2) Pre-pregnancy BMI, age and height No Yes Yes 
D 
Simmons[157]  
529 European, 540 Maori, 
916 Pacific Islanders 
Normal Glucose 
tolerance 
Population attributable fraction (PAF) for relationship of macrosomia 
with maternal glycaemia: Europeans vs Maori vs Pacific: 16.7 vs 
17.0 vs 18.7%, p  = 0.567. 
Gestational age, smoking and maternal weight tertiles No No NA 
Scholl et al[158] 
et al 
African-American (n = 
1,040), Hispanic (n = 750), 
White 
(n = 282) 
Normal Glucose 
tolerance 
Adjusted β for relationship between BW & Maternal glucose level 
(mg/dl) African American: 1.56 (0.63 0.34), Hispanic: 2.19 (0.66 
0.89), White: 1.98 (0.95 0.11). 
Age, parity, smoking (cigarettes/day), pregravid BMI, gestational 
weight gain, clinic payment status, a prior low birth weight infant, 
and duration of gestation 
No No NA 
Farrar et al [82] 9509 women (4821 SA and 
3888 WC) 
Normal Glucose 
tolerance 
Relationship between BW LGA and glycaemia not significantly 
different between SA and WC (interaction term 0.90) 
Gestational age at oral glucose tolerance test, family history of 
diabetes, family history of hypertension, previous GDM, previous 
macrosomia, smoking status, alcohol consumption during 
pregnancy, maternal age and BMI, maternal education, baby sex, 
and parity. 
Yes No NA 
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4.3 Methods 
A retrospective analysis of all deliveries between 1994-2006 was conducted across 
Leicester Royal Infirmary (1994-2002) and University Hospitals of Leicester (2002-
2006). Detailed maternal demographic and offspring data was extracted from 
routinely collected electronic booking and delivery records respectively. Only term, 
singleton, live births from WC and SA pregnancy were included for this analysis. 
Pre-term deliveries (less than 37 weeks of gestation) were excluded because of the 
possibility of alternate underlying pathology. Pregnancies coded as “diabetes 
developed in pregnancy” were considered as GDM and “diabetes before pregnancy” 
as pre-gestational diabetes. 
4.3.1 Data Cleaning 
The original data set comprising of 92, 685 deliveries from the original excel file 
containing 32 variables was cleaned as explained in the flow chart below. 
 
 
 
  
Original birthweight Dataset 
N = 92,685, 32 variables 
Identify 12 predictor variables for cleaning 
 Sex of baby 
 Gestational period 
 Ethnicity of baby 
 Height of mother (use to calculate BMI) 
 Weight of mother (use to calculate BMI) 
 Postcode (use to calculate IMD, rural/urban indicator) 
 Age of mother at delivery 
 Gravida 
 Parity 
 Whether the mother smoked during pregnancy 
 Whether mother had diabetes during pregnancy 
 Blood pressure (diastolic and systolic) 
Data exported and merged from Excel sheets 
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Clean postcode 
Match with IMD using census data at 
http://geoconvert.mimas.ac.uk 
N = 57, 458 
Clean smoking status 
Unknown n = 21, 306, assume non-smoker 
N = 57, 458 
Extract diabetes from medical problems 
N = 57, 458 
Only look at Indian and White ethnicity 
N = 53, 128 (final) 
 
        
  
Clean ethnicity 
N = 77, 254 
Clean blood pressure 
36,039 missing data (ignored) 
Clean mother height 
N = 69,103 
Clean mother weight 
N = 57, 879 
Clean gestational age 
N = 57, 782 
Clean age at delivery 
N = 57, 779 
Clean gravida 
N = 57, 750 
Clean sex of baby 
N = 57, 748 
Clean outcome (birth weight) 
N = 57, 735 
Clean parity 
51,599 missing data (ignored) 
 Majority of data lost during ethnicity and 
mother’s weight/height cleaning 
 During ethnicity cleaning we lose data from 
LRI 1994, LRI 1995 and half of data from LRI 
1996 (no such pattern with height, weight of 
mother) 
 If we decide to reinstate parity or blood 
pressure at the end we lose another 22,867 or 
20,304 respectively. Or about 30,000 if we 
include both 
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4.3.2 Definitions  
SA were defined as women of Indian, Pakistani, Sri Lankan, Nepali and 
Bangladeshi origin. LGA and SGA were defined as birth weight ≥90th centile and 
≤10th centile respectively using gestational age, ethnicity and sex standardised z 
scores. L, M and S values derived from this dataset were used to calculate ethnicity 
specific BW z scores as described previously[159]. In brief the L (Box-Cox power), 
M (median) and S parameters were estimated using the GAMLSS package in R 
version 2.9 as recommended by the World Health Organization (WHO). This 
method uses smoothed values of L, M and S to transform the observed distribution 
of birth weights to a standard normal distribution [160].  
Multiparity was defined as parity more than two, i.e. two or more live births beyond 
24 weeks gestation. Data on parity was incomplete hence gravidity was used to 
calculate parity, when parity was not available, under the assumption that previous 
pregnancies were singleton and progressed beyond 24 weeks. Obesity was defined 
was BMI ≥30kg/cm2. Ethnicity specific obesity definitions were also used where 
appropriate[161], depicted by obesity
e
. Obesity
e was defined as BMI ≥27.5kg/cm2 
for SA and BMI ≥30kg/cm2 for WC.  
Relative levels of deprivation scores were calculated using the The English Indices 
of Deprivation 2004 from the Department for Communities and Local 
Government[162] . IMD ranks were split into standard quintiles for the purpose of 
all analysis according to national standards with quintile 5 being the most deprived 
and 1 being the least deprived.  
4.3.3 Screening and definition of GDM 
During this period risk factor based selective screening was performed using any 
one of the following criteria: Previous macrosomia (offspring BW ≥4.5kg), booking 
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weight ≥85kg, family history of diabetes, previous GDM or a diagnosis of 
polycystic ovarian syndrome. The diagnostic criteria varied during the study period: 
1994-1999: FPG ≥5.8mmol/l or 2hPG ≥8.5mmol/l, 2000 - 2006: FPG ≥5.5mmol/l or 
2hPG ≥ 8.0mmol/l. 
4.3.4 Statistical analysis 
Student-t test and Chi
2
 test were used to compare continuous variables and 
proportions between ethnic groups. Multivariable linear and logistic regression 
models were used with birth weight and LGA as outcome variables to study the 
predictors of birth weight. Interaction terms between ethnicity and diabetes were 
calculated to assess the differential role of diabetes on birth weight in the two ethnic 
groups. Statistical significance was set at the 5% level. SPSS version 22.0 was used 
for analysis. 
4.4 Results 
A total of 88,606 deliveries were recorded during this time period. We limited our 
analysis to the two main ethnic groups i.e SA and WC, because of small numbers in 
other ethnic groups. A complete dataset on all variables of interest was available for 
a total of 53,128 singleton, term and live births of WC or SA origin over a period of 
13 years.  SA and WC comprised of 15.9% and 84.1% of the whole population.   
There were significant differences between SA and WC with respect to most 
maternal and offspring characteristics with the exception of offspring sex and 
multiparity (Table 2). Overall SA were younger, shorter, had lower BMI, less likely 
to be smokers, had a higher prevalence of maternal diabetes (GDM and pre-
gestational diabetes), had lower offspring BW with lower proportion of macrosomia 
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and higher proportion of LBW. SA were more likely to live in deprived 
neighbourhoods compared to WC. 
The baseline characteristics of women with GDM and pre-gestational diabetes split 
by ethnicity are shown in Table 3. The proportion of LGA and SGA infants did not 
differ between the SA and WC in either in GDM or pre-gestational diabetes. Ethnic 
differences in height, BMI, smoking, obesity and deprivation seen in the general 
pregnant population persisted even among women with diabetes. 
 
Table 4 depicts the predictors of BW, LGA and SGA in both ethnic groups using 
simple linear and logistic regression analyses. After adjustment for age, height, 
BMI, year of birth, multiparity, smoking and deprivation maternal diabetes was an 
independent predictor of BW, associated with a significant increase in BW and the 
odds of LGA in both SA and WC. However, the increase in BW and odds of LGA 
with maternal diabetes differed in the two ethnic groups. To investigate this further, 
we subdivided maternal diabetes into GDM and pre-gestational diabetes, and studied 
their interactions with ethnicity (Table 5). 
Table 5 shows the increase in BW and odds of LGA with both GDM and pre-
gestational diabetes in both ethnic groups. Both GDM and pre-gestational diabetes 
was associated with an increase in offspring weight in both ethnic groups. The effect 
of pre-gestational diabetes on offspring BW was more marked than that of GDM.   
4.4.1 Interactions of maternal diabetes with ethnicity 
Compared to pregnancies without diabetes, the BW increase seen with pre-
gestational diabetes was 139.24g lower in SA compared to WC, after adjusting for 
year of birth, maternal age, BMI, height, IMD rank, multiparity, smoking status and 
offspring gestational age and sex (Table 5, p=0.034 for interaction effect). A similar 
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difference was seen in the effect of pre-gestational diabetes on BW z scores between 
the two ethnic groups (0.378 points lower in SA; p=0.013 for interaction effect; 
Table 5). The OR for LGA in SA with pre-gestational diabetes was 1.7 fold lower 
than the corresponding OR in WC (3.69 vs 5.49, Table 5). However, this interaction 
term did not reach statistical significance (p=0.103 for interaction effect).  
The analysis of BW in the GDM group showed that the BW gain was 31.9g lower in 
SA after adjustment as above. Similar, trends were seen with BW z scores and LGA 
rates in SA with GDM, but the interaction did not reach statistical significance in 
any of these analyses (Table 5). 
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Table 2: Baseline maternal and offspring characteristics by ethnicity 
 
 SA (n = 8471) WC (n = 44657) P 
Age 28.1 (5.08) 28.6 (5.806) <0.0001 
Height 158.2(6.38) 164.3(6.78) <0.0001 
BMI 23.5(4.64) 24.9(5.3) <0.0001 
Obesity  9.1 (775) 14.1 (6291) <0.0001 
Obesitye 17.2 (1457) 14.1 (6291) <0.0001 
IMD 1 (least 
deprived) 
11.4 (964) 29.8 (13299) 
 
2 10.3 (875) 20.9 (9327) 
3 13.3 (1129) 15.0 (6687) 
4 32.5 (2755) 14.8 (6611) 
5 (most 
deprived) 
32.4 (2748) 19.6(8733) 
Smoking 1.6 (139) 19.2 (8580) <0.0001 
Gestational Diabetes 2.9 (247) 0.8 (375) <0.0001 
Pre-existing diabetes 0.6 (55) 0.4 (160) <0.0001 
Multiparity  34.7 (5528) 35.4 (28866) 0.275 
Birth weight 3102.4 (453.36) 3444.6 (487.66) <0.0001 
Gestational age 277.2 (8.1) 279.6 (8.28) <0.0001 
Sex of baby m:f % 50.6: 49.4 51.6: 48.4 0.700 
Macrosomia (>4000g) 2.9 (249) 12.6 (5639) <0.0001 
Low birth weight (LBW) 
(<2500g) 
8.5 (722) 2.6 (1154) 
<0.0001 
 
Data are presented as mean (SD) or % (n) for continuous and categorical variables respectively. 
Comparisons between ethnicities are made using the Student t-test for continuous variables and the 
Chi-Squared test for categorical variable 
 
Table 3: Baseline maternal and offspring characteristics by type of maternal 
diabetes in SA and WC 
 
 SA (247) WC (375) 
 
p SA (55) WC (160) 
 
p 
GDM mean (SD) or % Pre-gestational diabetes 
Age 31.7 (4.9) 31.3 (5.8) 0.391 30.58 (5.51) 29.77(5.27) 0.342 
Height 156.9 (5.94) 163.4(6.80) <0.0001 157.63 (5.92) 164.13 (6.59) <0.0001 
BMI 27.8 (5.9) 30.3 (7.3) <0.0001 27.27 (5.89) 28.43 (6.22) 0.219 
Smoking 1.6 10.9 <0.0001 1.8 16.9 0.004 
Multiparity 46.6 43.2 0.410 40 40 1.000 
Obesity 34.0 47.2 0.001 27.3 31.3 0.580 
Obesity
e
 47.8 47.2 0.889 45.5 31.3 0.057 
BW 3309.6 (540.4) 
3634.8 
(591.5) 
<0.0001 3270.9(599.5
) 
3671.1(577.1
) 
<0.0001 
Gestational 
age 274.2 (6.9) 273.2 (7.5) 
0.090 270.9 (5.7) 269.4 (6.7) 0.103 
LGA 26.3 31.5 0.168 27.3 40.6 0.077 
SGA 3.2 5.9 0.134 3.6 3.8 0.969 
IM
D 
1 10.5 30.7 <0.0001 7.3 23.1 0.016 
2 8.5 21.6 14.5 21.9 
3 12.1 12.0 14.5 13.8 
4 32.0 16.0 29.1 14.4 
5 36.8 19.7 34.5 26.9 
 
Data are presented as mean (SD) or % (n) for continuous and categorical variables respectively. 
Comparisons between ethnicities are made using the Student t-test for continuous variables and the 
Chi-Squared test for categorical variable 
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Table 4: Predictors of birth weight by ethnicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table shows results of multivariable linear (BW z scores) and logistic (LGA, SGA) regression for studying the predictors of BW, LGA and SGA. Age, height and BMI were treated as 
continuous variables. Diabetes is any diabetes in pregnancy including GDM and pre-gestational. IMD was divided into quintiles as described in methods section. In linear regression: β 
coefficient represents change in BW per quintile change in IMD. In logistic regression IMD quintile 1 (least deprived quintile) was used as reference category.  OR represents the Odds of LGA 
and SGA in IMD quintile 5 (most deprived) compared to IMD quintile 1 (least deprived). 
 
Table 5: Effect of GDM and pre-existing diabetes on BW and LGA in SA and WC 
 Controls (mothers without 
diabetes) 
Pre-existing diabetes Gestational diabetes 
  SA WC SA WC 
BW*: β (95% CI) 0.00 (ref) 263.436 (153.665, 373.208) 402.677 (338.245, 467.109) 212.232 (159.582, 264.883) 240.133 (197.672, 282.594) 
BW z score:  β (95% CI) 0.00 (ref) 0.610 (0.354, 0.866) 0.987 (0.837, 1.137) 0.466 (0.343, 0.589) 0.571 (0.472, 0.669) 
LGA: OR (95% CI) 1.00 (ref) 3.69 (1.660-5.672) 5.488 (3.926, 7.670) 2.697 (1.984, 3.667) 2.825 (2.231, 3.577) 
Table shows results of multivariable linear (BW and BW z scores) and logistic regression (LGA) using GDM and pre-gestational diabetes as covariates in separate models.  
β and OR represent adjusted β coefficients and Odds Ratios of outcome in women with diabetes compared to controls as reference. All models included adjustment for year of birth, maternal 
age, height, BMI, IMD rank, multiparity and smoking status. LGA are >90th centile for gestational age, sex and ethnicity.* Adjusted for above and gestational age and sex of baby.  All values 
are significant with p <0.0001.   
 
Birth weight Z scores LGA  SGA 
SA WC SA WC SA WC 
β coeff (95% CI) p 
β coeff (95% 
CI) 
p 
OR 
p 
OR 
p 
OR 
p 
OR 
p 
Year 
-0.006 
(-0.12, 0.0) 0.06 
0.001 
(-0.001,0.003) 
0.454 
0.992 
(0.970,1.14) 0.456 
0.997 
(0.989, 1.006) 0.513 
1.011 
(0.989, 1.033) 0.340 
0.995 
(0.987, 1.004) 0.279 
Age 
0.004 
(0.0-0.08) 0.109 
0.004 
(0.003, 0.006) 
<0.0001 1.024 
(1.007, 1.041) 0.005 
1.019 
(1.012, 1.025) 
<0.0001 1.007 
(0.990,1.024) 0.400 
1.005 
(0.999, 1.11) 0.110 
Height 
0.032 
(0.28, 0.35) <0.0001 
0.031 
(0.029, 0.032) 
<0.0001 1.071 
(1.058, 1.084) <0.0001 
1.066 
(1.061, 1.071) 
<0.0001 0.946 
(0.934, 0.957) <0.0001 
0.945 
(0.940, 0.949) <0.0001 
BMI 
0.042 
(0.37, 0.46) <0.0001 
0.036 
(0.035, 0.038) 
<0.0001 1.095 
(1.079, 1.111) <0.0001 
1.080 
(1.074,1.086) 
<0.0001 0.916 
(0.897, 0.935) <0.0001 
0.943 
(0.936, 0.950) <0.0001 
Multiparity 
0.198 
(0.245, 0.151) <0.0001 
0.160 
(0.180, 0.140) 
<0.0001 1.423 
(1.206, 1.679) <0.0001 
1.385 
(1.293, 1.483) 
<0.0001 0.701 
 (0.584, 0.842) <0.0001 
0.780  
(0.725, 0.840) <0.0001 
Diabetes in 
pregnancy 
0.486 
(0.372, 0.601) <0.0001 
0.661 
(0.578, 0.774) 
<0.0001 2.660 
(1.988,3.559) <0.0001 
3.413 
(2.812, 4.141) 
<0.0001 0.496  
(0.268, 0.918) 0.026 
0.671  
(0.456, 0.989) 0.044 
Smoking 
-0.267 
(-0.429,-0.106) 0.001 
-0.323 
(-0.347,0.299) 
<0.0001 0.682 
(0.357, 1.30) 0.245 
0.571 
(0.516, 0.632) 
<0.0001 1.451  
(0.849, 2.482) 0.174 
2.131  
(1.975, 2.300) <0.0001 
IMD   
-0.017 
(-0.001, 0.033) 0.035 
-0.044 
(-0.037, -0.05) 
<0.0001 1.0 
(0.768, 1.303) 0.999 
0.701 
(1.284, 1.585) 
<0.0001 1.394 
(1.053, 1.845) 0.020 
1.59 
(1.43, 1.75) <0.0001 
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4.5 Conclusion 
Our study depicts important differences in characteristics of SA and WC pregnant 
women. Overall SA were younger, shorter, had lower BMI, less likely to be 
smokers, had a higher prevalence of maternal diabetes (GDM and pre-gestational 
diabetes), had lower offspring BW with lower macrosomia rates and higher rates of 
LBW. In line with literature especially in the UK and the midlands[163], it was 
noted that SA with and without diabetes tended to live in more deprived 
neighbourhoods than WC. More than a third of SA lived in the most deprived 
neighbourhoods compared to just under a fifth of WC. 
4.5.1 Pre-gestational diabetes 
Pre-gestational diabetes was associated an increase in BW and LGA risk in both 
ethnic groups. Our study shows that ethnicity significantly modulates the impact of 
maternal diabetes on offspring BW. The increase in BW attributable to pre-
gestational diabetes was lower in SA compared to their WC counterparts after 
adjustment for likely confounding maternal variables including deprivation (Table 
5). This corresponds to 11.7% and 8.5% of the mean BW in WC and SA, 
respectively. This result was also confirmed using ethnic specific BW z scores. The 
odds of LGA with pre-gestational diabetes also tended to be lower in SA compared 
to WC, however this difference did not reach statistical significance (Table 5). We 
believe that our results from the linear analysis of BW and BW z scores reflect a true 
difference between ethnic groups and the lack of differential effect on LGA could 
simply be the result of thresholds chosen to define LGA.  
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Only two other studies have compared the effects of pre-gestational diabetes on 
offspring BW, with only one including SA. Both were conducted in American 
population. Hunt et al showed a higher risk of LGA with pre-gestational diabetes in 
Blacks compared to WC, (RR of LGA compared to controls: WC vs Blacks: 1.61 vs 
2.22)[18]. Rosenberg et al reported higher odds of LBW in a heterogeneous 
population of ‘Asian’ women compared to WC[149]. Both these studies used crude 
BW and did not use ethnic specific centiles (Table 1).  
To the best of our knowledge our study was the first to systematically compare 
between SA and WC, the impact of pre-gestational diabetes on birth weight and 
LGA risk, using ethnic specific centiles. Contrary to what was seen in Blacks in the 
literature presented above[18], our study showed that pre-gestational diabetes had a 
lower effect on BW in SA after adjusting for important maternal variables including 
deprivation. The reasons for this differential effect of diabetes on BW in different 
ethnic groups are unclear. We believe that these are independent effects of maternal 
ethnicity on BW, not mediated by smaller maternal size or deprivation. Other less 
studied factors such as inflammation or vascular dysfunction in diabetes that occur 
more commonly in SA [164] could in addition play a role in determining the effect 
of diabetes on BW. 
4.5.2 GDM 
The effect of GDM on BW or LGA did not differ between SA and WC. The overall 
BW increase and odds of LGA in offspring of GDM mothers was lower than that 
seen with pre-gestational diabetes in both ethnic groups.  
Our results are in agreement with three of four studies that reported that the odds of 
LGA in SA [14, 145, 153] was similar to WC. Nguyen [137] et al reported lower 
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odds of LGA but in a heterogeneous ‘Asian’ population compared to WC, using 
unadjusted BW centiles. 
We present a summary of the literature examining the effects of GDM, pre-
gestational diabetes on BW across ethnic groups and the associated mechanistic 
flaws associated with them, to summarise why our study provides unique 
complementary data to support previous observations (Table 1). Firstly, they failed 
to adjust for maternal size [148, 152], which is a well-recognised predictor of 
offspring BW. Secondly, several studies used crude BW and did not use ethnic 
specific centiles[137, 145, 149]. Thus they failed to account for the constitutional 
“smallness” or “largeness” of certain races, wrongly attributing this to pathological 
influences such as diabetes. Finally, many lacked a control population without 
diabetes making it was difficult to compare the BW increase attributable to diabetes 
across ethnic groups[14, 137]. The two studies that adjusted for maternal 
characteristics and used ethnic specific centiles included a heterogeneous “Asian” 
group without clear separation of South East Asians from South Asians [14, 153].  
Of the three studies [158, 165] that examined the effect of maternal glycaemia on 
BW in women with normal glucose tolerance between ethnicities, only one recent 
cohort included women of SA ethnicity [82]. There was no significant interaction 
between ethnicity and maternal glycaemia with respect to BW as an outcome. It is 
likely this difference was not apparent in GDM because of the milder degrees of 
glucose intolerance and a shorter duration of hyperglycaemia compared to diabetes. 
We believe that ours is the first study to examine the effects of both GDM and pre-
gestational diabetes separately in SA and WC, accounting for all above-mentioned 
mechanistic issues.  
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The strengths of our study are its large size and long period of study spanning over 
12 years, in a region of the UK with a large SA population. Limitations of our study 
include its retrospective nature, hence its liability to coding errors and incomplete 
data. There was no data on type of pre-gestational diabetes (type 1 or type 2), 
glycaemic control, details of treatment or maternal weight gain in pregnancy. Data 
on BP was incomplete and hence was omitted form analysis. In addition, the country 
of birth of the SA women was not available, which would have helped understand 
the effect of migration on adverse metabolic risk better. 
Implications of these findings are several. The results of our study question the 
traditional glucocentric goal of management of maternal diabetes, wherein intensive 
glycaemic control is advocated to all mothers. There is evidence to show that such 
intensive glycaemic control in pregnancy may increase the risk of SGA [166]. Early 
induction and tight control of maternal diabetes may further increase SGA risk and 
adversely impact future offspring health in SA, who are already known to be smaller 
at birth. Ethnic specific glycaemic goals should be considered based on the impact 
of maternal glycaemia on offspring BW. Our study provides further support to the 
argument of taking into account fetal size [167] when optimising glycaemic control 
in pregnancy. 
4.6 Future Directions 
 Further randomized prospective studies are needed to assess the impact of 
glycaemia of offspring BW in SA and WC, to guide management targets in 
the two ethnic groups 
 The above studies could examine not only overall BW but also objective 
measures of infant body composition and adiposity eg densitometry. 
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 The impact of insulin on metformin on offspring body weight and adiposity 
should be studied in different ethnic groups to individualize treatment goals. 
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5 Ethnic differences in fetal growth in GDM: 
5.1 Abstract 
 
Background: The effect of maternal diabetes on offspring BW is not uniform across 
ethnic groups. BW is however a crude composite outcome of fetal growth. The 
growth of individual fetal parameters in GDM has not been compared between 
ethnic groups. We aimed to study differences in fetal growth between SA and WC in 
GDM pregnancies. 
Methods: A retrospective study of pregnancies with GDM between 2009 & 2012 of 
White Caucasian or South Asian ethnicity from University Hospital Coventry & 
Warwickshire in the West Midlands of the United Kingdom. Fetal growth 
parameters i.e. Head Circumference [168], Abdominal Circumference (AC), and 
Femur Length (FL) at 28, 32 and 36 weeks were recorded for all women.  
Results: 177 WC and 160 SA were included in the analysis. SA mothers were 
shorter had lower BMI and multiparous compared to WC.  SA had lower AC at 28, 
32 and 36 weeks compared to WC, but other skeletal parameters such as FL and HC 
remained similar to WC. SA also had higher HC/AC and FL/AC ratios, with HC/AC 
remaining > 1 even at 36 weeks.  
Conclusions: It appears that SA fetuses of mothers with GDM had features of 
asymmetric growth when compared to WC. The SA offspring displayed head and 
femur sparing phenotype with smaller abdomens suggesting a possible asymmetric 
intrauterine growth restriction. Standard intensive glucocentric treatment may need 
to be tailored to ethnicity based on differences in fetal growth. 
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5.2 Introduction 
Estimated fetal weight (EFW) and hence prediction of macrosomia has been used as 
a part of management of GDM pregnancies and mothers with GDM are advised 
serial growth scans to monitor fetal growth [78]. Both the Shepard’s [169] and the 
Hadlock’s formula [170] for estimating fetal weight using a combination of 
Abdominal Circumference (AC), Femur Length (FL) and Biparietal diameter 
(BPD), were derived from populations of healthy WC women. However, there is 
evidence of a disproportionate and accelerated growth in diabetic pregnancies [171] 
[172] and therefore this relationship between various fetal parameters and EFW may 
not be the same. Wong found that there was underestimation of BW in 26.3 % of 
pregnancies with diabetes by more than 15 %, compared to 5.4% in the control 
group. Studies in type 1 diabetes show that EFW at term could be in error by up to 
900g [173].  
This estimation is especially erroneous in babies with macrosomia [174, 175].  
Hence there is increasing interest in studying individual components of fetal body 
composition rather than EFW. Special focus has been on the measurement of the 
AC, which was found to be a better predictor of macrosomia than EFW [176] and 
associated complications such as shoulder dystocia [177]. Altered HC/AC 
trajectories with reduced HC/AC ratio was also noted in offspring of maternal pre-
gestational diabetes and GDM [171].  
It is to be remembered that this link between GDM and altered fetal growth, i.e. 
disproportionate growth and altered growth velocities been explored predominantly 
in WC [172] and extrapolated to other ethnic groups for clinical practice.  
Despite having greater degrees of hyperglycaemia in pregnancy [146-148], SA 
babies are amongst the smallest in the world [13, 149-151]. There is evidence to 
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show that the effect of maternal glycaemia on BW may vary with ethnicity [137, 
149, 153]. Sparse evidence in SA suggests that the effect of maternal diabetes on 
BW may be smaller in SA compared to WC [137]. In Chapter 4, we reported that the 
effect of maternal diabetes on offspring BW was lower in SA compared to WC. 
Therefore it is possible that GDM can affect fetal growth differently in SA and WC. 
Despite the high risk of GDM in SA, studies examining fetal growth in GDM in SA 
are sparse [178]. In chapter 6, we report disproportionate fetal growth in SA living 
in India. There are no studies comparing fetal growth between SA and WC. 
5.3 Hypotheses 
 
SA foetuses have different growth patterns compared to WC in GDM pregnancies 
5.4 Aims 
To study the differences in fetal growth between SA and WC in GDM pregnancy 
5.5 Objectives 
 
To compare the growth of fetal growth parameters i.e HC, AC and FL in SA and 
WC in GDM pregnancies 
5.6 Methods 
This was a retrospective study of all pregnancies with GDM between 2009 & 2012 
of White Caucasian or South Asian ethnicity from University Hospital Coventry & 
Warwickshire in the West Midlands of the United Kingdom.  
All these centres used the selective screening based on the risk factors recommended 
by NICE: BMI ≥ 30Kg/cm2, first-degree relative with diabetes, previous GDM, 
previous unexplained stillbirth, previous macrosomia (BW ≥ 4.5 kg) or women of 
ethnic minority origin. Women meeting any one of the above criteria underwent a 75 
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g OGTT between 24-28 weeks. During this period all centres used the modified 
WHO 1999 criteria for the diagnosis of GDM following a 75g OGTT: FPG 
≥6.1mmol/l and/or 2-hour plasma glucose (2hPG) ≥7.8mmol/l. Obstetric and 
neonatal characteristics were obtained for all women undergoing an OGTT. BMI 
was measured at the booking visit. For the purpose of this study, ethnicity was 
grouped into South Asians (SA -Indian, Bangladeshi, Pakistani, Sri Lankan), White 
Caucasian (WC - British / European). Multiparity was defined as ≥2 live previous 
pregnancies that progressed beyond 24 weeks gestation.  
Routine fetal ultrasound was performed at 28 weeks, 32 weeks and 36 weeks 
gestation for all GDM women. Head circumference, abdomen circumference (AC) 
and femur length (FL) were recorded for all women electronically from View-point 
software, version 2.0.   
Statistical analysis: Mean and SD and student t tests were used to compare maternal 
and offspring characteristics between the two groups. Linear regression was used to 
compare the fetal biometry parameters between the two ethnic groups after 
adjustment for maternal age, BMI, gestation, sex of the baby and plasma glucose. A 
repeated measures ANOVA was performed to examine the differences in the trends 
of growth of individual fetal parameters. SPSS version 22.0 was used for analysis. 
LGA and SGA centiles at birth were calculated based on the customised Gestation 
Related Optimum weight (GROW) centiles obtained from the Bulk centile 
calculator available online at www.gestation.net.  These centiles are ethnic specific 
centiles for gestational age and sex of baby, adjusted for maternal height, weight and 
parity. 
5.7 Results 
Initial data for WC was obtained from pregnancies of GDM mothers between March 
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2011 and 2013. Of total 212 babies born during this period, complete sonographic 
data was available for 177 WC women, after excluding 8 sets of twins, 2 sets of 
triplets.  
To obtain a similar number of SA women, this time period was extended back to 
April 2009. Of 192 babies born to SA mothers with GDM, 160 had complete scan 
data after excluding women with multiple pregnancy. 
Table 1 shows baseline characteristics of the two ethnic groups. SA were 
significantly leaner, shorter, had a higher prevalence of multiparity, and had 
significantly higher FPG and 2hPG at OGTT compared to WC. 
Table 2 shows the comparison of fetal biometry between the two groups. SA had 
significantly lower AC at all time points despite similar skeletal measures of FL and 
HC, with the exception at 32 weeks when HC was also lower in SA. FL/AC was 
significantly higher in SA compared to WC at all times. H/C was also higher in SA 
than WC at 28 weeks and at 36 week. As expected the BW in SA was significantly 
lower than in WC, however on using the customized GROW centiles the two groups 
had similar proportion of LGA and SGA. 
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Table 1: Baseline characteristics of WC and SA women  
 WC: Mean (SD): n=177 SA: Mean (SD): n=160 p 
Age in years 31.27 (6.01) 31.87 (4.87) 0.131 
BMI (Kg/cm2) 32.21 (7.42) 28.57 (6.14) <0.0001 
Height (cm) 164.35 (6.48) 158.90 (6.55) <0.0001 
Multiparity (≥ 2) 28.2 % 42.8 % <0.0001 
FPG (mmol) 5.11 (0.76) 5.27 (0.71) 0.003 
2hPG (mmol) 7.64 (1.89) 8.07 (2.13) 0.007 
Table 1 shows the differences in baseline characteristics between SA and WC 
 
Table 2: Differences in fetal biometry between SA and WC according to 
gestation 
 WC: Mean (SD) SA: Mean (SD) p 
AC1 (28 weeks) mm 248.80(18.46) 242.67(19.29) 0.016 
HC1 (28 weeks) mm 269.04 (16.108) 267.21(15.247) 0.381 
FL1 (28 weeks) mm 53.25(3.57) 53.89(4.06) 0.197 
HC/AC 1.08 (0.06) 1.10 (0.06) 0.008 
FL/AC 0.21 (0.01) 0.22 (0.01) <0.0001 
Gestation 1 (28 weeks) 28.38 (1.06) 28.32 (1.16) 0.653 
AC2 (32 weeks) mm 297.17 (21.21) 288.11 (21.03) 0.001 
HC2 (32 weeks) mm 307.86 (14.25) 301.82 (14.78) 0.001 
FL2 (32 weeks) mm 63.05 (4.17) 62.35 (4.45) 0.199 
HC/AC 1.04 (0.06) 1.05 (0.08) 0.154 
FL/AC 0.21 (0.01) 0.22(0.02) 0.031 
Gestation scan 2 32.77 (1.06) 32.50 (1.09) 0.048 
AC 3 (36weeks) mm 330.47 (20.09) 322.62 (19.08) 0.002 
HC 3 (36 weeks) mm 327.20 (29.48) 325.08 (10.77) 0.46 
FL 3 (36 weeks) mm 68.68 (2.77) 68.60 (3.10) 0.199 
HC/AC 0.99 (0.098) 1.01 (0.05) 0.057 
FL/AC 0.21 (0.01) 0.21(0.01) 0.001 
Gestation at scan 3 35.97 (0.80) 35.98 (1.00) 0.957 
Birth weight (g) 3419.41 (630.28) 3223.55 (586.58) <0.0001 
Gestation at birth [179] 38.81 (1.81) 38.68 (1.82) 0.369 
LGA (GROW centiles) 14.8 % 14.1% 0.829 
SGA (GROW centiles) 10.9 % 8.8 % 0.449 
 Table 2 shows the differences in fetal biometry at the various gestational ages along with the birth 
weight data in SA and WC  
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A mixed, between subjects ANOVA (repeated measures ANOVA) was conducted to 
assess the main effect of ethnicity on the growth of AC, HC and FL with gestational 
age and also the interaction of ethnicity with gestational age. 
Figure 1 and table 3 show the results of the repeated measures ANOVA. There was 
a significant main effect of time on AC, HC and FL, showing as expected a 
significant change of the above with time. Only AC but not HC and FL showed a 
significant main effect of ethnicity. The trend in the change of AC, HC and FL with 
time was similar between both ethnic groups, with no significant effect of 
interaction between ethnicity and gestational age. Figure 2 and table 4 shows the 
results of repeated measures ANOVA for HC/AC and FL/AC ratio in SA and WC.    
Finally a multivariable linear regression showed that the differences in AC, HC/AC 
and HC/FL ratio between the two ethnic groups that was seen on descriptive 
analysis persisted following adjustment for maternal age, BMI, FPG at OGTT, 
gestational age, and baby’s sex all time points (Table 5). HC/AC ratio at 32 weeks 
was similar between the two ethnic groups as seen previously in descriptive 
analysis. Table 6 showed that AC was independently determined by FPG 
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Table 3 Trends of change of AC, HC and FL with time and ethnicity 
A mixed between-within subject’s analysis of variance (repeated measures ANOVA) shows that the change in AC, HC and FL with time was similar across both ethnic 
groups. While HC and FL were not affected by ethnicity, the main effect of ethnicity on AC was significant, indicating a significant ethnic difference in AC. 
 
 
Figure 1: Trend of change of fetal biometry: AC, HC and FL in SA and WC 
 
            
                1a) AC                    1b) HC               1c) FL 
 
Figure 1 depicts graphical representation of the repeated measures ANOVA showing trend of change of fetal biometry i.e AC, HC and FL in SA and WC. Green line 
represents WC, Blue line represents SA. In line with table 3 only the trend of AC with was significantly different between the two groups. 
 
 
 
 AC HC FL 
Gestational age Wilks’ Lambda = 0.054,  
F (2, 122) = 1069.67, p <0.0001 
Wilks’ Lambda = 0.107,  
F (2, 119) = 493.99, p <0.0001 
Wilks’ Lambda =0.062,  
F (2, 122) = 920.516 
p < 0.0001 
Ethnicity F (1, 123) = 8.45, p = 0.004 F (1, 120) = 0.279, p =0.599 F (1, 123) = 0.377,  
p = 0.540 
Interaction of Gestational age with 
ethnicity 
Wilks’ Lambda = 0.988,  
F (2, 122) = 755, p = 0.472 
Wilks’ Lambda = 0.983,  
F (2, 119) = 1.023 
p = 0.363 
Wilks’ Lambda = 0.964,  
F (2, 122) = 2.274,   
P=0.107 
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Figure 2: Trend of change of fetal biometry: HC/AC and FL/AC in SA and WC 
 
                                     
           2a)  HC/AC ratio                              2b)    FL/AC ratio  
 
Figure 2 depicts graphical representation of the repeated measures ANOVA showing trend of change of HC/AC and FL/AC in SA and WC. Green line represents WC, Blue 
line represents SA. In line with table 4, the trend of  HC/AC but not FL/AC was significantly different between the two groups. 
 
Table 4: Trends of change of HC/AC and FL/AC with time and ethnicity 
  
A mixed between-within subject’s analysis of variance (repeated measures ANOVA) shows that the change in HC/AC and FL/AC with time was similar across both ethnic 
groups. While FL/AC was not independently affected by ethnicity, the main effect of ethnicity on HC/AC was significant, indicating a significant ethnic difference in 
HC/AC. 
  
 HC/AC ratio FL/AC ratio 
Gestational age Wilks’ Lambda = 0.054, F (2, 122) = 1069.67, p <0.0001 Wilks’ Lambda = 0.107, F (2, 119) = 493.99, p <0.0001 
Ethnicity F (1, 123) = 8.45, p = 0.004 F (1, 120) = 0.279, p =0.599 
Interaction of Gestational age with ethnicity Wilks’ Lambda = 0.988,  F (2, 122) = 755, p = 0.472 Wilks’ Lambda = 0.983, F (2, 119) = 1.023, p = 0.363 
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Table 5: Ethnic differences in fetal growth after adjustment for confounders 
 
 28 weeks 32 weeks 36 weeks 
 β coefficient (95% CI) 
AC 1.964 (0.488, 3.440), p=0.009 2.585 (0.945, 4.226), p=0.002 2.468 (0.864,4.071), p=0.003 
HC/AC -0.007 (-0.013, -0.002), p=0.006 -0.004 (-0.010, 0.002), p=0.157 -0.002 (-0.003, -0.001), p=0.002 
FL/AC -0.003 (-0.004,-0.002), p<0.0001 -0.002 (-0.004, -0.001), p=0.002 -0.002 (-0.003, -0.001), p=0.002 
 
Multivariable linear regression was performed with AC as dependent variable and ethnicity as independent variable, after adjustment for maternal age, BMI, FPG, gestational 
age at scans and sex of baby. SA were the reference group: SA had a significantly lower AC at all gestations after full adjustment as shown below.  
 
Table 6: Effect of Fasting plasma glucose on AC in SA and WC 
 Whole group SA WC 
 β coefficient (95% CI) 
28  0.267 (-2.57, 3.107), p = 0.853 -1.41 (-5.69, 2.87), p=0.515 1.90 (-2.09, 5.88), p=0.348 
32 4.99 (1.76, 8.23), p = 0.003 3.21 (-1.29, 7.70), p = 0.160 7.38 (2.48, 12.29), p=0.003 
36 5.31 (2.27, 8.34), p = 0.001 3.83 (-0.006, 7.665), p=0.05 7.79 (2.64, 12.95), p=0.003 
 
Multivariable linear regression was performed with AC as dependent variable and FPG as independent variable, after adjustment for maternal age, BMI, ethnicity, gestational 
age at scans and sex of baby. FPG was an independent predictor of AC at 32 and 36 weeks after adjustment as shown. When analysed separately in the two ethnic groups, 
this relationship between FPG and AC was only significant in WC, not SA.  
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5.8 Discussion 
Our study is the first to compare patterns of fetal growth between SA and WC in 
GDM pregnancies. We report several important findings. 
Firstly we showed that SA with GDM have significantly smaller AC but largely 
similar skeletal growth (HC, FL) than WC foetuses despite having significantly 
lower maternal BMI and height than WC. The lower AC is seen as early as 28 
weeks despite the higher FPG and 2hPG in SA.  
These findings agree with the Intergrowth data in healthy women [180] and to the 
Sparks theory [181] that show that skeletal growth is largely conserved across race. 
The intergrowth study is a large study of fetal growth in healthy women without 
GDM of different ethnic groups, which explored ethnic differences in patterns of 
fetal growth. This study observed that skeletal parameters are fairly similar across 
ethnic groups and are unaffected by ethnicity. Country of origin explained only 1.9-
3.5% of variance in skeletal growth, i.e. crown-rump length, fetal head 
circumference, and newborn birth length in healthy pregnancies [180]. This study 
however did not report on AC, which is very closely related to Birth Weight (BW) 
especially in diabetic pregnancies. 
Our results are also partly in line with other observations in healthy SA and WC 
new-borns, where SA were observed to have a significantly lower AC at birth [43, 
182]. However, the Pune study also reported smaller skeletal parameters such as HC 
in contrast to our data that only showed differences in AC, with relative sparing of 
HC and FL. The Pune study differed from our study in two respects, which could 
contribute in this disparity in results. One: The Pune Maternal nutrition study only 
recruited healthy women without diabetes. Two: Offspring of SA women living in 
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India in the Pune study were overall smaller with lower BW compared to SA living 
in the UK in our study.  
This difference in AC appears to be an independent effect of ethnicity and persists 
despite adjustment for maternal age, BMI and FPG. It appears that this difference in 
AC largely drives the difference in offspring BW in the two ethnic groups. FPG but 
not 2hPG appears to be an independent predictor of AC at 32 and 36 weeks in WC 
but not in SA. Again, in line with our results in chapter 10, maternal glycaemia 
appears to have a less significant impact on fetal size in SA than WC. 
Furthermore, the growth in SA fetuses was asymmetric compared to WC. Increased 
HC/AC and FL/AC ratios with head and femur sparing and smaller abdomen, have 
been used in traditional sonographic fetal biometry to describe asymmetric fetal 
growth [183-185]. It has been shown previously that in healthy fetuses HC/AC 
exceeds 1.0 before 32 weeks, is approximately1.0 at 32 to 34 weeks, and is less than 
1 beyond 34 weeks [184]. An elevated HC/AC ratio, which remains greater than 1 
after 32-34 weeks is regarded as a sign of asymmetric intrauterine growth restriction 
(IUGR) [185]. HC/AC and FL/AC ratios were markedly higher in SA compared to 
WC. SA with GDM displayed higher HC/AC ratios, which remained >1 even at 32, 
and 36 weeks depicting a picture of asymmetric IUGR.  
The significance of smaller abdomen in SA fetuses of mothers with GDM is unclear. 
The lower AC is a cumulative effect of subnormal liver and adipose tissue growth 
[184]. However it has been shown that SA neonates had higher intra-abdominal and 
subcutaneous abdominal adipose tissue than WC [44], despite overall lower birth 
weight. Hence it is plausible that the lower AC is the result of poor visceral i.e. liver 
growth in SA. Whether this disproportionate growth is simply an effect of ethnicity 
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or the difference in effect of maternal GDM is unknown. Whether lower AC is an 
indicator of future metabolic risk akin to lower BW needs to be assessed.  
Lastly, these findings have important implications on the management of GDM in 
SA. We have shown that FPG has an insignificant effect on AC and also on BW as 
shown in chapter 6. Hence it could be speculated that standard intensive treatment 
goals may aggravate disproportionate IUGR in SA. These findings raise the question 
of whether ethnic specific treatment goals are required for the management of GDM. 
 
5.9 Future directions 
 Larger randomised studies in both ethnic groups incorporating GDM and 
control groups to study the effect of GDM on fetal growth in the two ethnic 
groups. 
 Studies incorporating other measures of fetal growth including fetal 
adiposity and liver length. 
 Above studies to add evidence to the argument for the incorporation of 
ethnic specific treatment targets. 
 Long term follow up of offspring of these mothers to study the link between 
lower AC and future metabolic risk. 
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6 Early impact of GDM on fetal adiposity in SA 
6.1 Abstract 
Background: Increased fetal growth is an important complication of GDM leading to 
both short-term delivery complications and long-term risks of obesity in adulthood. 
Intensive glycaemic management regimens in GDM aim to reduce overall offspring 
BW. Recent evidence in WC points to altered body composition and asymmetric 
fetal growth in infants of GDM mothers, with preferential increase in fetal adiposity. 
Despite having the highest risk of GDM and future metabolic risk evidence of fetal 
growth abnormalities in GDM is largely lacking in SA. We aimed to assess changes 
in fetal body size and adiposity in GDM in a SA population. 
Methods: A retrospective study of 153 GDM and 178 controls from an obstetric 
centre in Chennai, India. Serial scans data were obtained at 11, 20 and 32 weeks for 
all women along with maternal and offspring demographic data.  Traditional 
biometry including fetal HC, AC and FL at 11, 20 and 32 weeks and anterior 
abdominal wall thickness (AAWT) was measured as a measure of central adiposity 
at 20 and 32 weeks in all women. 
Results: Offspring of GDM women had significantly higher AAWT at both 20 (2.63 
(0.51) vs 2.39 (0.41) mm, p<0.0001) and 32 week (4.67 (0.81) vs 4.37 (0.67) mm, 
p=0.001) scan despite lower measures of AC, HC and FL at 32 weeks. Both groups 
had similar BW at term. FPG was an independent predictor of AAWT at both 20 
and 32 weeks after adjustment for age, maternal BMI, parity and gestational age. 
Conclusion: We present novel evidence of the early origins of adult obesity in 
offspring of SA women with GDM. Foetuses of GDM mothers show evidence of 
disproportionate fetal growth with increased adiposity and reduced lean body mass 
as early as 20 weeks gestation.  Increased abdominal wall thickness could serve as 
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an early marker of GDM. Therapy in GDM should be guided by fetal body 
composition.  
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6.2 Introduction 
6.2.1 GDM and offspring risk 
Gestational Diabetes Mellitus is typically described as a state of glucose intolerance 
first recognised in pregnancy. The incidence of GDM is increasing rapidly in line 
with the increase in prevalence of type 2 diabetes (T2D) [5, 6]. GDM is associated 
with a multitude of offspring complications that include macrosomia, neonatal 
jaundice, neonatal hypoglycaemia and shoulder dystocia [9] for the offspring and 
preeclampsia [61] in the mother. Offspring of mothers with GDM have a 2-4 fold 
higher future risk of T2D and adult onset obesity [63, 64, 186]. Macrosomia, is the 
most important consequence of the altered metabolic milieu of GDM pregnancies 
[187, 188] occurring in about 10-20% of GDM pregnancies[189, 190]. Fetal 
macrosomia is closely related to several other neonatal complications such as 
shoulder dystocia[191], caesarean delivery, stillbirth, neonatal mortality, neonatal 
asphyxia and birth injury [192]. Hence most international guidelines recommend 
serial fetal US at 28, 32 and 36 weeks gestation to monitor for increased foetal 
growth [76, 193].  
However macrosomia is a crude composite outcome of the growth of both fat mass 
and fat free mass, determined by a variety of genetic, maternal and environmental 
factors and it is to be remembered that the infant of a diabetic mother has 
significantly different body proportion from the general population [175]. Offspring 
with disproportionate macrosomia have been shown to have greater morbidity with 
higher risk of hypoglycaemia and hyperbilirubinemia compared to those with 
proportionate macrosomia [194]. Furthermore, the common formulae [170] derived 
for the estimated fetal weight (EFW) were derived from normal populations and are 
poor predictors of fetal weight in diabetic pregnancies and especially in in LGA 
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babies[174, 175]. Therefore there is renewed interest in studying individual 
components of fetal body composition, and fetal growth trajectories in GDM. 
6.2.2 Normal fetal growth 
The intrauterine growth trajectory is the composite outcome of substrate availability, 
genetic make up and hormonal milieu of the intrauterine environment. Changes in 
the intra-uterine environment largely determine the growth of fetal fat, while the fat 
free mass is determined by genetic factors [181, 195]. Fetal fat and hence fetal 
weight increases exponentially in the second half of pregnancy [196]. The 
differences in body composition between SGA and LGA neonates are largely 
determined by differences in adiposity rather than that of fat free mass, with fetal 
adiposity contributing to upto 50% of variance in birth weight [197, 198].  
6.2.3 Changes in fetal growth in GDM 
As a result of increased nutrient bioavailability and the permissive environment of 
fetal hyperinsulinism there is accelerated fetal growth of both fat and lean mass in 
later pregnancy [172]. However, more recently evidence points towards a 
preferential growth of insulin sensitive adipose tissue mass compared to growth of 
fat free lean tissues [199] with higher total fat mass and fat/lean mass ratio[172] in 
GDM offspring compared to normal.  Preferential increase in fetal adiposity has 
been reported in several studies in offspring of women with both pre-existing and 
gestational diabetes [199, 200]. Abdominal subcutaneous obesity, often measured as 
anterior abdominal wall thickness (AAWT) could in-fact be an early marker of 
gestational diabetes and its associated fetal risk [201]. However all the above studies 
examined fetal adiposity predominantly in the third trimester or at birth [172]. 
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Our aim was to assess the difference in fetal body composition and abdominal wall 
thickness between GDM and controls in early pregnancy to enable early pregnancy 
prediction of GDM and risk to the offspring. 
6.3 Hypothesis 
1. GDM is associated with altered fetal body composition 
6.4 Aims 
1. To compare differences in fetal biometry i.e. head circumference [168], 
abdominal circumference (AC) and femur length (FL) between GDM and 
control population 
2. To compared difference in fetal adiposity between GDM and control population 
6.5 Materials and methods 
This is a retrospective case control study of all pregnant women diagnosed with 
GDM and controls booked at Seethapathy clinic & hospital, Chennai, India from 
September 2011 to December 2013.  
All pregnant women had OGTT with 75 g glucose 22-26 weeks. GDM was 
diagnosed based on the IADPSG criteria i.e. Fasting plasma glucose (FPG) ≥ 
5.1mmol/l, 1hour PG (1hPG) ≥ 10.0 or 2hour PG (2hPG) ≥ 8.5 mmol/l. Diet and 
lifestyle advice was given to all women with GDM. The optimal targets was a FPG 
< 5.1 and a 1hPG < 7.8mmol/l. If glycaemic control was not achieved with diet, 
insulin was started. 
Ultrasound scans were performed at two centres, Mediscan and Seethapathy 
hospital. All patients underwent a dating scan at 11 weeks, a detailed anomaly scan 
at 20 weeks where fetal biometry (BPD, HC, AC and FL) was documented. A 
subsequent scan was done for assessing fetal growth at 28 and 32 – 34 weeks for 
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GDM women. For Control women a routine growth scan was performed at 32 
weeks. Measurement of the abdominal wall thickness (AAWT) was done 
retrospectively, on images archived from Sonocare, an ultrasound reporting and 
imaging software. The AAWT was measured at both the 20
th
 week and at 32 weeks, 
by two operators using standardised technique as described previously[202].  
The plane of the abdominal circumference was taken, with optimum gain control, as 
per standard described protocol. The abdominal wall was identified and the 
thickness of the echogenic rim was measured. Care was taken not to include the 
hypo echoic area between the abdominal wall and the liver. In addition traditional 
biometry measures such as bi-parietal diameter (BPD), AC, HC, and FL were 
measured at every time point. 
Patients with GDM on insulin were induced at 38 weeks. Patients with GDM on diet 
with good glycaemic control were induced at 40 weeks. Control women were 
induced at 40 
+ 5
 weeks if spontaneous labour did not occur. The nature and mode of 
delivery, the gestational age, sex and weight of the baby were documented.  
Statistical analysis: Parametric tests i.e student t test was used to compare means 
between the two groups. Multivariable linear regression was used to study 
differences in fetal growth parameters after adjustment for confounders.  Repeated 
measures ANOVA were used to study the difference in trend of growth of individual 
parameters between the 2 groups. SPSS version 22.0 was used for analysis. 
6.6 Results 
 
A total of 178 controls and 153 GDM women were recruited (total n= 331). The first 
dating scan was performed at 11-14 weeks. The second fetal biometry scan was 
performed at a mean of 20.9 (SD: 1.1) (scan 2) and again at 32.5 (SD: 1.6) weeks 
(scan 3). For Scan 2 fetal biometry was available for 325 women, and for scan 3 for 
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316 women in total. AAWT was available for 322 and 324 women for scan1 and 2 
respectively. GDM diagnosis was made at 24.7 (SD: 2.45) weeks. 
Baseline characteristics of the two groups are shown in table 1. GDM women had 
higher BMI and maternal weight than controls. They had significantly higher 
measures of glycaemia at OGTT at all time points. Nearly half of the women had 
family history or maternal or paternal diabetes. 
Table 2 shows the differences in fetal biometry and AAWT between the GDM and 
control groups. At 11-week scan both groups had similar measures of all biometry. 
At scan 2 GDM women had higher AAWT, but smaller HC and BPD. All other 
traditional fetal parameters were similar in both the groups. At Scan 3 the significant 
differences in AAWT persisted despite smaller measures of AC, HC, BPD and FL. 
Birth weight was similar in the two groups. With multivariable linear regression the 
above differences in traditional biometry and AAWT between the two categories 
persisted even after adjustment for maternal BMI, age, gestational age at scan and 
parity (table 3). 
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Table 1: Baseline characteristics of GDM and control groups 
 GDM: Mean (SD) Controls: Mean (SD) p 
Age 28.5 (3.8) 28.8 (4.2) 0.610 
BMI (KG/cm2) 25.9 (5.8) 23.7 (6.6) 0.002 
Ht cm 155.2 (19.1) 150.8 (33.40) 0.142 
Weight in Kg 65.9 (12.5) 60.6 (16.0) 0.001 
FPG (mmol) 5.3 (0.7) 4.4 (0.5) <0.0001 
1hPG (mmol) 9.7 (1.9) 7.0 (1.5) <0.0001 
2hPG (mmol) 8.1 (1.8) 5.9 (1.2) <0.0001 
Multiparity (>1) 4.6 % (7 / 145) 1.7 % (3 / 175) 0.123 
Previous GDM 3.9 (6 / 153) 0 (0/178) 0009 
Family H/O diabetes 49.1 (75/153) 33.1 (59 / 178) 0.003 
Table 1 shows the difference in baseline characteristics between GDM and control women. 
 
Table 2: Fetal biometry in GDM and control groups 
Table 2 shows the difference in fetal biometry between GDM and Control groups at various 
gestational ages. 
 
Table 3: Differences in fetal biometry between GDM and controls after 
adjustment for maternal characteristics and gestational age  
Multivariable linear regression was performed with fetal biometry parameters as dependent variable 
and glycaemic category (GDM vs control) as independent variable after adjustments made for age, 
BMI, parity and gestational age at scan. 
  
 GDM:  Mean (SD) Controls  Mean: (SD) p 
AC (11-14 weeks) mm 52.3 (25.1) 51.7 (22.9) 0.820 
HC (11-14 weeks) mm 66.2 (28.7) 65.5 (29.6) 0.824 
FL (11-14 weeks) mm 7.5 (7.3) 7.5 (7.5) 0.930 
BPD (11-14 weeks) mm 18.5 (7.9) 19.2 (9.9) 0.488 
AC1 (20 weeks) mm 154.4 (11.1) 156.6 (11.6) 0.084 
HC1 (20 weeks) mm 178.1 (11.7) 181.4 (11.2) 0.010 
FL1 (20 weeks) mm 34.3 (4.3) 34.9 (2.8) 0.153 
BPD1 (20 weeks) mm 48.9 (3.1) 49.9 (3.3) 0.004 
AAWT1 (20 weeks) mm 2.6 (0.5) 2.4 (0.4) <0.0001 
Gestation at scan 2  21.1 (1.2) 20.7 (0.9) 0.007 
AC 2 (32 weeks) mm 250.3 (66.3) 268.9 (49.9) 0.005 
HC 2 (32 weeks) mm 265.6 (71.6) 289.3 (51.6) 0.002 
FL 2 (32 weeks) mm 55.4 (16.9) 60.9 (11.2) 0.001 
BPD 2 (32 weeks) mm 74.4 (22.4) 80.9 (14.6) 0.002 
AAWT 2 (32 weeks) mm 4.7 (0.8) 4.4 (0.7) 0.001 
Gestation at scan 3 32.1 (1.8) 32.9 (1.4) <0.0001 
Birth weight (Kg) 3.0 (0.5) 3.1 (0.4) 0.070 
Gestational age at birth 
[179] 
38.5 (1.5) 38.8 (1.1) 0.056 
Fetal biometry parameters in mm B coefficient (95% CI) p 
AAWT1 (20 weeks) 0.25 (0.15,0.35) <0.0001 
HC1 (20 weeks) -4.47 (-6.46, -2.48) <0.0001 
BPD1 (20 weeks) -1.31 (-1.91, -0.72) <0.0001 
AC 2 (32 weeks) -3.50 (-6.78, -0.219) 0.037 
HC 2 (32 weeks) -8.64 (-15.53,  -1.74) 0.014 
FL 2 (32 weeks) -1.94(-3.43, 0.46) 0.010 
BPD 2 (32 weeks) -2.11 (-4.05, -0.16) 0.034 
AAWT 2 (32 weeks) 0.50 (0.35, 0.65) <0.0001 
  
 
119 
 
 
A repeated measures ANOVA was conducted to examine the differences in trend of 
change of AAWT, AC, HC and FL in the two groups across three time points of the 
gestational age: 11-14 weeks, 20 weeks and 32 weeks. Figure 1 shows the trend in 
change of AAWT, AC, HC and FL in the two groups. Table 4 shows the results of 
repeated measures ANOVA showing a significant effect of both gestational age and 
glycaemic category for all measures of fetal growth. The trend of change of HC, AC 
and FL with gestational age differed significantly between GDM and controls, with 
a significant interaction effect between ethnicity and category of glycaemia. 
However, the trend for AAWT was similar in both controls and GDM, with AAWT 
being greater in GDM group at all gestations. 
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Table 4: Fetal growth trends in GDM and controls: Repeated measures 
ANOVA 
A repeated measures ANOVA shows that there was a significantly different trend of change of AC, 
HC and FL with gestational age between GDM and control group. While the AAWT was different 
between the two groups at all time points, the change in AAWT with gestational age followed a 
similar pattern. 
 
Figure 1: Differences in fetal growth between GDM and controls 
     
               1a) HC                1b) AC   1c) FL 
 
There was a significant and independent relationship between glycaemia and fetal 
adiposity. Table 5 shows the relationship between fasting glycaemia at OGTT and 
measures of foetal adiposity at 20 and 32 weeks respectively. FPG at OGTT was 
significantly associated with AAWT at 20 and 32 weeks after adjustment for 
 HC AC FL AAWT 
Gestational age Wilks’ Lambda = 
0.037,  
F (2, 301) = 
3598.959, p = 0.001 
Wilks’ Lambda = 
0.018,  
F (2, 301) = 
8207.319, p 
<0.0001 
Wilks’ Lambda 
=0.036,  
F (2, 301) = 
3982.09,  
p < 0.0001 
Wilks’ Lambda 
=0.119,  
F (1, 313) = 
2306.40,  
p < 0.0001 
Category (GDM vs 
controls) 
F (2, 301) = 11.615, 
p = 0.001 
F (1, 302) = 9.042, 
p =0.003 
F (1, 302) = 11.067,  
p = 0.001 
F (1, 313) = 24.853,  
p < 0.0001 
Interaction of 
Gestational age 
with category 
Wilks’ Lambda = 
0.951,  
F (2, 301) = 7.749,   
p =0.001 
Wilks’ Lambda = 
0.941,  
F (2, 301) = 9.498,   
p <0.0001 
Wilks’ Lambda = 
0.949,  
F (2, 301) = 8.116,   
p <0.0001 
Wilks’ Lambda = 
0.998,  
F (1, 313) = 514, 
 p = 0.474 
1d) AAWT 
Figure 1: Trend of AC, HC, FL, AAWT in 
GDM and controls. AC, HC and FL measured 
at 11, 20 and 32 weeks. AAWT measured 
between 20 and 32 weeks.  
Blue lines indicate GDM 
Green lines indicate Controls 
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maternal age, parity, BMI and gestational age at scan. 1 and 2hPG were not 
independent predictors of abdominal adiposity. 
Table 5: Relationship between Fasting Glycaemia and abdominal adiposity 
 B coefficient (95% CI) p 
AAWT1 (20 weeks) mm 0.145 (0.073, 0.217) <0.0001 
AAWT 2 (32 weeks) mm 0.248 (0.140, 0.356) <0.0001 
Multivariable linear regression was performed with FPG as dependent variable and fetal biometry 
parameters as independent variable after adjustments made for maternal age, BMI, parity and 
gestational age at scan.  
6.7 Discussion 
Our results provide novel evidence for the increased fetal adiposity seen in offspring 
of GDM mothers as early as 20 weeks gestation, in a South Asian population. Our 
most significant finding was that of increased AAWT in GDM fetuses despite 
similar or lower measures of other traditional fetal biometry in the second trimester, 
pointing towards disproportionate fetal growth. This increased adiposity persisted 
despite correction for age, BMI, gestational age and parity and was closely related to 
maternal FPG. We also noted that similar measures of fetal adiposity persisted at 32 
weeks of pregnancy despite treatment of GDM. Several studies reported differences 
in AAWT in the third trimester, well beyond 26 weeks of pregnancy [172, 199-201, 
203, 204] (Table 6). Ours is the first study to report early differences in adiposity at 
20-22 weeks, even prior to diagnosis of GDM with OGTT. Larcipete [205] 
compared GDM women with high-risk controls at 20 weeks by serial scans but 
abdominal fat differences were not evident till 37 weeks. Hence sonographic 
measurement of AAWT at 20 week scan, which is routinely performed for anomaly 
screening and hence available for all pregnant women, could be incorporated into 
risk stratification, screening or early diagnostic process for GDM.
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 Table 6: Summary of the literature studying fetal biometry and fat mass in GDM
 Sample size Gestational weeks Adiposity Other fetal biometry BW GDM diagnostic 
criteria 
Larciprete[2
05] 
85 GDM,  
218 controls 
Enrolled at 20-22 
weeks 
No difference seen prior to 31 weeks. Abdominal fat mass higher at 
39-40 weeks, Mid-arm fat and  Supra-scapular fat mass higher at 31 
weeks, mid-thigh fat higher at 37 weeks in GDM 
Mid-thigh lean mass 
higher at 20-22 weeks 
Higher in GDM  NDDG criteria 
Aksoy[201] 55 GDM,  
69 controls 
26-28 weeks AAWT: 4.07 ± 0.46  vs 3.28 ± 0.37 (controls), p<0.0001 No difference Higher in GDM IADPSG criteria 
Tantanasis[
200] 
20 GDM,  
15 control 
24 and 26 weeks Increased Subcutaneous fat at Abdomen GDM: 5.30 (0.52) vs 
Controls: 2.94 (0.58) 
Not reported Not reported (FPG: 7mmol/l & 
2hPG:11.1mmol/l) 
De-
Santis[172] 
43 controls,  
171 GDM 
20 – 38 week serial 
measurements (only 
15 scans <22 weeks) 
Significantly higher fat mass (abdominal, supra-scapular, arm and 
thigh fat) 
HC and BPD similar. 
Faster growth of AC and 
FL 
Higher BW z 
score, similar 
length 
Carpenter Coustan 
Catalano[19
9] 
195 GDM,  
220 controls 
At birth Restricting comparisons between infants appropriate for gestational 
age with GDM and controls: Fat mass in g: (371 ± 163 g vs 329 ± 
150 g, p = 0.02) (GDM vs controls), p=0.0002: Body fat (%):11.4% 
± 4.6% vs 9.9% ± 4.0%, p = .002 (GDM vs controls).  
No difference in lean 
mass, HC, leg length, AC. 
(Whole GDM group vs 
controls) 
Higher 
proportion of 
LGA in GDM 
group. 
 
NDDG criteria 
Enzi[203] 17 GDM,  
17 controls 
At birth % body fat: GDM(17% ± 1.7%) vs controls (12.2% ± 0.5% ). 
(newborn anthropometry) 
Not reported No difference Whites 
Classification  
Vedavathi 
[178] 
30 GDM,  
30 controls 
32-40 Not Studied Higher AC and HC Higher in GDM Carpenter Coustan 
Hammoud 
[171] 
99 GDM, 
145 Controls 
17 weeks, 37 weeks Not studied Similar AC, HC, FL  Not reported 100g GTT ADA 
Nasrat [204] 51 GDM,  
501 controls 
At birth Increased skim fold: Biceps, subscapular, suprailiac, sum of all skin 
folds. 
Similar HC and AC Higher in GDM ADA  
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A point to note in our study is that these differences in adiposity were observed in 
the two groups despite similar overall BW at term, signifying an asymmetric growth 
pattern even in offspring of relatively well-controlled GDM. Most other studies that 
have reported increased fetal adiposity in utero have also reported overall larger BW 
in GDM offspring compared to controls (table 6). Our results provide further early 
evidence to Catalano’s observation of increased adiposity at term in the two groups 
of comparable weight [199]. 
The other intriguing finding in our study is that fetuses of GDM mothers displayed 
decreased lean mass, as early as 20 weeks. Both HC and BPD were significantly 
lower in GDM at 20 weeks even after adjustment for maternal characteristics and 
gestational age. AC displayed a trend to be lower than the controls at 20 weeks but 
this did not reach statistical significance. At 37 weeks all traditional parameters 
including AC, HC and FL were significantly smaller in GDM fetuses, with the 
difference more marked than at 20 weeks. These findings are in contradiction to 
most previous studies that either showed an increase [172, 178] or no difference 
[171, 199, 201, 204] in traditional fetal parameters. However in all of the above 
studies the offspring of GDM were either macrocosmic or had significantly greater 
BW than control fetuses (see table 6). Therefore it is conceivable that if the 
comparison was restricted to fetuses of similar overall weight, the reduced 
parameters of other fetal biometry would be more apparent. In fact, a study from the 
United states [199] reported similar lean fetal mass between GDM and controls, but 
on restricting the comparison to GDM fetuses who were appropriate for gestational 
age (AGA), the latter had lower lean mass than controls. Such early growth delay 
with lower BPD has also been reported in fetuses of mothers with pre-gestational 
diabetes [174, 206]. It is therefore possible our SA women with GDM had more 
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severe hyperglycemia or undiagnosed pre-gestational diabetes and therefore display 
features of early growth delay akin to women with pre-gestational diabetes. 
The smaller fetal biometry at 37 weeks in addition can be explained by the influence 
by treatment of GDM. Since the groups had similar BW, the increase in adiposity 
combined with decreased lean mass could be a consequence of tight maternal 
glycemic control coupled with the effect of medication such as insulin. Aggressive 
treatment of maternal glycaemia has been shown to increase the risk of overall small 
for gestational age neonates [166]. It has been shown that known that maternal 
treatment with insulin preferentially favors that increase of fetal adiposity over lean 
mass [199]. When compared to offspring of GDM mothers on diet alone, the 
offspring of GDM mothers on insulin have significantly greater skin fold thickness, 
greater total body fat mass and % body fat but similar measures of lean body mass 
[199]. Therefore it can be conceived that intensive treatment goals with insulin 
regimens may in fact reduce lean body mass and increase adiposity. 
Other possible explanations of the smaller overall size could be the presence of 
underlying placental dysfunction impairing the growth of skeletal and visceral 
growth. 
This is the first study examining early fetal growth in GDM along with measures of 
adiposity in SA. It is possible that this asymmetry in fetal growth is a feature that is 
more marked in glucose intolerant SA.   
Our study had few important limitations. It was retrospective and hence liable to 
incomplete data. Detailed information of treatment and glycemic control, which 
affects late pregnancy fetal growth, was not available. However this could not have 
influenced our results at 20 weeks.  
The implications of these results are several.   
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Firstly, fetal abdominal adiposity could be a useful marker of GDM in early 
pregnancy even prior to the traditional diagnosis using the OGTT. Hence a 
sonographic measure of AAWT could be used as an early marker. Further more 
AAWT measurements could be used to detect women who would benefit from early 
treatment of GDM. The effect of metformin in modulating fetal adiposity and hence 
disproportionate growth should be explored in future studies. 
Secondly, this study is evidence for the early origins of adult adiposity and 
metabolic risk in infants of GDM, and that this is apparent even in fetuses with 
comparable BW to controls. Previous studies have shown that increased adiposity in 
term infants of GDM mothers is linked to future adult obesity and diabetes risk [186, 
207]. Further studies are needed to extend this observation to measures of adiposity 
in early fetal life. 
Thirdly, our results raise the question if intensive treatment regimens to reduce 
overall fetal size will truly reduce fetal adiposity or in fact do more harm to worsen 
the asymmetry between lean and fat tissue. There is also evidence to show that 
gestational age is the strong predictor of fat free mass [208]. Treatment of GDM 
with insulin, coupled with early induction, may increase fetal adiposity and reduce 
lean mass further. It may be that tight glycemic control especially in SA may do 
more harm. Finally our evidence therefore encourages a more detailed study of 
adiposity and fetal composition to tailor therapy in GDM and move away from the 
glucocentric or fetal weight based approach. Again our study could not examine the 
effect of treatment, such as metformin, however future studies are needed to 
investigate this role. 
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6.8 Future directions 
 
 Need for larger prospective studies comparing early fetal body composition 
including AAWT between GDM and controls in SA and other ethnic groups 
and incorporation of this into early diagnosis, screening and risk 
stratification and early treatment of GDM.  
 Need for examining the role of GDM therapeutic regimens including 
metformin, insulin and diet on fetal and neonatal body composition and 
usefulness of fetal body composition to guide therapy in GDM 
 Long term follow up of neonates with increased fetal adiposity to assess 
future risk of childhood and adolescent obesity and insulin resistance 
 Studies assessing the role of other non glycaemic factors – eg Amino acids, 
cytokines and Free fatty acids in fetal growth, adiposity and lean mass.
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7 Differences in Hypothalamic Pituitary adrenal Axis 
(HPA) activity between SA and WC in relation to GDM 
7.1 Abstract 
Introduction: SA have more the double the prevalence of GDM even at lower levels 
of obesity. The mechanisms for increased risk of GDM in SA are still unclear. 
Hyperactive HPA with altered diurnal cortisol rhythms have been observed in 
metabolic syndrome, obesity and diabetes. We hypothesised that differences in HPA 
activity contribute to increased risk of GDM in SA. 
Methods:  A prospective multicentre study of high-risk SA and WC women was 
conducted (PRiDE-HPA study). All women of SA or WC origin less than 16 weeks 
of gestation, meeting selective screening criteria for GDM were recruited, after 
excluding topical, oral, inhaled steroids and multiple pregnancy. 
Maternal data, anthropometry, blood are obtained with timed salivary collections 
and a 24 hour urine. Saliva is collected at waking, 30 min after, 4pm and bedtime 
twice in pregnancy. At oral glucose tolerance test (OGTT) blood samples fasting 
and 2 hour plasma glucose was estimated. The differences in salivary cortisol 
behaviour and urinary excretion were studied in SA and WC in relation to glycaemia 
in later pregnancy. 
Results: SA had a significantly greater cortisone awakening response than WC and a 
more enhanced conversion of cortisol to cortisone because of increased renal HSD2 
activity. Waking and peak cortisone in early pregnancy correlated independently 
with fasting plasma glucose at 24 weeks. While BMI was an independent predictor 
of total GC excretion in WC, adiposity but not BMI independently predicted total 
glucocorticoid excretion in SA. 
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Conclusion: There are distinct differences in HPA activity and cortisol clearance 
between SA and WC in early pregnancy. Early pregnancy waking salivary cortisone 
was an independent predictor of glycaemia in later pregnancy and could be used as 
an early predictor of GDM. It is possible that the differences in the HPA activity and 
cortisol clearance could in part explain the higher risk of GDM and overall 
metabolic risk in SA. 
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7.2 Introduction 
7.2.1 Ethnic differences in GDM risk 
GDM is a pre-diabetes state, associated with 7-8 fold increase in maternal risk and 
2-4 fold increase in offspring risk of type 2 diabetes (T2D)[207, 209]. Currently 
GDM is diagnosed at 24-28 weeks of gestation with a 75g oral glucose tolerance test 
(OGTT). Early prediction of GDM is poor and the search for reliable early 
biomarkers in GDM is ongoing. It is well known that SA have more than double the 
prevalence of GDM and T2D than WC, even at lower levels of obesity [13, 14]. 
Mechanisms for this heightened susceptibility are not fully understood.  
7.2.2 Cortisol and its metabolism 
Cortisol is a steroid hormone produced by the zona-fasciculata of the adrenal gland. 
It has several functional roles which includes regulation of inflammatory and 
immune responses, energy metabolism i.e glucose and fat metabolism, and 
regulation of vascular function. Its secretion is controlled by the Adreno Cortico 
Trophic Hormone (ACTH), secreted by the anterior pituitary, which in turn is 
controlled by Corticotropin releasing hormone (CRH) from the hypothalamus. 
(Figure1).  
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Cortisol in circulation is largely bound to cortisol binding globulin (CBG) and in 
basal conditions less then 5% of cortisol is unbound [210]. It is metabolized in the 
body to inactive Cortisone by the enzyme 11β hydroxy-steroid dehydrogenase (HSD 
2) present in the kidneys [211] and the salivary glands and the female reproductive 
system including the placenta [212]. This enzyme assumes special importance in 
mineralocorticoid sensitive tissues such as the kidneys to prevent the excessive 
mineralocorticoid action of cortisol. In the renal tubules cortisol is also metabolised 
to tetra-hydro cortisol (THF) and αTHF by 5β and 5α reductase respectively. 
Cortisone is further metabolised by 5β reductase to tetra-hydro cortisone (THE). 
(Figure 2).  11β hydroxy-steroid dehydrogenase 1(HSD1) regenerates cortisol from 
cortisone and is largely present in the adipose tissue, liver, muscle and bone. 
Figure 1: Feedback control of cotisol secretion. The 
Hypothalamic-pituitary-adrenal axis. HPA. (Adapted 
from Baron and Boulpaep, Medical physiology, 1st Edition 
Saunders, 2003) 
 
CRH from hypothalamus stimulates the anterior pituitary to 
release ACTH from the anterior pituitary which in-turn 
stimulates the Zona-Fasciculata of the adrenal cortex to 
produce cortisol. Cortisol exerts negative feedback on both the 
pituitary and hypothalamus to inhibit both CRH and ACTH. 
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7.2.3 Functions of cortisol 
Circulating cortisol exerts its actions by binding to cytosolic corticoid receptors, 
which are a part of the nuclear steroid-thyroid-retinoid receptor superfamily [213] 
and influence transcription of target genes. Cortisol is an important hormone for 
cellular energy metabolism, and plays an important role in adaptive mechanisms 
during periods of stress. The acute metabolic effects of cortisol are largely adaptive 
in nature i.e increasing mobilization of glucose [214], free fatty acids [215] and 
amino acids [216] from endogenous stores for mitochondrial oxidation and energy 
production. In addition to its role in cellular growth and energy metabolism it also 
regulates blood pressure, immune function and fluid balance [215].  
7.2.4 Cortisol and metabolic risk 
As opposed to acute adaptive responses of cortisol, chronic increased cortisol 
exposure on the other hand is maladaptive, as seen in the typical example of 
Cushing’s syndrome, which is associated with a number of morbidities such as 
central obesity, insulin resistance and dysglycaemia, osteoporosis, hypertension, and 
immune suppression [217]. Here, cortisol is largely catabolic leading to decreased 
lean body and muscle mass associated with increased central obesity and increased 
fat mass.  
Subclinical hypercortisolism with raised plasma cortisol levels have been seen in 
insulin resistance states, obesity and metabolic syndrome [218] [219, 220]. 
Figure 2: Cortisol metabolism in 
the kidneys. (Adapted from Van 
Uum Et al) [1]  
11βHSD2 metabolises cortisol to inactive 
cortisone. Cortisol is also metabolised to 
tetra-hydro cortisol (THF) and αTHF by 5β 
and 5α reductase respectively. Cortisone is 
further metabolised by 5β reductase to tetra-
hydro cortisone (THE). 
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Individuals with diabetes have been shown to have higher 24-hour urine free cortisol 
and basal plasma cortisol compared to controls [221]. A picture of hypercortisolism 
along with increased urinary clearance suggests a hyperactive hypothalamic 
pituitary adrenal axis (HPA). Adults with glucose intolerance have increased 
activation of the HPA with higher fasting cortisol and exaggerated responses to the 
repeated stress of venepuncture [222, 223]. The causal relationship between HPA 
regulation and metabolic risk is still unclear [224]. While the peripheral hypothesis 
states that adiposity in obesity states cause altered cortisol metabolism, the central 
hypotheses believes that HPA dysregulation is the cause of adverse metabolic states 
such as obesity[224].  
In addition to hypercortisolism, changes in the diurnal patterns of cortisol have been 
observed in conditions of adverse metabolic risk. In healthy adults, cortisol rises 
steeply from awakening up to 30 min (cortisol awakening response-CAR), a 
measure of HPA reactivity followed by a decline throughout the day [225, 226]. The 
decline is characterised by an initial steep phase (early decline) followed by a more 
gradual decline (late decline). The Multiethnic study of Atherosclerosis (MeSA) 
showed that individuals with diabetes had a trend towards a lower awakening 
cortisol and a significantly lower CAR than individuals without diabetes [57].
 
In 
another study, BMI negatively correlated with awakening salivary cortisol and a 
showed a greater decline of cortisol following the initial peak [227]. In contrast to 
what was seen in diabetes states, metabolic syndrome in women was associated with 
a higher CAR but lower awakening cortisol than those women without metabolic 
syndrome (figure 3)[228].  
Whether HPA dysregulation is associated with hyperglycaemia of pregnancy or 
GDM, which predates diabetes is not known. One study of 23 women reported 
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higher 9am cortisol in GDM but no studies have looked at diurnal cortisol patterns 
[229]. 
Figure 3: Higher CAR in metabolic syndrome 
  
7.2.5 Cortisol patterns in normal pregnancy 
 
Both total and free cortisol and cortisone increase about 2-3 fold in later pregnancy 
compared to the post-partum state [230]. Although there is a surge of both cortisol 
and CBG levels simultaneously [231, 232] the normal diurnal rhythm of cortisol is 
preserved in pregnancy [230]. The placental HSD2 inactivates cortisol to cortisone 
to prevent fetal exposure to excess cortisol. 
7.2.6 Ethnic differences in cortisol patterns 
Ethnic differences in diurnal cortisol in non-pregnant adults have been reported in 
studies between Blacks, Hispanics and WC [59]. Blacks were shown to have flatter 
diurnal cortisol patterns compared to WC [233]. It has been demonstrated previously 
that although morning cortisol concentrations were lower there was a stronger 
positive correlation of cortisol with components of metabolic syndrome (including 
glucose intolerance) in SA compared to WC [60]. There are no studies 
systematically studying the differences in diurnal or cortisol clearance patterns 
Women with 
metabolic syndrome 
have greater CAR and 
lower awakening 
cortisol compared to 
those without This 
difference was not 
seen in men. Adapted 
from Bengtsson [228]  
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between SA and WC. Studies examining ethnic differences in HPA activity are 
described below in table 1. 
Table 1: Summary of literature examining cortisol patterns between ethnic 
groups 
 
Studies Ethnic groups Sample analyzed Result 
DeSantis [234] Blacks, Hispanic, 
WC 
Diurnal Salivary 
Cortisol 
Flatter curves in Hispanics and Blacks compared to 
WC 
Hajat [59] 
(MeSA study) 
Blacks, Hispanic, 
WC 
Diurnal Salivary 
Cortisol 
Lower Waking Cortisol and less steep decline in 
Blacks and Hispanics compared to WC 
Reynolds [60] SA and WC Single Plasma 
Cortisol  
SA had lower morning Cortisol than WC 
Karlamangla 
[233] 
WC and Blacks Diurnal Salivary 
Cortisol 
Blacks had lower waking and peak Cortisol 
but higher nadirs (i.e., flatter cortisol rhythms) 
compared to WC  
Cohen [235] WC and Blacks Diurnal Salivary 
Cortisol 
Blacks had a flatter evening declines compared to WC 
Suglia [236] Blacks and 
Hispanics 
Diurnal Salivary 
Cortisol 
In Black but not Hispanic women, 
cumulative stress was associated with lower morning 
cortisol levels. 
Martin [237] WC, Blacks and 
Latinos 
Diurnal Salivary 
Cortisol 
Blacks have flatter morning-to evening 
cortisol slopes and Latinos have lower evening 
cortisol levels than WC 
7.2.7 Salivary cortisol  
Measuring total serum cortisol, as a measure of bioavailable cortisol is fraught with 
problems especially in conditions associated with alterations in CBG (eg pregnancy 
and contraceptive use) where there is a rise in both total cortisol and CBG. Free 
serum cortisol assays are rarely used in practice because of cost and complexity 
involved. Saliva provides a filtrate, free of CBG and salivary cortisol has been found 
to have a good correlation with free serum cortisol, irrespective of CBG variability 
(17). Hence salivary cortisol has been used recently as a surrogate for free serum 
cortisol [238]. In addition salivary cortisol is a non-invasive test, can be performed 
at home and does not include the stress of venae puncture. In pregnancy and 
oestrogen excess states salivary cortisone is thought be a better predictor of free 
circulating cortisol than salivary cortisol and is unaffected by changes in CBG [230, 
239]. 
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7.3 Hypothesis and research question 
 SA women have a higher cortisol exposure compared to WC in pregnancy  
 Higher cortisol exposure contributes to higher risk of GDM.  
7.4 Aims 
The main aim is to study the differences in cortisol exposure between SA and WC  
Secondary aims are to study the relationship between cortisol exposure and 
glycaemia of pregnancy 
7.5 Outcomes 
Primary outcome: 
Difference in waking and peak cortisol between SA and WC in early pregnancy. 
Secondary outcomes: 
1. Ethnic differences in AUC (Area under the Curve), CAR, decline, bedtime 
and 24-hour urinary cortisol and metabolites. 
2. Relationship of maternal cortisol indices with GDM risk 
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7.6 Methods: The PRiDE-HPA Clinical study 
7.6.1 Subjects 
This was a prospective cohort study of 100 pregnant women (50 SA and 50 WC), 
who were recruited from the ongoing, PRiDE (micronutrients in Pregnancy as a 
Risk factor for Diabetes and Effects on mother and baby) study.  SA include women 
of Indian, Sri-Lankan, Nepalese, Pakistani and Bangladeshi origin. The two ethnic 
groups were matched for age, smoking status and BMI. Women were recruited in 
early pregnancy (<12 weeks) and followed up until OGTT at 24-28 weeks. Data and 
samples were collected at each visit along with additional data available from the 
parent PRiDE study as outlined in the table 2 below. 
Table 2: Summary of clinical and biochemical data collected for the PRiDE-
HPA study 
 
 Data and samples collected  
Visit PRiDE study (available) PRiDE-HPA study  Analytes 
Recruitment 
(<12 weeks) 
Visit - 1 
History 
Questionnaires (quality of life, socio-economic, 
well-being, anxiety, depression, physical activity) 
Anthropometry Waist circumference, height, 
weight, skin fold thickness. 
24-hour urine 
Saliva (waking, 
30min, 16:00 and 
bedtime)  
 
 
Urine – 24-hour Cortisol 
excretion 
Saliva- Cortisol 
 
 OGTT (24-28 
weeks) 
Visit - 2 
Anthropometry  
Questionnaires  
Blood samples at 
30, 60, 90 min 
during OGTT 
Saliva as above 
Fasting and 120 min 
blood samples 
Saliva- Cortisol 
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7.6.2 Laboratory Analysis 
Salivary cortisol (SalF) and cortisone were estimated form the saliva samples by 
Mass Spectrometry at the University of Manchester. Techniques used were as 
described previously [240]. 
Urine glucocorticoid (GC) analysis was performed at the university of Edinburgh: 
Urine GC metabolites were quantified in 24-hour urine collections by gas 
chromatography electron impact tandem mass spectrometry following solid phase 
extraction hydrolysis of conjugates and formation of their methoxime-trimethylsilyl 
derivatives, as previously described previously [241].  
The list of metabolites include 
1. Urinary Free cortisol (F) 
2. Cortisol metabolites: 5β-tetrahydrocortisol (THF), 5α-tetrahydrocortisol (α-
THF), α-cortol, and β-cortol 
3. Free urinary Cortisone (E) 
4. Cortisone metabolites: tetrahydrocortisone (THE), α-cortolone, β-cortolone 
5. Total GC excretion: sum of all above  
Enzyme activity was measured as previously described [242]: 
1. F/E ratio:  11beta-hydroxysteroid-dehydrogenase-type 2 (HSD2) enzyme 
activity, which converts active cortisol into inactive cortisone 
2. α-THF / cortisol ratio: a measure of 5α-reductase activity, which converts 
cortisol to α-THF 
3. (THF+α-THF) / THE ratio: Whole body 11β-HSD1 and 11β-HSD2 activity 
7.6.3 Sample size calculations  
With no literature on salivary cortisol in SA in pregnancy, we used the accepted 
Cohen’s estimate of d>0.5SD as a clinically meaningful difference. A sample size of 
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100 (50 SA and 50 WC) would detect a difference of 0.6SD in both waking and 
peak cortisol between SA and WC with 80% power and 5% significance, allowing 
for 10% incomplete data. We however expect the difference to be much higher 
based on studies which showed the difference in waking SC between Hispanics and 
WC to be at least twice SD[59]. Another study measuring a difference in awakening 
and peak salivary cortisol between WC and non-WC also showed a difference of 
>2SD[233]. Our sample size would therefore have even greater power (>95 %) to 
detect a larger difference as seen in the above studies. 
7.6.4 Calculations and Statistical analysis 
Cortisol indices such as AUC, awakening, peak, CAR, early, late decline and bed 
time cortisol were calculated from SC. CAR is defined as the cortisol increase form 
awakening to 30 min, early decline as the decrease from 30 min to 16.00, late 
decline as the decrease from 16.00 to bed time. AUC was calculated using the linear 
trapezoid method using the formula AUC = Σ (½*(Ct1+Ct2)/(t1-t2)), where t1 and t2 
represent the two consecutive time points and C represents the concentration of 
cortisol or cortisone at the specific time point.  All indices were log transformed for 
all analysis. 
7.6.5 Minimizing Bias 
Age, BMI, waking time, and smoking status have been shown to affect cortisol 
levels. Therefore, adjustments were made for these covariates in all models.  
Student t test was performed to study differences in cortisol and cortisone at 
different time points and the differences in CAR, early decline and late decline.  
Linear multivariable regression was performed for all outcome measures after 
adjustment for aforementioned confounders. 
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 Primary outcome (differences in peak and waking cortisol between SA and 
WC): simple parametric student t-test and linear multivariate regression of 
peak and waking cortisol will be performed. 
 Secondary outcomes: 
1. AUC, CAR, early, late decline and bed time cortisol will be used as 
dependent variables with ethnicity as the independent variable after 
appropriate adjustment. 
2. Ethnic differences in Urinary GC metabolites 
3. Relationship between maternal glucose at OGTT and early pregnancy 
cortisol indicators 
Repeated measures ANOVA was performed to examine the differences in trend of 
diurnal salivary cortisol between the two groups 
7.6.6 Plan of investigation  
Participants for the current PRiDE-HPA study were recruited from the ongoing 
PRiDE study cohort. 
PRiDE Study  
Is a large, multicentre, MRC-funded prospective pregnancy cohort designed to 
recruit 4500 mothers in early pregnancy who have been identified to have a high risk 
of developing GDM according to the selective screening criteria. (Women must 
satisfy at least one of the following criteria: Obesity, previous history of GDM or 
unexplained still birth, 1
st
 degree relative with T2D, previous history of 
macrocosmic babies or ethnic minority origin i.e South-Asian, Middle –Eastern or 
Afro-Caribbean). The study is funded to test the hypothesis that early pregnancy 
vitamin B12, folate and homocysteine levels independently predict the risk of GDM 
in WC and SA. 
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PRiDE HPA study 
Inclusion: Pregnant women aged 18-45 years from the PRiDE cohort 
   Duration of pregnancy <16 weeks  
Exclusion: Pre-existing diabetes 
                 Ethnic groups other than SA or WC 
          Oral, inhaled or topical steroid use within last 3 months 
                 Multiple pregnancy 
Recruitment and study visits: 
Participant Identification 
 Eligible participants were identified in early pregnancy (<12 weeks) from 
dating scan clinics 
 Study explained and consent obtained 
Recruitment - Visit 1 
 History, anthropometry details obtained 
 Participants given salivettes for timed salivary collection and 24-hour urine 
collection bottles to return before 16 weeks 
 Further salivettes given for saliva collection between 24-28 weeks.  
 A mobile-phone text reminder system was used to alert women for saliva 
collection one day prior to sample collection date. Women were asked to 
record the exact time of waking and saliva collection. 
OGTT - Visit 2 (24-28 weeks) 
 Anthropometry, history, saliva and blood samples are obtained 
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7.7 Results 
7.7.1 Differences in Salivary cortisol and metabolites – Unadjusted analysis 
Table 3 shows the baseline characteristics of the women in SA and WC groups. 
Apart from differences in anthropometry, both groups were similar with respect to 
age, glycaemia and gestational age at recruitment. Despite significant differences in 
BMI, and abdominal circumference, SA had similar measures of subcutaneous 
adiposity at both triceps and subscapular skin folds. 
Table 3: Baseline characteristics of women in PRiDE-HPA study in SA and 
WC 
 
 WC: Mean (SD) SA: Mean (SD) P  
Age in years 29.52 (5.19) 30.58 (5.49) 0.332 
Gestational age at recruitment  13.08 (2.32) 13.69 (1.56) 0.128 
Height cm 164. (7.41) 158.98 (5.65) <0.0001 
Waist circumference cm 101.20 (15.97) 86.29 (10.35) <0.0001 
Skin fold thickness (triceps) mm 25.23 (7.41) 23.35 (7.01) 0.201 
Skin fold thickness (subscapular)mm 28.07 (9.45) 25.17 (9.03) 0.127 
BMI kg/cm2 29.89 (6.95) 24.56 (3.97) <0.0001 
FPG mmol/l 4.36 (0.34) 4.40 (0.51) 0.786 
2hPG mmol/l 5.72 (1.02) 6.09 (1.18) 0.238 
Smokers n (%) 3 (6.4%) 0  0.055 
Table 3 depicts the differences in baseline characteristics between SA and WC. 
Table 4 and 5 show differences in diurnal cortisol and cortisone patterns in the 
saliva. In the unadjusted analysis, SA had similar salivary cortisol and cortisone 
levels despite having significantly lower BMI than WC. CAR of cortisone tended to 
be higher in SA compared to WC with p=0.059.  
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Table 4: Ethnic differences in salivary cortisol  
 WC: Mean (SD) SA: Mean (SD) p 
Cortisol Waking (nmol/l) 8.43 (4.95)  7.68 (4.12) 0.342 
Cortisol @30min (nmol/l) 9.19 (5.4) 8.90 (4.97) 0.946 
Cortisol@4pm (nmol/l) 3.53 (6.53) 2.53 (1.32) 0.983 
Cortisol@Bed (nmol/l) 2.77 (5.18) 2.21 (4.66) 0.651 
CAR Cortisol (nmol/l) 1.51 (4.11) 1.17 (4.29) 0.932 
Early decline Cortisol (nmol/l) 6.45 (4.63) 6.47 (4.21) 0575 
Late-decline Cortisol (nmol/l) 0.56 (3.2) 0.39 (3.09) 0.751 
AUC Cortisol (nmol/l) 249478.84 (203474.01) 229951.48 (126043.62) 0.91 
Table 4 shows the salivary cortisol at different time points along with CAR, decline and AUC. p 
values indicates difference in log10(cortisol) using the student t test. 
 
Table 5: Ethnic differences in salivary cortisone  
Cortisol metabolites (nmol/l) WC: Mean (SD) SA: Mean (SD) p 
Cortisone Waking  29.42 (10.77) 28.35 (8.65) 0.658 
Cortisone (30min) 32.91 (12.19) 35.62 (12.99) 0.254 
Cortisone (4pm) 14.84 (7.84) 14.97 (5.48) 0.743 
Cortisone (Bed) 10.68 (9.82) 9.04 (4.43) 0.838 
CAR Cortisone  3.49 (12.39) 7.29 (12.03) 0.059 
Early decline Cortisone  17.51 (11.63) 20.73 (14.07) 0.582 
Late decline Cortisone  4.67 (8.30) 5.73 (8.17) 0.959 
AUC Cortisone  1,023,217.21 (492669.7) 1,028,613.5 (294076.2) 0.514 
salE/salF waking 3.98 (1.21) 4.27 (1.51) 0.316 
salE/salF @30 min 4.16 (1.27) 4.54 (1.37 0.176 
salE/salF @ 4pm 6.60 (1.97) 6.58 (2.06) 0.962 
salE/salF @ bedtime 5.79 (1.83) 6.33 (2.21) 0.207 
Table shows the salivary cortisone at different time points along with CAR, decline and AUC. p 
values indicates difference in log10(cortisone) using the student t test. SalE = salivary cortisone, SalF 
= salivary cortisol 
 
Analysis of the diurnal trends of Cortisol and Cortisone between the 2 ethnic groups 
is shown in Fig 4 & 5. A repeated measures or Mixed between subjects ANOVA 
was conducted for both cortisone and cortisol between SA and WC ethnicities. In 
line with previous results there was no significant interaction between ethnicity and 
time or independent effect of ethnicity on either of the two analytes. 
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Figure 4: Diurnal trends of cortisone in SA and WC 
 
 
 
 
Figure 5: Diurnal trends of cortisol in SA and WC 
 
 
7.7.2 Adjusted analysis 
To account for the significant differences in maternal characteristics between the 
two ethnic groups, linear regression was conducted after adjustment for covariates 
such as gestational age, maternal age, maternal age, smoking, waking time and BMI 
(Table 6). SA had significantly higher CAR of cortisone compared to WC after 
adjustment for the above characteristics. Similar analysis of salivary cortisone: 
cortisol ratio (which could be regarded as a surrogate of HSD2 activity in the saliva) 
 A mixed between subjects ANOVA (repeated 
measures) was performed for log cortisone at 4 time 
points for SA and WC 
 There was no significant interaction between ethnicity 
and time: Wilks’ Lambda = 0.965, F (3, 81) = 0.967, 
p=0.413.  
 There was a significant main effect for time: Wilks’ 
Lambda = 0.108, F (3, 81) = 223.43, p < 0.0001, 
partial eta squared = 0.892 (large effect size), with 
both ethnic groups showing a significant change in 
cortisone across all 4 time points.  
 The main effect comparing the two ethnic groups was 
not significant, F (1, 83) = 2.710, p = 0.103, partial eta 
squared =0 .032, suggesting no difference in cortisone 
between SA and WC. 
 
 A mixed between subjects ANOVA (repeated measures) 
was performed for log cortisol at 4 time points for SA 
and WC 
 There was no significant interaction between ethnicity 
and time, Wilks’ Lambda = 0.964, F (3, 81) = 1.007, 
p=0.394.  
 There was a significant main effect for time, Wilks’ 
Lambda = .116, F (3, 81) = 205.652, p < 0.0001, partial 
eta squared = 0.884, with both ethnic groups showing a 
significant change in cortisone across all 4 time points.  
 The main effect comparing the two ethnic groups was 
not significant, F (1, 83) = 0.079, p = 0.779, partial eta 
squared =0 .001, suggesting no difference in cortisone 
between SA and WC. 
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showed significantly higher ratio at 30 min in SA compared to WC after adjustment 
for BMI. (table 7) 
Linear regression analysis of other cortisol and cortisone variables did not yield 
significant ethnic differences. 
Table 6: Relationship between Ethnicity and CAR (Cortisone) 
 Log CAR (Cortisone) 
 (β coefficient (95% CI)) 
Model 1 0.272(-0.11, 0.55), p=0.059  
Model 2 0.27 (-0.39, 0.58), p=0.086 
Model 3 0.401 (0.031, 0.771), p=0.034 
Multivariable linear regression analysis using CAR (Cortisone) as dependent variable and ethnicity as 
a independent variable and addition of covariates as below. 
Model 1: Ethnicity only (0 = WC, 1 = Asian) 
Model 2: Ethnicity + gestational age + waking time + smoking 
Model 3: Model 2 + BMI 
 
Table 7: Association between peak cortisone: cortisol ratio and ethnicity 
 Log (cortisone: cortisol  @30 min) 
 (β coefficient (95% CI)) 
Model 1 β = 0.037, p=0.169 
Model 2 β =0.058, p=0.051 
Model 3 β =0.067, p=0.039 
Multivariable linear regression analysis using Cortisone : Cortisol ratio as dependent variable and 
ethnicity as a independent variable and addition of covariates as below. 
Model 1: Ethnicity only (0 = WC, 1 = Asian), Model 2: Ethnicity + gestational age + waking time 
Model 3: Model 2 + BMI 
 
Further analysis to study the relationship between glycaemia and cortisol 
metabolites showed that both waking and peak cortisone in early pregnancy were 
independent predictors of fasting plasma glucose at OGTT even after adjustment for 
all covariates as shown in table 8. No other cortisol indices were associated with 
glycaemia. 
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Table 8:  Associations of cortisone with fasting plasma glucose at OGTT 
 Cortisone at waking 
 (log cortisone waking)  
Cortisone peak 
(log cortisone @30min) 
 (β coefficient (95% CI)) 
Model 1 0.718 (-0.3, 1.7), p= 0.162 0.389 (-0.119, 0.898), p=0.13 
Model 2 1.459 (0.431, 2.487), p=0.006 0.468 (-0.35, 0.970), p=0.067 
Model 3 1.469 (0.256, 2.681), p=0.019 0.591 (0.04, 1.13), p=0.035 
Multivariable linear regression analysis using waking and peak cortisone as dependent variables and 
fasting plasma glucose as independent variable and adjustment for covariates as below.  
Model 1: Waking time and gestational age only 
Model 2: Waking time + gestational age + ethnicity + age 
Model 3: Model 2 + BMI 
7.7.3 Differences in Urinary cortisol and its metabolites 
Table 9 shows differences in urinary cortisol metabolites between SA and WC. 
Total urinary cortisol, cortisone, total GC metabolites were not different between SA 
and WC. Multivariable linear regression was performed for using cortisol 
metabolites as dependent variables and ethnicity as an independent variable and 
adjusting for covariates such as gestational age at sample collection, maternal age, 
BMI and smoking (table 10). SA had significantly higher HSD2, lower 5α-reductase 
activity, and lower total HSD activity compared to WC. The differences in urinary 
cortisone and 5α-reductase activity were not significant on adjustment for maternal 
age, and BMI respectively. There were no significant differences in any of the other 
cortisol metabolites between the ethnic groups.  
BMI appeared to be a significant predictor of total GC excretion (table 11) but no 
significant relation was seen between BMI and other cortisol metabolites like F, E, 
F:E ratio or 5α-reductase activity either in unadjusted or adjusted models. On 
repeating the analysis in the two ethnic groups separately, BMI did not predict total 
GC excretion in SA. (p=0.196) after adjustment for maternal age and gestational 
age. In WC this relationship remained significant (p=0.02) after adjustment. Other 
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measures of adiposity, especially abdominal circumferences and skin fold thickness 
were stronger predictors of urinary GC excretion (table 12) in SA compared to WC. 
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Table 9: Ethnic differences in urinary cortisol metabolites and enzyme activity 
Student t test performed for log-transformed variables.  
p indicates difference in log transformed variables 
 
Table 10: Relationship between Ethnicity and urinary cortisol metabolites 
Multivariable linear regression using cortisol metabolites or enzyme activity as dependent variable 
and ethnicity as an independent variable after adjustment for below mentioned variables. 
Model 1: Ethnicity + gestational age (WC = reference category), Model 2: Model 1 + age + smoking 
Model 3: Model 2 + BMI 
 
Table 11: Relationship between BMI and cortisol metabolites in the whole 
group: 
Multivariable linear regression, using total GC excretion as dependent variable and BMI as 
independent variable after adjustment for other variables as shown below. Model 1: BMI only  
Model 2: BMI + age+ ethnicity + gestational age at urine test (WC reference category) 
 
Table 12: Relationship between urinary GC excretion and measures of 
adiposity in the two ethnic groups 
Multivariable linear regression, using total GC excretion as dependent variable and measures of 
adiposity as independent variables after adjustment for gestational age and maternal age and 
smoking. Table shows that measures of adiposity such as skin fold thickness and abdominal 
circumference were better predictors of urinary GC excretion than BMI in SA.  
Cortisol metabolites in ug/day WC: Mean (SD) SA: Mean (SD) p  
Cortisol (F) 197.35 (114.09) 194.84 (102.89) 0.889 
Cortisone (E) 135.70 (83.78) 160.58 (81.05) 0.074 
Total GC metabolites  6778.01(4742.71) 6369.62 (4149.74) 0.794 
F: E (HSD2) 1.54 (0.59) 1.29 (0.51) 0.016 
αTHF: F (5α-reductase) 1.69 (0.93) 1.24 (0.62) 0.019 
(THF+ αTHF): THE (whole body HSD1+HSD2) 0.73 (0.31) 0.59 (0.49) <0.002 
 24 hour Cortisone F: E  Ratio  5α-reductase 
activity 
Total body HSD  
 (β coefficient (95% CI)) 
Model 1 0.093 (0.002, 0.184), 
p=0.045 
-0.089 (-0.151, -
0.027), p=0.005 
-0.157 (-0.295, -
0.018), p=0.027 
-0.112 (-0.183, -
0.041), p=0.002 
Model 2 0.081 (-0.009, 0.170), 
p=0.078 
-0.079 (-0.139, -
0.019) 
p=0.010 
-0.177 (-0.317, -
0.038), p=0.013 
-0.112 (-0.185, -
0.039), p=0.003 
Model 3 0.092 (-0.10, 0.193), 
p=0.076 
-0.069 (-0.137, -
0.002), p=0.045 
-0.154 (-
0.321,0.014), 
p=0.071 
-0.162 (-0.230, -
0.094), p<0.0001 
 Total GC excretion (log)  (β coefficient (CI)) 
Model 1  0.012 (0.003, 0.021), p=0.009 
Model 2  0.014 (0.004, 0.024), p=0.005 
 SA (β coefficient (95% CI)) WC  (β coefficient (95% CI)) 
BMI 0.011(-0.006, 0.027), p=0.196 0.016 (0.003, 0.029), p=0.020 
Triceps skin fold thickness 0.012 (0.000, 0.023), p=0.044 0.011 (0.000, 0.022), p=0.047 
Subscapular thickness 0.009 (0.001, 0.018), p=0.038 0.004 (-0.005, 0.013), p=0.329 
Abdominal circumference 0.010 (0.003, 0.017), p=0.005 0.005 (0.000, 0.010), p=0.063 
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7.8 Discussion 
This study was the first to examine differences in cortisol secretion patterns (with 
diurnal salivary cortisol) and cortisol clearance (urinary cortisol) between SA and 
WC women. Our study examined these differences in a high-risk population in early 
pregnancy. 
7.8.1 Diurnal Salivary cortisol patterns 
In the initial unadjusted analysis, we found that despite having significantly lower 
BMI, SA did not differ with respect to cortisol levels either at awakening, peak, 4 
pm or bed-time from WC indicating that leaner SA had similar HPA activity to 
more overweight WC. Studies in WC have indicated that BMI is inversely related 
with awakening cortisol and AUC of cortisol [227, 243]. Studies in pregnant WC 
showed that obese women had significantly lower salivary cortisol at all time points 
compared to lean controls. Despite having significantly lower BMI it was intriguing 
that SA had similar cortisol secretion and diurnal pattern as WC. However, it was 
seen in our study that despite BMI differences, SA had similar measures of adiposity 
to WC as measured by skin fold thickness. It is also well known that SA have 
greater degrees of adiposity at similar BMI when compared to WC [244]. Therefore 
is likely that this relationship between cortisol and obesity are mediated by adiposity 
rather than BMI in SA.  
After adjustment for BMI differences SA were shown to have a significantly greater 
CAR than WC. A higher CAR in SA could be regarded as a clinical predictor of 
adverse metabolic risk in line with previous observation that has shown an increased 
CAR in women with metabolic syndrome. However, the significance of CAR in 
relation to metabolic risk in pre-diabetes states such as metabolic syndrome, insulin 
resistance and obesity is still unclear. While some studies show a an increased CAR 
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in women with metabolic syndrome, others have shown a blunting of CAR in 
insulin resistant adolescents [245], and still others have found no association 
between CAR and metabolic syndrome or BMI [56] [227]. Bengtsson [228] also 
showed that the increase in CAR with metabolic syndrome was only seen in women 
but not in men. This lack of association between CAR and metabolic syndrome in 
the latter studies could hence be a result of a significant proportion of men in both 
studies.  
Secondly, it was also seen that both waking cortisone and peak cortisone in early 
pregnancy was closely associated with fasting plasma glucose in later pregnancy and 
hence could be used as an early first trimester predictor of GDM. Only one other 
study examined the association between cortisol and hyper glycaemia in pregnancy 
[229] and showed higher am cortisol in women with GDM. Our results confirm this 
previous finding using salivary cortisone results and extend this relationship to 
women without GDM. 
It is important to note that all our above results were seen only with respect to 
salivary cortisone but not with cortisol. As previously explained it has been shown 
that salivary cortisone but not cortisol was a better marker of free serum cortisol in 
pregnancy [230] and other states associated with high CBG levels [239]. Therefore, 
our results with respect to salivary cortisone could be extrapolated to free serum 
cortisol, and indicate that the HPA activity, i.e hypercortisolemia is closely related 
to glycaemia in pregnancy.  
7.8.2 Urinary clearance of cortisol and its metabolites 
We did not observe any significant differences in urinary excretion of cortisol or its 
metabolites between SA and WC, despite significant BMI differences. It is well 
known that urinary GC excretion increases with obesity [219, 246, 247] and in those 
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with metabolic syndrome [248], however again contrary to this observation, leaner 
SA exhibited similar urinary GC excretion as overweight WC.  
However, when this relationship was assessed separately in the two ethnic groups, 
BMI did not predict urinary GC excretion in SA. Other measures of adiposity, 
particularly the subscapular skin-fold thickness, which can be regarded, as a marker 
of central adiposity, was a significant predictor of urinary GC excretion in SA but 
not WC (table 10). Our results are supported by other observations that showed that 
central fat distribution was more closely linked to cortisol excretion rates than those 
with peripheral adiposity [219, 249, 250].  
SA appear to have increased urinary clearance of Cortisone and increased HSD2 
activity as indicated by reduced urinary F:E ratio compared to WC. The significance 
of this is unclear. It has been shown that both the expression and activity of renal 
HSD2 were increased in rodent models of obesity [251]. This was also observed in 
humans with extreme obesity who had marked elevated renal HSD2 activity 
compared to lean controls [252]. It appears that SA despite their lower BMIs have 
similar metabolic clearance of cortisol to more overweight WC women, again 
reemphasising the possible overriding role of adiposity despite lower BMI in SA. 
It must be remembered that the estimated HSD2 activity from the urinary cortisol 
metabolites represents not only renal HSD2 activity but also placental HSD2 
activity. There is evidence to show that placental HSD2 is up regulated and HSD1 is 
down regulated in the placenta of women with GDM compared to controls [229]. It 
is possible that a similar picture was seen in SA in early pregnancy given their 
higher degrees of glucose intolerance. 
The significance of reduced 5α-Reductase activity in SA is unclear. 5α-Reductase 
has an important role in the clearance of cortisol and 5α-Reduced steroids 
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compromise about a third to a half of all urinary cortisol metabolites [242]. Two 
isoforms of this enzyme have been detected i.e 5α-Reductase type 1 (5αR1) - mainly 
present in the liver, adipose tissue and skeletal muscle and type 2(5αR2) - mainly 
present in the male reproductive tract and to a small extent in the liver [253-256]. 
Recent evidence in rodents show that reduced 5αR1 activity was associated with 
hepatic steatosis, weight gain and hyperinsulinemia[257]. This finding was further 
confirmed in humans where 5αR blockade with duasteride for 3 months was 
associated with reduced insulin sensitivity and increased body fat by 1.6%[258]. It is 
possible that reduced 5α-Reductase Type 1 activity could potentially be one of the 
mechanisms for increased adiposity and higher insulin resistance seen in SA. 
In conclusion our study is the first to examine and report novel differences in HPA 
activity and GC excretion between SA and WC, and the relationship between early 
pregnancy HPA activity and glycaemia in later pregnancy. SA had a significantly 
greater awakening response than WC and a more enhanced conversion of cortisol to 
cortisone because of increased renal HSD2 activity and reduced conversion to 5α-
Reduced steroids due to reduced 5α-Reductase activity. Importantly our study also 
re-emphasises the close relationship between adiposity and the GC excretion in SA, 
reiterating the poor applicability of BMI in studying metabolic risk in SA. Early 
pregnancy cortisone independently predicted glycaemia in later pregnancy. 
Since these observations were in early pregnancy it can be postulated that similar 
patterns could be seen in the pre-pregnant state as well. However larger prospective 
studies are needed in both the pregnant and non-pregnant population to examine the 
differences in diurnal cortisol pattern in relation to higher metabolic risk in SA. 
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7.9 Future Directions 
 Study the relationship between salivary cortisol metabolites and insulin 
sensitivity and HOMA-IR at GTT  
 Further follow up studies to examine the relationship between cortisol and 
offspring outcome i.e. adiposity and BW 
 Estimation of placental HSD2 activity in SA and WC to measure placental 
clearance of maternal cortisol and fetal exposure to cortisol 
 Larger prospective randomised trials to study the utility of using waking 
salivary cortisone as a diagnostic tool for GDM 
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8 Conclusion and summary 
In summary, this research addresses important gaps in the diagnosis and follows up 
of GDM, effect of GDM on fetal growth and birth weight and explores a potential 
mechanism for the increased risk of GDM in SA and WC. The following are the key 
findings of our research. 
 The new IADPSG criterion for GDM is equally applicable in both SA and 
WC and is more likely to detect obese women with mild fasting 
abnormalities. The real benefit of treating mild GDM in these women is not 
well established. After accounting for BMI differences between SA and WC, 
it is likely that the IADPSG criteria will identify more SA than the previous 
mWHO-1999 criteria.  
 The uptake of post-natal screening by OGTT is poor overall with no 
significant ethnic differences. Post-natal screening rates increase 
significantly with using postnatal HbA1c. SA are more likely to attend 
postnatal screening by HbA1c than WC. Using FPG during the postnatal 
period to detect persisting abnormalities fails to detect IGT and diabetes in 
both SA and WC, however non-WC ethnic minority groups are more likely 
to be missed out by using FPG.  
 Maternal diabetes increases offspring BW in both SA and WC. However it 
appears that the magnitude of this increase in BW with maternal diabetes is 
not uniform across ethnic groups with SA having a significantly smaller 
increase in offspring BW compared to WC. This calls for the consideration 
of ethnicity specific glycaemic targets in pregnancy, and more studies on 
adverse fetal outcome in SA. 
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 SA and WC have different fetal growth patterns in GDM. Despite having 
higher levels of glycaemia at diagnosis of GDM, SA offspring display 
patterns of disproportionate fetal growth with patterns of fetal growth 
restriction, i.e. having smaller abdominal circumference but similar skeletal 
growth parameters such as Head Circumference and Femur Length. Standard 
intensive insulin regimens may need to be revisited and ethnic tailored 
glycaemic targets may need to be considered. 
 GDM is associated with disproportionate fetal growth. Fetuses of SA 
mothers with GDM display increased abdominal adiposity as early as 20 
weeks gestation, along with evidence of smaller overall size with reduced 
AC, HC and FL. Anterior abdominal wall thickness could be used as an early 
marker of GDM even prior to biochemical diagnosis of GDM. Larger studies 
are needed in other ethnic groups, to study the effects of treatment, i.e insulin 
and metformin on fetal growth and the long-term metabolic risk of these 
offspring. 
 There are distinct differences in HPA activity and cortisol clearance between 
SA and WC in early pregnancy. SA have a significantly greater awakening 
response than WC, a more enhanced conversion of cortisol to cortisone 
because of increased renal HSD2 activity and reduced conversion to 5α-
Reduced steroids due to reduced 5α-Reductase activity. Early pregnancy 
waking salivary cortisone was an independent predictor of glycaemia in later 
pregnancy and could be used as an early predictor of GDM. It is possible that 
differences in the HPA activity and cortisol clearance could in part explain 
the higher risk of GDM and overall metabolic risk in SA. 
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 Postnatal testing following gestational diabetes: time to 
replace the oral glucose tolerance test?
Gestational diabetes is associated with up to an 
eight times increase in risk of future type 2 diabetes: 
the incidence of type 2 diabetes is 3–24% in the ﬁ rst 
year postpartum and up to 50% in the ﬁ rst 5 years.1 
Therefore, postnatal testing for these women provides 
a crucial opportunity for the early detection of diabetes, 
intervention, and preconceptional care in subsequent 
pregnancies. Despite this evidence, uptake of postnatal 
testing for diabetes is poor, with only 23–58% of women 
with gestational diabetes attending the oral glucose 
tolerance test (OGTT)2—a sharp contrast with the uptake 
of postnatal cervical screening (94%) and antenatal 
gestational diabetes screening (98%).3
Despite this, most international guidelines,4 including 
those of the Fifth International Workshop Conference on 
Gestational Diabetes, the American Diabetes Association 
(ADA), the Canadian Diabetes Association, and the 
Australasian Diabetes in Pregnancy Society continue 
to recommend postnatal OGTT. However, in 2015, the 
National Institute of Health and Care Excellence (NICE) 
recommended either a fasting plasma glucose (FPG) or 
HbA1c test rather than OGTT for postpartum screening.5 
We collected contemporary data from 14 477 women 
who attended antenatal OGTT during 2009–12 across 
three UK centres. The appendix contains a summary 
of our methods. Our results further support the need 
to investigate alternatives to OGTT. Of 1289 (9%) 
women diagnosed with gestational diabetes, only 
630 (49%) attended a postnatal OGTT. Furthermore, 
non-attenders were more likely to have increased 
metabolic risk (table), because multiparity (odds ratio 
1·80, 95% CI 1·24–2·58), smoking (2·80, 1·58–4·97), 
and macrosomia (2·52, 1·46–4·34) were independent 
predictors of non-attendance at postnatal OGTT 
after adjustment for maternal BMI, age, glucose 
concentrations at antenatal OGTT, gestational age, and 
oﬀ spring sex. Other studies6 have reported that women 
who did not attend postnatal OGTT were more likely to 
have had worse glycaemic control and needed insulin 
during pregnancy than were those who attended. Our 
ﬁ ndings, combined with previous evidence, suggest 
that women who do not attend a postnatal OGTT 
are at increased risk for subsequent type 2 diabetes. 
We also analysed preliminary data from one of our 
centres that subsequently adopted HbA1c for postnatal 
testing in gestational diabetes from December 2013 to 
assess HbA1c uptake. Of 348 women with gestational 
diabetes, 217 (62·4%) women attended HbA1c 
testing, representing an increase of 28% (p<0·0001) 
compared with OGTT at that centre. Reassuringly, 
risk characteristics did not diﬀ er between those who 
attended and failed to attend HbA1c tests (unlike OGTT), 
suggesting increased uptake of HbA1c by women at high 
risk of type 2 diabetes postpartum. 
Barriers to postnatal screening for persisting glucose 
abnormalities after gestational diabetes mellitus have 
not been studied extensively. The inconvenience of 
OGTT and time pressures were the most commonly 
cited reasons for non-attendance in patient surveys.7 
FPG tests have been recommended as a simpler and 
cheaper alternative to OGTT. However, FPG requires 
fasting, is restricted to mornings, and might especially 
inconvenience mothers with young children. The 
alternative is a non-fasting HbA1c test. 
Both ADA and NICE recommend HbA1c for the 
diagnosis of diabetes in high-risk non-pregnant 
adults without symptoms8 and for preconception risk 
stratiﬁ cation of women with pre-existing diabetes.9 
Studies10 to assess the role of HbA1c in the postpartum 
Did attend 
(n=630)
Did not attend 
(n=659)
p value
Age (years) 32·3 (5·2) 31·6 (5·7) 0·016
BMI (at booking) 29·6 (6·6) 29·6 (7·2) 0·974
Antenatal FPG (mmol/L) 5·0 (1·0) 5·1 (1·1) 0·106
Antenatal 2 h PG (mmol/L) 9·0 (1·6) 8·8 (1·9) 0·032
Smokers 19/390 (5%) 51/369 (14%) <0·0001
Ethnic origin ·· ·· 0·705
South Asian 174/627 
(28%)
175/654 (27%) ··
White British 404/627 
(64%)
435/654 (66%) ··
Other 49/627 (8%) 44/654 (7%) ··
Multiparity (≥2) 82/391(21%) 118/370 (32%) 0·001
Macrosomia (>4 kg) 23/391 (6%) 47/366 (13%) 0·001
Data are mean (SD) or n/N (%). FPG=fasting plasma glucose. PG=plasma glucose.
Table: Characteristics of women who attended and did not attend 
postnatal oral glucose tolerance tests 
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period have reported poor sensitivity of an isolated 
HbA1c test.10 However, these studies compared 
the performance of HbA1c against OGTT with the 
assumption that the OGTT is the gold standard. This 
assumption is ﬂ awed, as we have previously described 
for the non-pregnant population.11 Although HbA1c and 
OGTT do not necessarily detect the same individuals, the 
best available data show FPG and HbA1c to be superior 
to OGTT in signalling the onset of microvascular 
risk.12,13 Therefore, it is conceivable that FPG and HbA1c 
are better choices than OGTT for the screening of 
women for undiagnosed diabetes in the postpartum 
period. Although HbA1c and FPG have poor sensitivity 
to detect impaired glucose tolerance, the existing 
recommendations state that all women with gestational 
diabetes, irrespective of postnatal glycaemic status, 
should be oﬀ ered the same lifestyle intervention as 
those with impaired glucose tolerance.14 Nevertheless, 
the new NICE guidance5 also recommends a wide 
postnatal (measured after 13 weeks) HbA1c window of 
5·7% to 6·4% (39 to 47 mmol/mol) to deﬁ ne women 
at further increased risk of diabetes, at which more 
intensive interventions should be oﬀ ered than that 
oﬀ ered to other women with gestational diabetes.5 
Another aim of postnatal testing is to detect 
undiagnosed diabetes before subsequent pregnancies, 
thus enabling provision of the best preconception care 
to reduce risk to oﬀ spring. Evidence suggests that a 
log-linear relationship exists between preconception 
HbA1c and fetal risk of congenital anomalies, with the 
highest risk for HbA1c well into the diabetes range.15 
Furthermore, all women with previous gestational 
diabetes are oﬀ ered early testing for glucose intolerance 
in subsequent pregnancies worldwide, irrespective of 
their postnatal glycaemic status. Therefore, a postnatal 
HbA1c test also serves as a valuable preconception risk 
stratiﬁ cation tool for subsequent pregnancies.
HbA1c can be done at any time of the day, at the 
patient’s home, in the non-fasting state, has higher pre-
analytical stability and a lower coeﬃ  cient of variation 
than does OGTT, and is far easier to repeat. The other 
advantages of HbA1c compared with OGTT include its 
established use in diabetes monitoring, and availability 
of point-of-care testing, especially in resource-limited 
settings where remote laboratory facilities increase 
time delays before analysis can be done. Studies10 
to compare the performance of postpartum OGTT 
with HbA1c have used HbA1c at 3 months postpartum; 
however, more research is needed to assess the eﬀ ects 
of volume shifts in pregnancy and postpartum anaemia 
on HbA1c and advise the optimum timing of the test. 
Notably, however, the lowest postnatal HbA1c threshold 
(5·7% [39 mmol/mol]) recommended by NICE to 
detect women at high risk of diabetes is lower than 
that recommended for the general population (6·0% 
[42 mmol/mol]) to potentially account for any issues 
linked to red cell turnover at this stage. 
In summary, the existing reliance on OGTT to screen 
for type 2 diabetes after gestational diabetes needs to 
be reassessed. OGTT has inadequate uptake, especially 
by women at highest risk. More studies are needed to 
assess whether changing to HbA1c will indeed improve 
uptake in such high-risk women and to assess its cost-
eﬀ ectiveness, but preliminary data are encouraging. 
We believe that changing to a non-fasting HbA1c test 
will improve screening for long-term outcomes that 
matter for postpartum women, and that such changes 
are highly unlikely to adversely aﬀ ect subsequent 
pregnancy outcomes. In fact, HbA1c tests might even 
improve prediction of such outcomes. The new NICE 
guidelines that recommend either an FPG or HbA1c test 
in the postpartum period are a step forward in the care 
of women at high risk of type 2 diabetes and should be 
welcomed by physicians and patients alike worldwide. 
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The authors argue that the main 
reason to do an OGTT is to detect 
patients with impaired glucose 
tolerance—a subgroup with a high 
risk of progression to type 2 diabetes 
that could merit early intervention. 
We wish to reiterate that persevering 
with the more complex and time-
consuming postnatal OGTT has no 
clinical justiﬁ cation for the following 
reasons. 
First, although impaired glucose 
tolerance (defined on the basis of 
an OGTT) is thought to be a better 
predictor of risk of future type 2 
diabetes than fasting plasma glucose 
(FPG) or HbA1c tests, diagnosis of 
diabetes should be based on glycaemic 
thresholds commensurate with 
increased risk of adverse outcomes 
(such as microvascular complications). 
Evidence suggests that HbA1c and 
FPG tests are better than an OGTT at 
signalling the onset of retinopathy.1,2 
Thus the OGTT deﬁ nition of diabetes 
cannot be regarded as the gold 
standard.3
Second, the American Diabetes 
Association (ADA) guidance cited 
by Noctor and Dunne recommends 
lifestyle intervention or metformin 
not only for individuals with impaired 
glucose tolerance, but also for those 
with other glucose abnormalities 
including impaired fasting glucose 
or abnormal HbA1c (5·7–6·4%) after 
gestational diabetes.4 UK National 
Institute for Health and Care (NICE) 
guidance for prevention of type 2 
diabetes recommends only FPG or 
HbA1c tests for risk stratiﬁ cation and 
intervention in individuals at high risk 
(eg, previous gestational diabetes).5 
Thus, postnatal risk stratification 
and intervention to prevent future 
diabetes can be done using HbA1c or 
FPG as well.
Third, the Diabetes Prevention 
Program (DPP)6 is often cited as 
interventional evidence to justify 
the need for detection of impaired 
glucose tolerance after gestational 
diabetes; however, this warrants closer 
inspection. Women with gestational 
recommendations to women with 
previous gestational diabetes and 
normal glucose tolerance, because 
they have been shown to beneﬁ t from 
lifestyle intervention or metformin 
therapy.3
Most international guidelines are 
correct in recommending that women 
undergo a 75 g OGTT in the early 
postpartum period, and we believe 
that this test should not be substituted 
with other tests that have proven to 
be less sensitive. Rather, efforts to 
increase the uptake of postpartum 
testing with OGTT might be more 
suitable. Indeed, implementation 
of such a programme in our group 
resulted in a postpartum testing rate 
of 77% among women diagnosed with 
gestational diabetes.4
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Abstract
Background: Metformin, a standard therapy in type 2 diabetes, reduces vitamin B12 levels. Studies linking low
vitamin B12 levels and cardiovascular disease are equivocal and suggest improving B12 levels may help in primary
prevention. The role of vitamin B12 deficiency on cardiovascular risk factors, especially in type 2 diabetes has not
been explored. The aim of this study is to investigate whether vitamin B12 deficiency in type 2 diabetes patients is
associated with cardiovascular risk factors in two different ethnic groups in UK and India.
Methods: Type 2 diabetes patients from two secondary care diabetic centres (Europeans - UK and Indians - India)
were studied. Serum vitamin B12, folate and biochemical parameters were measured.
Results: The prevalence rates of vitamin B12 deficiency (<191 ng/L) were 27% and 12% in Europeans and Indians,
respectively and higher in metformin treated type 2 diabetes patients. In linear regression analysis, after adjusting
for all likely confounding factors, vitamin B12 independently associated with triglycerides in both the populations
and cholesterol/HDL ratio in Indians. Logistic regression showed type 2 diabetes patients with vitamin B12
deficiency were at significantly higher odds of having coexisting coronary artery disease (CAD) in Europeans with
similar but non-significant trend in Indians, after adjusting for all likely confounding factors.
Conclusions: The prevalence of vitamin B12 deficiency is common in type 2 diabetes patients and is associated
with adverse lipid parameters. Type 2 diabetes management guidelines should include the recommendation for
regular testing for B12 levels, especially for those on metformin.
Introduction
Vitamin B12 is a key micronutrient responsible for DNA
methylation and has various metabolic roles ranging from
lipid metabolism to endothelial dysfunction [1]. Studies
show association of low vitamin B12 with macro-vascular
diseases such as myocardial infarction [2] and cerebral is-
chemia [3] as well as coronary artery disease (CAD) [4].
However, a systematic review of all published cohort stud-
ies was inconclusive [5]. B12 deficiency causes micro-
vascular complications such as neuropathy [6] and can
worsen the existing neuropathy due to other conditions
such as diabetes [7].
Metformin therapy is now considered a standard first
line therapy for type 2 diabetes (ADA, NICE, EASD
guidelines) [8,9] and is commonly used. Metformin re-
duces the circulating B12 levels by about 25% [10-12].
One cross-sectional study of 203 type 2 diabetes patients
reported the prevalence of B12 deficiency is 22% [13].
However, only 60% of patients with B12 deficiency have
anaemia [14] and at milder forms patients with B12 defi-
ciency are asymptomatic. This highlights the importance
of regular screening but none of the above mentioned
guidelines recommend measuring B12 levels regularly in
type 2 diabetes, even when they are on metformin.
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Indians have higher risk of metabolic disorders includ-
ing type 2 diabetes and cardiovascular diseases (CVD)
compared to Europeans [15,16] and these diseases also
occur at younger age [17]. They also have higher homo-
cysteine levels, which have been mainly attributed to low
B12 levels [18]. Vegetarianism is thought to be cause of
such high prevalence of B12 deficiency in this popula-
tion. Whether high prevalence of B12 deficiency contrib-
utes to higher risk of CVD is not known [19].
The purpose of our study is (1) to assess the preva-
lence of vitamin B12 deficiency in type 2 diabetes pa-
tients and (2) its association with cardiovascular risk
factors and micro- and macro-vascular diseases in two
different ethnic groups in UK and India.
Methods
Study population
Cross-sectional data from two different secondary care
diabetic centres were utilized for this study. (1) UK
participants: 342 consecutive patients of European ori-
gin with type 2 diabetes, who had their vitamin B12
and folate levels checked in the George Eliot Hospital
(GEH), Nuneaton, UK. (2) Indian participants: 321
type 2 diabetes patients of Indian origin had their vita-
min B12 checked at the Dr Mohan’s Diabetes Special-
ties Centre were included for the analysis. Patients who
were taking vitamin supplements and who were preg-
nant were excluded from the study. Detailed history,
anthropometric and biochemical measures such as age,
sex, type of diabetes, duration of diabetes, HbA1C, smok-
ing status, medications, blood pressure, micro- and
macro-vascular complications of diabetes, lipid profile,
vitamin B12 and folate levels were collected from both the
study population. Information on dietary intake (vegetar-
ian/non-vegetarian) was not collected. These were routine
anonymous clinical data extracted from records.
Analytical determinations
Serum glucose, HbA1C, cholesterol, triglycerides, HDL
cholesterol were determined by standard methodologies
followed in the respective labs in both the study popula-
tion. LDL cholesterol was calculated using Friedewald
formula. Serum B12 and folate were determined by elec-
trochemiluminescent immunoassay using a Roche Cobas
immunoassay analyzer (Roche Diagnostics UK, Burgess
Hill, UK). The reference values in both the laboratories
were as follows: 191–663 ng/L for vitamin B12 and 2.5-
18.7 ug/L for folate. Vitamin B12 and folate deficiencies
were defined as levels below 191 ng/L [20] and 2.5 μg/L
[21], respectively.
Definition of comorbidity
The following definitions were used to diagnose the co-
morbidity. Retinopathy: Digital retinal photographs were
graded by trained ophthalmologists (India) or retinal
graders (UK) by the ETDRS grading system. Neuropathy:
Vibratory perception threshold of the great toe > mean +
2SD of healthy non-diabetic study population aged 20–45
years (cut point ≥20 V). Nephropathy: Albumin excre-
tion ≥30 μg/mg of creatinine in urine sample after an
overnight fast (microalbuminuria - 30–299 μg/mg of
creatinine and macroalbuminuria - ≥300 μg/mg of cre-
atinine). Patients with documented retinopathy, periph-
eral and autonomic neuropathy, and nephropathy were
recorded individually and classified to have microvascu-
lar complications. Coronary artery disease (CAD): Past
history of documented myocardial infarction, stable and
unstable angina, coronary artery bypass graft, stent
and/or electrocardiographic changes suggestive of ST
segment depression and/or Q-wave changes using ap-
propriate Minnesota codes. Cerebrovascular accidents
(CVA): Past history of documented stroke (computed
tomography, magnetic resonance imaging, or cerebral
angiography). Peripheral vascular disease (PVD): Lack
of peripheral pulses or Doppler studies with Ankle Bra-
chial Index <0.9. Those with documented CAD, CVA
and PVD were recorded individually and classified to
have macrovascular complications.
Statistical analysis
Continuous variables are reported as mean ± standard
deviation (SD). Categorical variables are reported in per-
centages. The distributions of the parameters such as
cholesterol, triglycerides, HDL, LDL, vitamin B12 concen-
trations were skewed; these data were log-transformed.
Means of continuous variables were compared using inde-
pendent t-tests. Bivariate correlations between different
variables were done using Pearson correlation test. Risk
variables that had significant association were included as
independent variables in multiple linear regression ana-
lysis. Logistic regression analysis was used to examine the
relation between vitamin B12 levels and the risk of micro-
and macro-vascular complications. Associations between
vitamin B12 and cardiovascular outcomes were adjusted
for age, gender, BMI, duration of diabetes, smoking,
HbA1C, cholesterol, HDL, triglycerides, systolic and
diastolic pressure, use of metformin, statin and aspirin.
p values of <0.05 were considered as statistically signifi-
cant. All analyses were performed using IBM SPSS Sta-
tistics version 19 (IBM Corp, NY, USA).
Results
The clinical characteristics of the study population are
shown in Table 1. The use of metformin in Europeans
was 65% and in Indians is 75%. The prevalence rates of
serum vitamin B12 deficiency (<191 ng/L) in Europeans
were 27% and Indians were 12% (Table 1). For those on
metformin, these rates were 32.1 and 12.4%, respectively.
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There were no gender differences in vitamin B12 and
folic acid (Additional file 1: Table S1). The sex specific
values of the other variables are also shown in the
Additional file 1: Table S1. In both the populations, tri-
glycerides and cholesterol/HDL ratio were significantly
and inversely associated with vitamin B12 levels. HDL
was positively associated with vitamin B12 levels in
Europeans but cholesterol was not significantly associated
with vitamin B12 in both the populations (Additional file 1:
Table S2). No associations of vitamin B12 with other estab-
lished cardiovascular risk factors such as BMI, systolic and
diastolic pressure and HbA1C were observed (data not
shown).
Linear regression analysis was carried out to assess
whether vitamin B12 independently associated with
these cardiovascular risk factors in the type 2 diabetes
patients by adjusting for all likely confounders. The
model included age, gender, BMI, duration of diabetes,
smoking, HbA1C, use of metformin, statin and aspirin as
independent variables. After all these adjustments, vita-
min B12 independently associated with triglycerides in
both the populations (Figure 1a,b) but cholesterol/HDL
ratio only in Indians (Figure 1d).
Association of vitamin B12 levels and individual co-
morbidities were assessed by logistic regression analysis
(Table 2). After adjustment for age, gender, BMI, dur-
ation of diabetes, smoking, HbA1C, cholesterol, HDL,
LDL, triglycerides, systolic and diastolic pressure, use of
metformin, statin and aspirin, type 2 diabetes patients
with low vitamin B12 levels were at a significantly higher
odds of having coexisting CAD in Europeans (OR =
3.91; 95% CI: 1.09 - 14.05). A similar but non-significant
trend of higher risk was observed in Indians (OR = 1.77;
95% CI: 0.376 - 8.33). No associations with other micro-
or macro- vascular diseases were observed.
Discussion
Our study involving two different ethnic groups with
type 2 diabetes patients had three main findings. Firstly,
there was high prevalence of vitamin B12 deficiency in
Europeans but interestingly lower than observed preva-
lence in Indians from South India. Secondly, vitamin
B12 deficiency was associated with adverse lipid profiles.
Thirdly, low vitamin B12 levels in type 2 diabetes pa-
tients were associated with an increased risk of CAD.
Studies in type 2 diabetes patients of European origin
on metformin have reported the prevalence of vitamin
B12 deficiency to range from 5.8% to 33% [10,11,13,22].
Our study confirms this in the British population, with a
prevalence of 27% in all type 2 diabetes and 32.1% in
type 2 diabetes with metformin. Our study is the first
one to report the prevalence of B12 deficiency in the
South Indian population with type 2 diabetes. Previous
studies in north Indian population showed much higher
rates of 67% in middle-aged men [18] and 54% in dia-
betes patients [23]. This is likely due to the differences
in dietary habits between north and south Indians. South
Indians consume higher quantity of fermented foods,
which are rich in vitamin B12 [24,25].
In this study, vitamin B12 deficiency independently as-
sociated with triglycerides and cholesterol/HDL ratio in
type 2 diabetes patients. Our findings were similar to the
study in Indians with history of CAD [4]. Similar corre-
lations were also found between B12 levels and total
cholesterol and triglycerides in a group of Polish patients
with established atherosclerosis, but this relationship
was lost in regression analysis, which may be due to the
smaller sample size in the study [21]. Vitamin B12 func-
tions as a coenzyme in the conversion of methylmalonyl-
Table 1 Basic Characteristics of the study population
Parameters Europeans Indians
total total
n = 342 n = 321
Age (years) 63.0 ± 12.3a 56.8 ± 10.6
BMI (Kg/m2) 32.8 ± 6.1 28.0 ± 5.7
Duration of diabetes (years) 14.1 ± 9.4 8.4 ± 7.6
HbA1C (%) 7.89 ± 1.62 8.30 ± 2.1
Cholesterol (mmol/L) 4.10 ± 1.10 4.0 ± 1.12
Triglycerides (mmol/L) 2.01 ± 1.48 1.77 ± 0.89
HDL (mmol/L) 1.25 ± 0.35 0.98 ± 0.25
LDL (mmol/L) 1.97 ± 0.81 2.20 ± 0.91
Cholesterol/HDL ratio 3.46 ± 1.19 4.18 ± 1.16
SBP (mmHg) 137 ± 20 132 ± 18
DBP (mmHg) 74 ± 11 81 ± 9.3
Vitamin B12 (ng/L) 290 ± 139 464 ± 228
Vitamin B12 deficiency, n (%) 91 (27)b 37 (12)
Folate (ug/L) 7.71 ± 9.77 13.6 ± 5.2
Folate deficiency, n (%) 29 (8.5) 0
Smoking, n (%) 26 (8.5) 75 (24)
Microvascular complications:
Retinopathy, n (%) 124 (36) 132 (45)
Neuropathy, n (%) 53 (16) 99 (33)
Nephropathy, n (%) 41 (12) 83 (29)
Macrovasuclar complications:
Coronary artery disease (CAD), n (%) 62 (18) 27 (9)
Cerebro vascular accidents (CVA), n (%) 19 (5.6) 6 (1.9)
Peripheral vascular disease (PVD), n (%) 23 (6.7) 17 (6)
Insulin use, n (%) 215 (63) 149 (46)
Metformin use, n (%) 221 (65) 242 (75)
Statin use, n (%) 286 (84) 154 (48)
Aspirin use, n (%) 246 (72) 44 (14)
aMean ± SD (all such values); bNumbers (percentages) (all such values).
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CoA (MM-CoA) to succinyl-CoA [26,27]. This reaction is
blocked if there is vitamin B12 deficiency, resulting in ac-
cumulation of MM-CoA which inhibits the rate-limiting
enzyme of fatty acid oxidation (CPT1 – carnitine palmi-
toyl transferase) [28], thus causing lipogenesis. This may
be the likely mechanism for the link between B12 defi-
ciency and adverse lipid parameters.
Our observation of an association of increased risk of
CAD in type 2 diabetes patients with low B12 levels after
controlling for all likely confounding factors is supported
Figure 1 Regression of Vitamin B12 with (a) Triglycerides in Europeans, (b) Triglycerides in Indians, (c) Cholesterol: HDL ratio in
Europeans and (d) Cholesterol: HDL ratio in Indians. *Log-transformed for statistical comparisons. Model included vitamin B12, age, BMI, sex,
duration of diabetes, HbA1C, smoking, use of metformin, statin & aspirin.
Table 2 Logistic regression analysis of vitamin B12 with co-morbidities
Co-morbidities Europeans Indians
B (SE) Odds ratio (95% CI) p-value B (SE) Odds ratio (95% CI) p-value
Microvascular complications:
Retinopathy 0.294 (0.604) 1.342 (0.411, 4.386) 0.626 −0.085 (0.440) 0.919 (0.388, 2.176) 0.848
Neuropathy 0.132 (0.663) 1.141 (0.311, 4.186) 0.842 −0.208 (0.558) 0.812 (0.272, 2.424) 0.709
Nephropathy 0.790 (1.132) 2.203 (0.239, 20.267) 0.485 −0.721 (0.519) 0.487 (0.176, 1.346) 0.165
Macrovascular complications:
Coronary artery disease (CAD) 1.364 (0.653) 3.911 (1.088, 14.054) 0.037 0.571 (0.790) 1.770 (0.376, 8.332) 0.470
Cerebro vascular accidents (CVA) −1.226 (1.508) 0.294 (0.015, 5.644) 0.416 0.775 (1.584) 2.170 (0.097, 48.369) 0.625
Peripheral vascular disease (PVD) 0.552 (0.608) 1.737 (0.527, 5.722) 0.364 - -* -
Model included vitamin B12, age, BMI, sex, duration of diabetes, HbA1C, Cholesterol, HDL, LDL, triglycerides, SBP, DBP, smoking, use of metformin, statin
and aspirin.
*- Odds ratio cannot be computed because in the PVD group, the number of B12 deficient cases were zero.
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by other findings in subjects with type 2 diabetes and
non-type 2 diabetes. A study by Shargorodsky et al.
found that vitamin B12 independently correlated with
pulse wave velocity in type 2 diabetes patients, an ac-
cepted cardiovascular risk factor [29]. Weikert et al. [3]
in a population-based prospective study showed the as-
sociation between low vitamin B12 levels and increased
risk of cerebral ischemia. Similarly, in south Asian
women living in the UK with vitamin B12 deficiency an-
aemia had a higher prevalence of myocardial infarction
and CAD [30]. We did not find any sex specific changes
in our study. Thus our findings in support of the previ-
ous observations extend the knowledge on the role of
vitamin B12 on CAD and its risk factors in type 2 dia-
betes patients. In spite of the fact that B-vitamins could
provide an inexpensive and effective method for the pre-
vention of CVD, their use was rejected, based on the
negative results of randomized controlled clinical trials
[31,32]. But, when examining the design of these trials,
it appeared that concomitant medication such as statin/
aspirin therapy applied along with the vitamin substitu-
tion could have obscured the separate effects of vitamins
in cardiovascular prevention. However, a recent meta-
analysis of these vitamin trials suggest that B vitamins
are effective in primary prevention of cardiovascular dis-
eases [33]. Similarly, a study in type 2 diabetes patients
with another micronutrient supplementation, vitamin D,
showed more significant improvements in the cardio-
metabolic profile [34].
Lipid abnormalities are unique in individuals with T2D
and those are at risk of T2D (obesity, metabolic syn-
drome and pre-diabetes): the total cholesterol and LDL
are lower in those with statins but higher in those with-
out. In addition, in both groups the triglyceride levels
are higher and the HDL levels are lower as statins have
little effect on them [35-37]. In post-menopausal women
with T2D and CAD who were not on lipid lowering
medications, in addition to higher total and LDL choles-
terol and higher triglycerides, homocysteine was also
higher, suggesting a potential link between vitamin B12
and folic acid and abnormal lipid profiles [38-41]. It is
known that increasing triglycerides and reducing HDL
are early features of atherosclerosis, well before increas-
ing LDL [38,42]. Therefore, our findings showing inde-
pendent association of B12 with triglycerides and HDL
in two different ethnic groups provide a possible mech-
anism how vitamin B12 could offer primary prevention
of cardiovascular diseases in type 2 diabetes and may
also be an option in the secondary prevention of disease,
if statin therapy is accompanied by serious adverse
effects.
The strength of this study is the inclusion of two
cross-sectional study populations of type 2 diabetes pa-
tients from UK and India and comprehensive data from
both the groups. However, it also has the following limi-
tations. The study population were based in secondary
care and not a true representative sample of all type 2
diabetes. A true primary care representative sampling of
type 2 diabetes would have strengthened our findings.
However, metformin is routinely prescribed in primary
care. This therefore might have under estimated the
prevalence of B12 deficiency and may have overesti-
mated its association with CAD as the prevalence of
CAD is likely to be higher in secondary care settings. A
group of Indian diaspora living in the UK as well as the
availability of biomarkers of vitamin B12 deficiency such
as MMA and homocysteine would have strengthened
the findings. In addition, being a cross-sectional study, it
does not prove causality.
In summary, our study demonstrates for the first time
that vitamin B12 deficiency in type 2 diabetes patients in
two different ethnic groups is associated with adverse
lipid parameters and higher risk of CAD. Currently,
there are no guidelines advocating for routine screening
for vitamin B12 deficiency among patients with type 2
diabetes. While optimal screening frequency remains to
be determined, baseline tests at initiation of metformin
therapy and subsequent annual testing of B12 levels may
be appropriate. Our study also warrants updating of
international guidelines for the management of type 2
diabetes.
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